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Autophagy is a crucial cellular catabolic process that degrades unwanted cytoplasmic 
material (cargo) by engulfing the material into a double-membrane vesicle (autophagosome) 
and then presenting it to the lysosome. The work in this thesis explores interactions between 
the proteins involved in the autophagy pathway.  
Focal adhesion complex Interacting Protein of 200 kDa (FIP200) and autophagy 
related protein 13 (Atg13) are members of the autophagy initiation complex. Attempts were 
made to locate the region on FIP200 that binds the Atg13 by dividing FIP200 into six 
fragments of equal length and performing pull-down assays with Atg13. However, because of 
a false positive interaction observed for all six FIP200 fragments, binding between the Atg13-
interaction region on FIP200 and Atg13 could not be identified.  
Pleckstrin homology domain-containing protein family member 1 (PLEKHM1) is a 
selective autophagy receptor that interacts with the autophagy-related protein 8 homologues 
(Atg8 proteins: LC3A, LC3B, LC3C and GABARAP, GABARAPL1, GABARAPL2). The 
affinity of PLEKHM1 for the LC3 family is higher than that for the GABARAP family of 
proteins. The Atg8 proteins are involved in tethering cargo to the autophagosome. The crystal 
structures of five human ATG8 proteins were solved in complex with a peptide with the 
sequence of the PLEKHM1 LC3-Interacting Region (LIR) to understand the structural basis 
of their differing binding affinities. These structures demonstrated that residues Arg28 and 
Glu17 of the GABARAP family proteins interact with Asn637 and Trp635 residues of the 
PLEKHM1 LIR peptide. However, these interactions were either weak or not present in the 
LC3 family proteins, suggesting that they may contribute to the higher binding affinity for the 
PLEKHM1 LIR observed with GABARAP proteins. In addition, a structural comparison of 
the human ATG8 proteins suggested that the “W-site” hydrophobic pocket, where Trp635 in 
PLEKHM1 binds, is deeper in GABARAP family proteins than in LC3 family proteins. 
Together, the structural analysis provided a rationale for varying binding affinities between 
GABARAP and LC3 family proteins.  
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The serine/threonine-protein kinase ULK1, which is part of the autophagy initiation 
complex, also interacts with the Atg8 family proteins. Using surface plasmon resonance, 
molecular dynamic (MD) simulations, mutational analysis and X-ray crystallography, the 
interaction of the ULK1 LIR with GABARAP and LC3A was studied to understand the 
difference in the LIR interaction mechanism. Structural comparison of the LC3A and 
GABARAP proteins in their LIR-bound and unbound states showed that LC3A shows more 
variation in the structure of its “W-site” hydrophobic pocket between its bound and unbound 
states than the “W-site” of GABARAP. This was verified by MD simulations. Additionally, 
the MD simulations suggested an electrostatic interaction between LC3A Arg70 and ULK1 
Met359. This was demonstrated by the decrease in binding affinity when Arg70 was mutated 
to leucine. In contrast, mutation of Arg67 (which is equivalent to Arg70 in LC3A) to leucine 
did not have any effect on LIR binding. 
Overall, this work provides key insights into the differences in the mechanisms of 
interaction demonstrated by the GABARAP and LC3 family proteins, which is an initial step 
towards understanding the different functions of the members of the two human ATG8 
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Chapter 1.  INTRODUCTION 
1.1 Background 
Cells are the most basic unit of life. They transcribe and translate the genetic 
code into proteins, the workhorses of life. Apart from providing structure to the cells, 
proteins perform various important functions, such as catalysing biochemical 
reactions, cellular signalling and communication, transporting molecules, defending 
against foreign invaders, and providing contraction and movement. It is essential that 
the right quantities of proteins are maintained in a properly functional and folded 
state.  
Autophagy (from the Greek words auto, meaning “self”, and phagein, 
meaning “to eat”) is a eukaryotic cellular pathway that degrades and recycles 
unwanted cytoplasmic materials into simple amino acids. Autophagy plays a critical 
role in striking a balance between protein synthesis and protein degradation (Mitch & 
Goldberg, 1996). When survival becomes strenuous, unwanted and long-lived 
proteins and organelles are degraded by autophagic pathways into simple amino 
acids, which are then recycled for synthesis of new proteins to maintain cellular 
homeostasis. 
Autophagy is a carefully coordinated pathway involving many protein partners 
and locations within the eukaryotic cell. The following literature review begins with 
an overview of the various pathways involved in protein degradation, followed by a 
detailed description of autophagy. 
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1.1.1 Types of protein degradation 
Proteolytic activity in cells was first detected in 1898 (Hahn, 1898). Following 
the discovery of the lysosome, researchers focused on the field of protein degradation 
(De Duve, 1963). In eukaryotic cells, protein degradation can be broadly classified 
into two separate pathways (Figure 1.1): the non-lysosomal pathway (i.e. the 
ubiquitin-proteasome pathway, which is briefly reviewed here), and the lysosomal 
protein degradation pathway (which includes autophagy and will be reviewed in-
depth).  
 
Figure 1.1: The two protein degradation pathways in eukaryotic cells: The ubiquitin 
proteasome pathway degrades ubiquitinated protein via the proteasome. The lysosomal 
pathway mainly degrades protein through endocytosis and autophagy.  
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1.1.1.1 Non-lysosomal ubiquitin-proteasome pathway 
The ubiquitin proteasome pathway (UPP) degrades short-lived and aberrant 
intracellular proteins by covalently attaching a small 76-amino acid protein, called 
ubiquitin, to the protein that is to be degraded (Heinemeyer et al., 1991) (Figure 1.1). 
Tagged proteins are recognised by the 26S proteasome, a large multi-catalytic protein 
complex that degrades ubiquitinated proteins into small peptides (Baumeister et al., 
1998). Ubiquitin is attached to the targeted protein via three enzymatic reactions 
(mediated by the enzymes E1, E2 and E3), in which E1 activates ubiquitin, E2 carries 
ubiquitin and prepares it for conjugation and E3 identifies the protein to be degraded 
and ligates it to the activated ubiquitin (Lecker et al., 2006). Often, a protein is tagged 
with a chain of more than one ubiquitin in a process called poly-ubiquitination.  
The 26S proteasome is comprised of approximately 60 subunits. It has two 
main components: the 20S core particle, which is the central hollow cylinder where 
the ubiquitin-labelled protein is degraded, and the 19S regulatory particle, located on 
either side of the cylinder, where the protein to be degraded is unfolded and the 
ubiquitin tag is detached for reuse (Figure 1.1). Dysfunction in the UPP can lead to 
cancer, neurodegenerative disorder, immune disorders and chronic kidney disease 
(Cooper, 2000a, Hochstrasser, 2009, Lecker et al., 2006). 
1.1.1.2 Lysosomal protein degradation pathway 
Cells contain closed membrane vesicles, called lysosomes, that store 
approximately 50 different acidic hydrolases involved in the degradation of a wide 
range of materials, including proteins, nucleic acids, organelles, lipids and 
carbohydrates. These enzymes are active inside the lysosome at pH ~5.  
One of the main functions of lysosomes is to degrade extracellular proteins 
that are transported into the cell through endocytosis. In addition to the endocytic 
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pathway, lysosomes also degrade materials via two other pathways: phagocytosis and 
autophagy. In phagocytosis, the phagocytic vesicles (called phagosomes), engulf large 
particles, such as bacteria and cell debris, and then fuse with the lysosome to form the 
phagolysosome. The phagolysosome degrades the materials that have been taken up 
into the vesicle (Cooper, 2000b). The main focus of this thesis will be autophagy, as 
explained below. 
1.1.1.3 Autophagy 
Autophagy is a bulk degradation process that is conserved in eukaryotic cells 
(De Duve & Wattiaux, 1966). Under cellular stress conditions, such as starvation, 
autophagy is used to degrade misfolded proteins, long-lived proteins and damaged 
organelles by sequestering them in a double-membraned vesicle, and then fusing this 
vesicle with the lysosome for degradation (Mortimore & Schworer, 1977). 
Dysfunction in autophagy leads to certain types of cancer (colorectal cancer, prostate 
cancer and lymphoma) (Liang et al., 1999, Qu et al., 2003, Yue et al., 2003, Mariño 
et al., 2007, Takamura et al., 2011, Morselli et al., 2011), neurodegenerative disorders 
(Berger et al., 2006, Ravikumar et al., 2002, Webb et al., 2003, Shibata et al., 2006, 
Menzies et al., 2010, Williams et al., 2008, Zheng et al., 2010), immunological 
disorders (Lee, Mattei, et al., 2010, English et al., 2009, Li et al., 2008, Campbell & 
Spector, 2011, Schmid et al., 2007), cellular ageing and cell death (Lipinski et al., 
2010, De Kreutzenberg et al., 2010, Caramés et al., 2010, Lee et al., 2009). 
Autophagy can be categorised into microautophagy, chaperone-mediated autophagy 




Microautophagy, which is best characterised in yeast, is a process where the 
cytoplasmic material is engulfed by direct invagination into the lysosomal membrane 
and then degraded (Ahlberg & Glaumann, 1985). Two separate multistep pathways 
have been identified in microautophagy: the type I pathway, in which soluble 
components are degraded, and the type II pathway, in which selected organelles are 
degraded (Kunzt et al., 2004). In both pathways, budding is initiated by the formation 
of a structure called the “autophagic tube” (Kunzt et al., 2004). This is followed by 
vesicle formation, expansion, scission, degradation and recycling (Figure 1.2). 
Improper functioning of microautophagy can lead to various human diseases, such as 
Creutzfeldt-Jakob disease, Gerstmann-Straussler-Scheinker, Huntington’s disease, 
albinism and Pompe disease (Kunzt et al., 2004, Li et al., 2012). 
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Figure 1.2: Overview of the three types of autophagy. Macroautophagy involves sequestration 
of cytoplasmic material in a vesicle called an autophagosome, and fusion with a lysosome. In 
microautophagy, cytoplasmic material buds into a lysosome to form a vesicle before being 
degraded. Finally, in chaperone-mediated autophagy, chaperones present the protein directly 
to the lysosome to be degraded. © 2013 Zhang S, Wang J, Du Y, Shang J, Wang L, Wang K, 
Bai K, Lv T, Li X, Liu H. Under CC BY 3.0 license. Available from: 
http://dx.doi.org/10.5772/53442. 
1.1.1.3.2 Chaperone-mediated autophagy (CMA) 
CMA is best understood in higher eukaryotes, such as mice and humans 
(Kaushik & Cuervo, 2012). Proteins that are to be degraded are recognised by the 
Hsc70 chaperone and presented to the lysosome for degradation. The chaperone 
recognises a specific peptide motif (KFERQ or a KFERQ-like sequence) and binds to 
 7 
the protein. The protein is delivered to the lysosome by lysosome-associated 
membrane protein type 2A (LAMP-2A). Unlike other lysosomal pathways, CMA 
does not require vesicle formation; instead, it presents the cargo directly to the 
lysosome (Figure 1.2). Malfunction in the CMA pathway leads to neurodegenerative 
disorders such as Parkinson’s disease (Cuervo & Wong, 2014), kidney disease 
(Cuervo, 2010) and lysosomal storage disorder (Cuervo & Dice, 1996). 
 
1.1.1.3.3 Macroautophagy 
Macroautophagy, the pathway at the centre of this work, is the best-
understood autophagic pathway. Autophagic vesicles (autophagosomes) were first 
observed by Christian deDuve in 1966 (De Duve & Wattiaux, 1966).  
Macroautophagy is a stepwise process. It can be categorised into the following 
stages: initiation, elongation, maturation and fusion. During the initiation stage, a 
double membrane, called the phagophore, is formed from the isolation membrane 
(Figure 1.2). The isolation membrane is a cup-like, double-membrane structure 
floating in the cytoplasm. The source of the isolation membrane is poorly understood. 
Various studies suggest that the double membrane is obtained from the smooth 
endoplasmic reticulum, the plasma membrane or the mitochondria (Hailey et al., 
2010, Ravikumar et al., 2010, Hayashi-Nishino et al., 2009). The elongation phase 
begins with the addition of the double membrane to the phagophore and sequestration 
of unwanted cytoplasmic material. Phagophore elongation leads to closure and 
formation of a vesicle called an autophagosome. The autophagosome is transported to 
the lysosome during the maturation phase, then the two bodies fuse to form an 
autolysosome in the fusion phase. Finally, the autolysosome degrades the sequestered 
materials inside the vesicle (Metcalf et al., 2012). Interest in macroautophagy 
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increased after the genes involved in this pathway were identified. Autophagy is 
regulated by the autophagy-related (ATG) genes, first reported by Ohsumi’s group in 
1997 (Matsuura et al., 1997). Soon after, Mizushima identified mammalian 
counterparts of the yeast proteins Atg5 and Atg12 in mammals (Mizushima et al., 
1998). 
1.2 Autophagy in disease 
Dysfunction of autophagy leads to various disorders, making it an interesting 
and compelling target of study. Most neurodegenerative disorders are caused by the 
accumulation of protein aggregates or toxic proteins in neurons (Rubinsztein, 2006). 
Studies in mice, Drosophila and zebrafish have shown that upregulation of autophagy 
results in reduced levels of these protein aggregates and toxic proteins, making the 
pathway an attractive drug target (Shibata et al., 2006). In other studies, upregulating 
autophagy reduced the levels of proteins encoded by genes involved in disorders such 
as obesity (Codogno & Meijer, 2010, He et al., 2012), cancer (Bursch et al., 1996) 
and encephalitis (Liang et al., 1998). For certain types of cancer, including colorectal 
cancer, prostate cancer and lymphoma, inhibiting autophagy is being considered as a 
therapeutic strategy (Janku et al., 2011, Yang et al., 2011). Induction of autophagy 
also increases longevity, making it a possible target for ageing and longevity research 
(Rubinsztein et al., 2011). The roles of autophagy in various disorders are discussed 
in detail below. 
1.2.1 Autophagy and metabolic disorders 
Lipophagy, an alternative lipid metabolism pathway, uses lysosomes to 
degrade liver lipid droplets (Liu & Czaja, 2013). The free fatty acids produced from 
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this pathway are oxidised by mitochondria (Singh, Kaushik, et al., 2009). The ATG7 
gene encodes E1-like ligase, which is involved in the formation of the 
autophagosome. ATG7 knock-out mice show an increase in hepatic lipid levels that 
leads to obesity (Yang et al., 2010). Restoration of this gene decreased obesity and 
insulin resistance, and improved glucose tolerance (Zhang et al., 2009, Singh, Xiang, 
et al., 2009). Furthermore, a decrease in lipophagy was observed in both genetic and 
diet-induced obese mouse models (Yang et al., 2010, Zhang et al., 2009, Singh, 
Xiang, et al., 2009). Mouse models with increased autophagy in response to exercise 
are protected against impaired glucose tolerance and triglyceride levels induced by a 
high fat diet (He et al., 2012). Such beneficial effects were not noticed in mouse 
models where autophagy was not induced in response to exercise (Rubinsztein et al., 
2012). These findings suggest that autophagy plays a beneficial role in obese patients. 
Thus, the autophagy pathway is an attractive drug target to treat various metabolic 
disorders like obesity and diabetes (Codogno & Meijer, 2010).  
1.2.2 Autophagy and neurodegenerative disorders 
Accumulation of protein aggregates in neurons leads to various 
neurodegenerative disorders, such as Parkinson’s disease (Berger et al., 2006), 
Alzheimer’s disease (Lee, Yu, et al., 2010, Pickford et al., 2008) and Huntington’s 
disease (Shibata et al., 2006). Most of these protein aggregates are autophagy 
substrates. Clearance of the toxic mutant protein huntingtin, which causes 
Huntington’s disease, is slowed down when autophagy is impaired (Shibata et al., 
2006). In contrast, upregulation of autophagy enhanced clearance of this toxic protein 
(Shibata et al., 2006). Similar studies performed on other mutant proteins, such as 
mutant α-synuclein, which causes Parkinson’s disease, and mutant ataxin 3, which 
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causes spinocerebellar ataxia type 3, showed that upregulation of autophagy had 
beneficial effects (Berger et al., 2006, Ravikumar et al., 2002, Webb et al., 2003).  
Because defective autophagosome formation can cause neurodegenerative 
disorders, drugs that upregulate autophagosome formation can be used to treat these 
diseases. For example, Lafora epilepsy is caused by mutant laforin, which activates 
the mammalian target of rapamycin (mTOR) complex (see Section 1.4.1) (Aguado et 
al., 2010). This complex, in turn, negatively regulates autophagy by impairing 
autophagosome formation (Hosokawa et al., 2009). Therefore, drugs like rapamycin 
can be used to inhibit mTOR and activate autophagy to cure this disease (Aguado et 
al., 2010). Evaluating the proteins involved in autophagy for their potential as drug 
targets may allow researchers to develop cures for these disorders. 
1.2.3 Autophagy and cancer 
Interestingly, autophagy can be a tumour suppressor, as well as help in the 
survival of tumour cells during metabolic stress and chemotherapy. For example, 
ATG gene BECN1, which encodes beclin 1, is part of the phosphatidylinositol-3-
kinase (PI3K) complex that mediates vesicle-trafficking processes in autophagy (Su et 
al., 2015). Deletion of BECN1 increases susceptibility to breast, ovarian and prostate 
cancer in humans (Liang et al., 1999, Yang et al., 2011). It has also been shown that 
tumour suppressor genes activate autophagy, which might in turn inhibit tumour 
initiation. For example, tuberous sclerosis 1 (TSC1) and tuberous sclerosis 2 (TSC2) 
inhibit mTOR, which in turn activates autophagy. On the other hand, tumour 
signalling pathways such as oncogenic receptor tyrosine kinase, class I PI3Ks and 
protein kinase B (AKT) inhibit autophagy by activating mTOR (He & Levine, 2010, 
Pimkina et al., 2009). Thus, autophagy represents a useful drug target for cancer. 
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Further research and clinical trials will help to shift the focus on autophagy for cancer 
therapy (Rubinsztein et al., 2012).  
1.2.4 Autophagy and infectious disease 
The first evidence of the involvement of autophagy in infectious disease was 
reported in 1998, when Liang et al. showed that expression of the ATG gene BECN1 
protected mice against alphavirus encephalitis (Liang et al., 1998). A selective 
autophagy pathway, called xenophagy, acts as a defence mechanism in which 
microorganisms, such as bacteria, fungi, and viruses, are presented to the lysosomes 
for degradation (Virgin & Levine, 2009). In addition to directly degrading pathogens, 
upregulation of autophagy increases the innate immune response and prevents 
excessive inflammation.  
Autophagy also plays a vital role in adaptive immunity (Levine et al., 2011). 
The ATG5 gene is required for proper presentation of microbial antigens to major 
histocompatibility complex class II molecules (Lee, Mattei, et al., 2010). Autophagy 
proteins are also involved in innate and adaptive immunity in an autophagy pathway-
independent manner (English et al., 2009, Levine et al., 2011). Autophagy is a 
promising drug target to treat infectious disease, with some compounds already being 
tested in preclinical trials (Rubinsztein et al., 2012). 
1.3 The Unc51-like kinase 1 (ULK1) complex 
Regulation of macroautophagy is well-studied in yeast (Tsukada & Ohsumi, 
1993). It is initiated by the ATG1 complex, which consists of the Atg1, Atg13, Atg11 
and Atg17 proteins (Kamada et al., 2000). Upon starvation, the members of the ATG1 
complex associate together and undergo a cascade of phosphorylation, which induces 
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macroautophagy (Kamada et al., 2000). The mammalian homologue of the ATG1 
complex, the Unc51-like kinase 1 (ULK1) complex, was identified initially by the 
Ohsumi lab in 1993 (Tsukada & Ohsumi, 1993), and later confirmed by the Tooze lab 
in 2006–2007 (Hara et al., 2008, Chan et al., 2007, Young et al., 2006). The members 
of the ULK1 complex were first identified by co-immunoprecipitation experiments 
that identified focal adhesion kinase family-interacting protein of 200 kDa (FIP200) 
and Atg13 (Hara et al., 2008, Hosokawa et al., 2009). Like the ATG1 complex in 
yeast, the mammalian ULK1 complex consists of four proteins: ULK1, Atg13, 
FIP200 and Atg101 (Chan et al., 2007). 
Interestingly, the human ULK1 complex remains stably associated regardless 
of the activation or inactivation of autophagy. In contrast, the yeast ATG1 complex 
does not form stable complexes without the induction of autophagy (Kamada et al., 
2000, Kabeya et al., 2005). Gel filtration chromatography experiments showed that 
ULK1 formed a stable 3-MDa complex in precipitates isolated from both starved and 
nutrient-rich mouse embryonic fibroblasts (Hosokawa et al., 2009). These results 
were further confirmed using co-immunoprecipitation experiments (Hara et al., 
2008). 
1.3.1 Cellular distribution 
The cellular distribution of the ULK1 complex was first determined by 
expressing ULK1 proteins fused with green fluorescent protein (Hara et al., 2008). 
Because macroautophagy can be induced by starvation (Mortimore & Poso, 1987), 
the cellular distribution of the ULK1 complex under starvation and nutrient-rich 
conditions was examined to verify the involvement of the ULK1 complex in 
macroautophagy. Under nutrient-rich conditions, the ULK1 protein was distributed 
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throughout the NIH/3T3 cells, whereas during starvation, the ULK1 protein was 
localised at punctate structures within the autophagosome, suggesting that the ULK1 
protein was involved in macroautophagy (Hara et al., 2008). Consistent with this 
result, both FIP200, which associates with ULK1, and Atg13 were spread throughout 
the cytoplasm under nutrient-rich conditions, but were localised near the isolation 
membrane and the punctate structure, respectively, during starvation (Hara et al., 
2008) (Hosokawa et al., 2009). The localisation of these proteins to the 
autophagosome vesicle during starvation-induced macroautophagy suggests the 
involvement of ULK1-Atg13-FIP200 in macroautophagy. 
1.3.2 Importance of the ULK1 complex in macroautophagy 
To study which of the proteins in the ULK1 complex are necessary for 
autophagy, the genes encoding ULK1, Atg13 and FIP200 were mutated to produce 
loss-of-function variants (e.g. by mutating key residues involved in kinase activity) or 
complete knock-outs of individual genes. Autophagy was inhibited in kinase-dead 
ULK1 mutant cells (Hara et al., 2008), and FIP200 knock-out mice showed 
embryonic lethality, caused by defective heart formation (Gan et al., 2006). In 
addition, mouse embryonic fibroblast cells derived from these knock-out mice 
showed drastic suppression of macroautophagy (Hara et al., 2008). Electron 
microscopy experiments demonstrated that GFP-tagged ULK1 was found near 
autophagosome punctates only in the wild type cells, and assembly was not observed 
in FIP200 knock-out cells (Hara et al., 2008). These results suggest that FIP200 is 
essential in macroautophagy, and functions in complex with ULK1 (Hara et al., 
2008). Similar to ULK1 and FIP200, silencing of Atg13 using siRNA inhibits 
autophagosome formation (Hosokawa et al., 2009).  
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1.3.3 Binding regions of the ULK1 complex 
Binding assays suggest that FIP200 and Atg13 interact at the C-terminal 
region of ULK1 (Jung et al., 2009), and ULK1 and FIP200 bind to the C-terminal 
region (384–517 aa) of Atg13 (Jung et al., 2009). Although Atg13 interacts with 
ULK1 and FIP200 directly, in vitro studies suggest that ULK1 and FIP200 do not 
interact in the absence of Atg13 (Jung et al., 2009). Thus, Atg13 mediates the 
interaction between FIP200 and ULK1 (Hosokawa et al., 2009, Jung et al., 2009). 
1.4 Macroautophagy signalling pathways 
Macroautophagy is well studied under starvation conditions, but is also 
induced by other environmental changes, such as energy depletion (Kim et al., 2011), 
decreases in growth factors like interleukin-3 (Lum et al., 2005), heat and oxidative 
stress (Scherz-Shouval et al., 2007). There are various signalling pathways that 
regulate autophagy, which can be broadly classified as either mTOR-dependent or 
mTOR-independent (Metcalf et al., 2012). The main focus of this thesis is the mTOR-
dependent activation of the ULK1 complex. 
1.4.1 mTOR-dependent signalling pathway 
mTOR is a serine/threonine kinase that controls cell growth and protein 
synthesis by sensing energy and nutrients (Fleming et al., 2011). The mammalian 
TOR exists in two complex forms: mTORC1 and mTORC2 (Laplante & Sabatini, 
2012). The two complexes vary in their functions, as well as the subunits that they 
consist of. mTORC1 is defined by the association of regulatory-associated protein of 
mTOR complex 1 (RPTOR) subunit, whereas mTORC2 is defined by the association 
of RPTOR-independent companion of mTOR complex 2 (RICTOR) (Hara et al., 
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2002, Dos et al., 2004). Inactivation of mTORC1 leads to the activation of autophagy 
via the ULK1 complex (Hosokawa et al., 2009). mTOR is activated by signals from 
insulin receptors that activate protein kinase B (PKB/Akt), which in turn 
phosphorylates the tuberous sclerosis complex (TSC1-TSC2 complex) (Huang & 
Manning, 2008), a heterodimer that acts as a GTPase-activating protein (Fleming et 
al., 2011) (Figure 1.3). Co-immunoprecipitation experiments have shown that 
autophagy is negatively regulated by mTORC1, but not by mTORC2. In these studies, 
the RPTOR protein, which is part of mTORC1, interacted with ULK1, whereas 
components from mTORC2 did not interact with ULK1, suggesting the involvement 





Figure 1.3: Schematic depicting the proteins involved in mTOR-dependent as well as mTOR-
independent signalling pathways. mTOR is a well-studied starvation-induced regulator of the 
autophagy pathway that is activated by signals from insulin receptors. These signals activate 
protein kinase B (PKB/Akt), which in turn phosphorylates the TSC1-TSC2 complex. Inhibition 
of the TSC1-TSC2 complex activates mTOR, leading to the inhibition of autophagy. Adapted 
by permission from Macmillan Publishers Ltd: Nature Cell Biology, Fleming A., et al., 
December 16, 2010. 
An in vitro kinase assay performed on a kinase-dead ULK1 mutant (to avoid 
autophosphorylation) from starved cells and mTORC1 from non-starved cells 
(Hosokawa et al., 2009) suggested that ULK1 was phosphorylated when incubated 
with mTOR (Hosokawa et al., 2009). Phosphorylation of Atg13 was also detected, 
showing that mTOR phosphorylates both ULK1 and Atg13. However, Atg13 was still 
phosphorylated when ULK1 was silenced, suggesting that Atg13 could be a direct 
substrate for both mTOR and ULK1 (Hosokawa et al., 2009). Similar studies 
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performed on FIP200 and ULK1 revealed that ULK1 phosphorylates FIP200 in an 
Atg13-dependent manner (Hosokawa et al., 2009, Jung Ch Fau - Jun et al., 2009). 
Under starvation, mTOR dissociates from the ULK1 complex (Hosokawa et al., 
2009), leading to the conclusion that inhibition of mTOR prevents the 
phosphorylation of ULK1 and Atg13, which subsequently causes ULK1 to 
phosphorylate FIP200 (Jung Ch Fau - Jun et al., 2009). 
In the mTOR-dependent pathway, energy depletion or nutrient stress activates 
AMP-activated protein kinase, which in turn inactivates mTORC1 and negatively 
regulates autophagy. Insulin and other growth factor signals also inactivate mTORC1 
(Metcalf et al., 2012). In contrast, the mTOR-independent signalling pathways are 
regulated by calcium, cyclic AMP, calpains and inositol triphosphate receptor 
(Metcalf et al., 2012). 
1.5 Selective autophagy 
Autophagy was originally considered a non-selective pathway for bulk 
degradation of protein. However, recent evidence shows that it can selectively bind to 
a cargo and degrade it (Johansen & Lamark, 2011). Selective autophagy was first 
identified in yeast, which use the cytoplasm-to-vacuole pathway (Cvt) to selectively 
degrade aminopeptidase (Ape1) and α-mannosidase (Ams1) (Harding et al., 1995, 
Hutchins & Klionsky, 2001). After recognition of the cargo by a receptor, adaptor 
proteins link the cargo to the main autophagic machinery for degradation (Johansen & 
Lamark, 2011). Different cargo-dependent terms for autophagy are described in Table 
1.1, and are shown in Figure 1.4. The ubiquitin-binding protein p62 is a well-studied 
selective autophagy receptor that binds to ubiquitinated protein aggregates, bacteria, 
peroxisomes and post-mitotic mid-body ring structures and links them to the 
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autophagy machinery (Ichimura, Kumanomidou, et al., 2008). Other examples of 
selective autophagy receptors include NBR1 (Kirkin et al., 2009), NDP52 (Thurston 
et al., 2009) and Nix (Novak et al., 2010). These receptors have a cargo-recognition 
domain containing a specific motif, called the LC3 interacting region (LIR), which is 
recognised by the mammalian Atg8 protein family (LC3A, LC3B, LC3C, 
GABARAP, GABARAPL1, GABARAPL2) (Kirkin et al., 2009, Novak et al., 2010, 
Thurston et al., 2009). The LIR interaction is discussed in Section 1.6.1. 
Table 1.1: Types of selective autophagy and their definitions.  
Type of selective Autophagy Definition 
Aggrephagy Selective autophagic sequestration of protein 
aggregates. 
Crinophagy Direct fusion of secretory vesicles with 
lysosomes. 
Cytoplasm to vacuole targeting (Cvt) A biosynthetic pathway in yeast that 
transports resident hydrolases to the vacuole 
(the yeast lysosome) through a selective 
autophagy-related process. 
Mitophagy Selective autophagic sequestration and 
degradation of mitochondria. 
Pexophagy Selective autophagy involving the 
sequestration and degradation of 
peroxisomes; can occur by a micro- or 
macropexophagic process. 
Piecemeal microautophagy of the nucleus Intrusion of portions of the nucleus into the 
vacuole, followed by scission and 
degradation. 
Reticulophagy Selective autophagic sequestration and 
degradation of endoplasmic reticulum. 
Vacuole import and degradation Selective uptake of cytosolic fructose-1,6-
bisphosphatase, and possibly other proteins, 
within 30-nm single membrane vesicles, 
followed by fusion with the vacuole and 
degradation. 
Xenophagy Selective degradation of microbes (e.g., 
bacteria, fungi, parasites and/or viruses) 





Figure 1.4: Figure depicting the various selective autophagy pathways. All of the autophagy 
pathways shown result in fusion with the lysosome, which degrades the cargo and unwanted 
cytosolic material carried by the vesicles.  
 
1.6 Atg8 family proteins 
Atg8 is a ubiquitin-like protein that was first identified in yeast and is required 
for autophagosome formation (Nakatogawa et al., 2007). Conjugation of Atg8 with 
phosphatidylethanolamine (PE) is an important event in autophagosome formation 
(Kabeya et al., 2000). Atg4, a cysteine protease, processes Atg8 by removing the C-
terminal residue, leaving a glycine at the newly formed C-terminus (Kabeya et al., 
2000, Kabeya et al., 2004, Tanida et al., 2004). Atg7 and Atg3, which are similar to 
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E1-like activating and E2-like conjugating enzymes, respectively, conjugate the C-
terminus of Atg8 to PE (Kabeya et al., 2000, Kabeya et al., 2004). PE-conjugated 
Atg8 localises to the phagophore assembly site and helps in autophagosome formation 
(Nakatogawa et al., 2007). It also controls the size of the autophagosome and the level 
of autophagy in cells (Mizushima et al., 2011, Xie et al., 2008).  
 
 
Figure 1.5: Various steps involved in the conjugation of phosphatidylethanolamine (PE) to 
LC3-I. First, the C-terminal of LC3 is cleaved by Atg4 to form LC3-I, with an exposed C-
terminal glycine. Next, Atg7 and Atg3, which are similar to E1 and E2 ligase, conjugate the 
PE to LC3-II. 
 
Microtubule-associated protein I light chain 3 (LC3) was identified as a 
mammalian homologue of Atg8, with 28% identity shared between the two proteins 
(Mann & Hammarback, 1994). At least eight Atg8 homologues have been identified 
in mammals (He et al., 2003, Igloi, 2001), and can be divided into two subgroups 
based on sequence homology: the LC3 isoform subgroup, consisting of LC3A, LC3B 
and LC3C, and the GABARAP isoform subgroup, consisting of GABARAP, 
GABARAPL1, GABARAPL2 and GABARAPL3 (He et al., 2003, Igloi, 2001). The 
LC3 isoforms exist as LC3-I (found in cytosol) and LC3-II (bound to the 
autophagosome membrane) (Sou et al., 2006). Similar to yeast Atg8, cleavage of LC3 
isoforms at the C-terminus forms LC3-I, which also has a glycine at the newly formed 
C-terminus (Figure 1.5). Mammalian Atg7 (E1-like enzyme) forms a thioester bond 
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between its activated cysteine residue and the C-terminal glycine of LC3-I, which is 
then transferred to mammalian Atg3 (E2-like ligase) (Figure 1.5). Mammalian Atg3 
recognises PE and conjugates it to LC3-I, forming LC3-II (LC3-PE) (Figure 1.5) 
(Kabeya et al., 2000, Sou et al., 2006). Because there are several orthologues of Atg8 




Figure 1.6: Various functions of the LC3 and GABARAP subfamilies of mammalian Atg8 
orthologues. The LC3 family is involved at the beginning of autophagosome formation, 
whereas the GABARAP family act at the autophagosome closure step. © 2013 Weiergräber 
OH, Mohrlüder J, Willbold D. under CC BY 3.0 license. Available from: 
http://dx.doi.org/10.5772/55647. 
Studies by Weidberg et al. (2010) suggest that both the LC3 and GABARAP 
subfamilies promote autophagosome biogenesis, but that they act at different stages of 
the process. The LC3 subfamily is more involved at the beginning of autophagosome 
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formation, whereas the GABARAP subfamily is involved during the closure step of 
autophagosome formation (Weidberg et al., 2010). 
 
1.6.1 LIR interaction 
Atg8 family proteins are the adaptors that link the cargo-recognizing receptors 
to the core autophagy machinery (Ichimura, Kumanomidou, et al., 2008, Pankiv et al., 
2007). In addition to this role, LC3 and GABARAP family proteins also act as 
scaffolds for the ULK1 complex (Figure 1.6) (Alemu et al., 2012). This requires the 
interaction of ATG proteins with LC3s and GABARAPs through the specific LIR 
motif (Alemu et al., 2012, Pankiv et al., 2007). A common core sequence of 
[W/F/Y]x1x2[L/I/V] (where x = any amino acid) in the LIR motif was identified from 
crystal structures of cargo receptors in complex with Atg8 family protein, and by 
deletion and point mutation analysis of p62 and Atg19 (an adaptor in the Cvt 
pathway) (Ichimura, Kumanomidou, et al., 2008, Kirkin et al., 2009, Noda et al., 
2008, Novak et al., 2010, Pankiv et al., 2007, Rogov et al., 2013, Suzuki et al., 2014, 
Thurston et al., 2009, Lystad et al., 2014). Various LIR-containing proteins and their 
LIR motifs are shown in Table 1.2. 
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Figure 1.7: LC3B crystal structure in surface representation bound to the p62 LIR peptide. 
The hydrophobic pockets HP1 and HP2 are shown as yellow surfaces, and the LIR amino 
acids that interact with these binding pockets are shown as yellow sticks. The acidic residues 
(red) in the LIR peptide interact with a basic (blue) region of LC3B.  
The LIR motif consists of a core of hydrophobic residues in which the N-
terminal residue is usually aromatic (Tyr, Phe or Trp) (Alemu et al., 2012). 
Mutational studies on these core aromatic residues showed that Trp had higher 
binding affinity than Phe and Tyr (Rozenknop et al., 2011). The N-terminal aromatic 
residue sits into hydrophobic pocket 1 (HP1) of the LIR docking site in Atg8 proteins 
(Ichimura, Kumanomidou, et al., 2008, Pankiv et al., 2007). The C-terminal 
hydrophobic residue (leucine, isoleucine or valine) binds to hydrophobic pocket 2 
(HP2) (Figure 1.7) (Ichimura, Kumanomidou, et al., 2008, Pankiv et al., 2007). LIRs 
containing phenylalanine display a preference for specific amino acid residues at the 
 24 
“x1” position (Noda et al., 2008, Ichimura, Kominami, et al., 2008), with mutational 
studies showing that only valine, cysteine, isoleucine and glutamic acid are acceptable 
at this position (Alemu et al., 2012).  
Some LIRs are specific to particular Atg8 family members. For example, the 
NDP52 LIR is specific to LC3C (von Muhlinen et al., 2012a). This LIR does not have 
an N-terminal aromatic residue, which means it is unable to bind to other Atg8 
proteins (von Muhlinen et al., 2012a). However, a structural rearrangement of the LIR 
creates an interaction with LC3C sequence-specific residues (von Muhlinen et al., 
2012b). Acidic residues surround the LIR motif and play an important role in forming 
polar interactions at the LIR docking site, which was verified by alanine screening 

















Table 1.2: Different LIR motif-containing binding partners of mammalian Atg8 family proteins. 
Protein LIR motif Pos. 
ULK1 SCDTDDFVMVPA 357 
ULK2 SCDTDDFVLVPH 353 
DmATG1B HEDSDDFVLVPK 391 
ScAtg1 RSFEREYVVVEK 391 
ATG13 GNTHDDFVMIDF 429 
FIP200 DAHTFDFETIPH 702 
p62 SGGDDDWTHLSS 338 
NBR1 SASSEDYIIILP 732 
AtNBR1 LCGVSEWDPILE 661 
ATG4B DAATLTYDTLRF 8 
TP53INP1 EKEDDEWILVDF 31 
TP53INP2/DOR EDEVDGWLIIDL 36 
FYCO1 PPDDAVFDIITD 1280 
Dv12 EVRDRMWLKITI 444 
c-Cb1 ASSSFGWLSLDG 802 
NIX AGLNSSWVELPM 36 
FUNDC1 ESDDDSYEVLDL 18 
Calreticulin GSLEDDWDFLPP 183 
Clathrin HC VGYTPDWIFLLR 513 
OATL1/TBC1D25 SPLLEDWDIISP 136 
TBC1D5 LIR2 SSKDSGFTIVSP 788 
Optineurin GSSEDSFVEIRM 178 
Stbd1 RVDHEEWEMVPR 203 
ScAtg3 LDGVGDWEDLQD 270 
ScAtg19 NEKALTWEEL 412 




1.7 Aims of this project 
The aim of this thesis was to study the interactions between the proteins 
involved in macroautophagy. These interactions can be broadly classified into LIR-
dependent and LIR-independent interactions (Behrends et al., 2010). The interaction 
between FIP200 and Atg13, which are components of the ULK1 initiation complex, 
was probed as an example of LIR-independent interactions. As mentioned in Section 
1.3.3, the region of Atg13 (C-terminal 384–517) that interacts with FIP200 is known, 
whereas the Atg13-binding region of FIP200 is unknown. To map the Atg13-binding 
region on FIP200, the full-length FIP200 gene was divided into six smaller constructs, 
and pull-down assays were performed to identify the FIP200 construct that binds to 
the C-terminal region of Atg13.   
To study LIR-dependent interactions, two LIR motifs were chosen: pleckstrin 
homology domain-containing protein family member 1 (PLEKHM1) LIR and ULK1 
LIR. As mentioned in Section 1.6, there are six mammalian Atg8 homologues, as 
compared to one Atg8 protein in yeast. Unpublished data from our collaborators 
demonstrated that all six members of the mammalian Atg8 family have different 
binding affinities towards LIR peptides, with GABARAP family proteins 
demonstrating significantly higher affinity than LC3 family proteins. In this thesis, 
determination of the crystal structures of all six human Atg8 proteins in complex with 
the PLEKHM1 LIR was attempted to gain insight into the reasons for the different 
binding affinities. 
To study the differences in the mechanism by which LC3 and GABARAP 
family members interact with LIRs, the interaction of the ULK1-LIR peptide with 
LC3A and GABARAP was probed using surface plasmon resonance (SPR), X-ray 
crystallography and molecular dynamics simulations.  
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Crystal structures of LC3s with Atg13 LIRs demonstrated Lys49 in LC3s 
undergoes structural rearrangement upon LIR binding and has a significant biological 
function. Mutating Lys49 to Ala reduces autophagosome formation (Suzuki et al., 
2014). In this thesis, the significance of Arg70 and Phe52 in LC3A, and Arg67 and 
Tyr49 in GABARAP were studied using SPR. Overall, this thesis aims to shed light 





















Chapter 2.  EXPERIMENTAL 
2.1 Materials and equipment 
2.1.1 Reagents 
Unless otherwise stated, chemicals were purchased from Sigma-Aldrich 
Chemicals Ltd. (St Louis, MO, USA). Media for growing bacterial cultures were 
purchased from Life Technologies Ltd. (Christchurch, New Zealand). General 
reagents used are summarised in Table 2.1. Solutions were prepared using purified 
water from a MilliQ (MQ) system (Millipore, Billerica, MA, USA). Sodium dodecyl 
sulphate polyacrylamide gel electrophoresis (SDS-PAGE) gels and protein ladders 
were purchased from Life Technologies Ltd. Column chromatography media were 
purchased from GE Healthcare Life Sciences (Little Chalfont, UK). Centrifugation 
was performed using Eppendorf 5810R (fixed-angle rotor F-34-6-38; Hamburg, 
Germany) and Sorvall RC 6 plus (rotor F10S6×500Y; ThermoFisher Scientific, 









Table 2.1: Summary of general reagents used in this work 
Item Supplier 
Acetic acid, glacial Ajax Finechem 
Agar (bacteriological) Life Technologies 
Ampicillin Life Technologies 
Ammonium sulphate Astral 
Benchmark protein ladder Life Technologies 
Bromophenol blue Progen 
Calcium chloride BDH 
Chloramphenicol BDH 
Coomassie brilliant blue BDH 
Dimethylformamide Astral 
Dithiothreitol BDH 






Hydrochloric acid Ajax Finechem 
Imidazole AppliChem 
Isopropyl-β-D-thiogalactopyranoside (IPTG) Astral 
Lactose Merck 
Lysozyme Astral 
Magnesium sulphate AppliChem 
Potassium chloride BDH 
Potassium phosphate Astral 
Protease inhibitor cocktail Sigma-Aldrich 
RNase A Astral 
Sodium acetate Ajax Finechem 
Sodium chloride Ajax Finechem 
Sodium dodecyl sulphate AppliChem 
Sodium hydroxide pellets BDH 





Yeast extract Life Technologies 
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2.1.2 Growth media and buffers 
2.1.2.1      Luria-Bertani (LB) medium  
Bacto-tryptone (10 g), yeast extract (5 g) and NaCl (10 g) were added 
to 1 L of MQ water and sterilised by autoclaving. LB plates were prepared 
by including 15 g/L agar prior to autoclaving. 
2.1.2.2      SOC medium 
Bacto-tryptone (20 g), yeast extract (5 g), NaCl (0.58 g), KCl (0.18 
g), MgCl2 (0.95 g) and MgSO4 (1.20 g) were added to 1 L of MQ water and 
sterilised by autoclaving. Filter-sterilised glucose (20% w/v) was then added. 
2.1.2.3      LB agar plate preparation 
LB agar plates were prepared by adding 1.5% w/v agar to LB media (Section 
2.1.2.1) prior to autoclaving. After LB agar had cooled, but was still in the molten 
state, antibiotics were added and the medium was poured into plates, which were then 
allowed to cool. 
2.1.2.4      Lysis buffer 
A buffer with final concentrations of 50 mM Tris-HCl (pH 9.0), 250 mM 
NaCl and 10 mM imidazole was prepared in MQ water. 
2.1.2.5      Phosphate buffered saline (PBS) 
Five PBS tablets (Sigma-Aldrich) were dissolved in 1 L of MQ water to give a 
buffer containing 0.01 M phosphate buffer, 2.7 mM KCl, and 137 mM NaCl. The pH 
was altered to either 7.2 or 7.4, as required. The buffer was filtered using a 0.4-µM 
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filter and stored at 4°C. 
2.1.2.6      Elution buffer 
A buffer with final concentrations of 50 mM Tris-HCl (pH 8.0), 250 mM 
NaCl and 500 mM imidazole was prepared in MQ water.  
2.1.2.7      Size exclusion buffer 
A buffer with final concentrations of 20 mM Tris-HCl (pH 8.0) and 100 mM 
NaCl was prepared using MQ water. 
2.1.3 Expression hosts and plasmid 
The bacterial strains and mammalian cells used in this work are listed in Table 
2.2.  
Table 2.2: Summary of bacterial strains and mammalian cells used in this work 
Escherichia coli strains Use Source 
BL21 (DE3) expression host Life Technologies 
Rosetta (DE3) expression host Life Technologies 
BL21 (DE3) pLysS expression host Life Technologies 
DH5α plasmid isolation Life Technologies 
XL1-Blue plasmid isolation Life Technologies 
Mammalian cells Use Source 
FreeStyle 293-F Cells expression host Life Technologies 
 
Antibiotics used in the media were filter-sterilised and stored as 1000× stock 
solutions at −20°C (Table 2.3). The final working concentrations are those used to 





Table 2.3: Antibiotic concentrations. 
Antibiotic Stock (mg/mL) Working (µg/mL) 
Ampicillin 100 100 
Chloramphenicol 30 30 
Kanamycin 50 50 
 
Sequences encoding the LC3 [LC3A (accession: NP_115903), LC3B 
(accession: NP_073729), and LC3C (accession: NP_001004343)] and GABARAP 
[GABARAP (accession: CAG33324), GABARAPL1 (accession: CAG38511), and 
GABARAPL2 (accession: CAG47013)] family proteins were cloned into vectors 
pET30delSE and pGEX-4T-1 (GE Healthcare Life Sciences). All the amino acids 
mentioned in this thesis were numbered according to the numbering scheme followed 
in National Centre for Biotechnology Information (NCBI) database. The mutants 
LC3A-R70L, LC3A-F52Y, GABARAP-R67L and GABARAP-Y49F were cloned 
into pET30delSE. Chimeric constructs of the PLEKHM1-LIR fused to the N-terminus 
of LC3A, GABARAP and GABARAPL1, and the ULK1-LIR fused to the N-terminus 
of GABARAP, were cloned into pET30delSE. The Atg13 and ULK1 constructs were 
cloned into pGEX-4T-1. FIP200 constructs were cloned into pCOLD TF (Clontech, 
Mountain View, CA, USA). The full-length genes of GABARAP, GABARAPL1 and 
GABARAPL2 were kindly provided by Prof. Ivan Dikic, Goethe-University, 
Frankfurt, Germany. Dr Hironori Suzuki, a previous post-doc in our lab, kindly 
provided all the other full-length genes used in this work. A summary of all the 





Table 2.4: Summary of all the proteins used in this work 
Protein Number of amino 
acids 
ATG13 (Full length) 517 
ATG13 380–517 137 
FIP200 2–265 (P1) 263 
FIP200 266–531 (P2) 265 
FIP200 532–796 (P3) 264 
FIP200 797–1061 (P4) 264 
FIP200 1062–1326 (P5) 264 
FIP200 1327–1591 (P6) 264 
LC3A 2–121 119 
LC3B 2–124 122 
LC3C 8–125 117 
GABARAP 2–117 115 
GABARAPL1 2–117 115 






PLEKHM1LIR-LC3A  125 
PLEKHM1LIR-GABARAP 123 
PLEKHM1LIR-GABARAPL1 123 
2.1.4 Chromatography equipment, columns and media 
Chromatography was performed on an ӒKTApurifier system (GE Healthcare). 
Hi-Trap chelating columns (1 mL, GE Healthcare) and HisTrap columns (1 mL, GE 
Healthcare) were used for immobilised metal affinity chromatography (IMAC), 
precharged with different metal ions (Section 2.5.2). Superdex 200 GL 10/300 (GE 
Healthcare) columns (24 mL) and HiLoad 16/600 Superdex 200 pg (GE Healthcare) 
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columns (120 mL) were employed for analytical and preparative size exclusion 
chromatography (SEC), respectively. 
2.2 Molecular biology 
2.2.1 Isolation of plasmids 
Using aseptic technique, a single colony of transformed DH5α cells was 
picked from a transformation plate using an autoclaved pipette tip, and then 
transferred to 10 mL of sterile LB medium containing the appropriate antibiotic for 
plasmid selection. Cells were cultured overnight at 37°C with shaking at 180 rpm in a 
Minitron incubator (Infors HT, Basel, Switzerland). Cells from a 5-mL aliquot of 
overnight culture were then harvested by centrifugation at 4°C for 5 min at 10,000 
rpm. The plasmid was extracted from the cells and purified using a Purelink® Quick 
Plasmid Miniprep Kit (Invitrogen™ by Life Technologies™, Carlsbad, CA, USA) 
according to the manufacturer’s instructions. Plasmid DNA was eluted in 50 µL of 
Tris-EDTA (TE) buffer (supplied with kit), and the concentration of plasmid was 
checked using a NanoDrop ND-1000 UV-VIS spectrophotometer (ThermoFisher 
Scientific) at 260 nm. All purified plasmids were stored at −20°C. 
2.2.2 Cloning 
2.2.2.1       Polymerase chain reaction (PCR) 
DNA amplification was carried out using KOD Hot Start DNA Polymerase® 
(Novagen® by Merck Millipore, Billerica, MA, USA). A 10× buffer for KOD Hot 
Start DNA Polymerase, 2 mM dNTPs and 25 mM MgSO4 were provided in the KOD 
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Hot Start DNA Polymerase® kit. PCR reactions were set up in PCR tubes according 
to Table 2.5.  
Table 2.5: PCR reaction set up 
PCR components Volume 
DNA template 1 µL 
10× PCR buffer 2.5 µL 
MgSO4 1.5 µL 
dNTPs 2.5 µL 
Forward primer 0.75 µL 
Reverse primer 0.75 µL 
KOD Hot Start DNA Polymerase® 0.5 µL 
Autoclaved MQ water 15.5 µL 
Total volume 25 µL 
 
PCR assays were performed using a MultiGene™ PCR Thermal Cycler 
(LabNet International Inc., Edison, NJ, USA), using the cycling parameters in Table 
2.6. 
Table 2.6: PCR cycling parameters. 
STEP TIME TEMPERATURE CYCLES 
Initial denaturation  2 min 94 °C 1 
Denaturation 1 min 94 °C  
Annealing 1 min 53 °C 25 
Extension 1.5 min 72 °C  
Final extension 7 min 72 °C  1 
 
A final extension time of 7 min at 72°C was included to ensure all PCR 
products were full-length and 3′ adenylated (required for TA cloning). Following the 
final cycle of PCR amplification, the reaction was maintained at 4°C. PCR 
amplification products were analysed by DNA electrophoresis by loading 5 µL of 
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each PCR reaction with DNA loading dye into each well of a 1% w/v agarose gel 
(Section 2.2.3). 
2.2.2.2      Sequence insertion for chimeric constructs 
Chimeric constructs were prepared by fusing a sequence encoding a peptide to 
the N-terminal of the gene of interest in the expression vector. The oligonucleotide 
encoding the peptide region (ULK1 LIR or PLEKHM1 LIR) with restriction sites at 
each end was annealed with its complementary sequence using a MultiGene™ PCR 
Thermal Cycler. The oligonucleotides were dissolved in autoclaved MQ water to 
obtain 100 µM stock solutions of each. The reaction mix was prepared in a PCR tube 
by adding 1 µL of each oligonucleotide, 1 µL of 5 M NaCl and 17 µL MQ water. 
Thermal cycling parameters are provided in Table 2.7. 













Following restriction enzyme digestion (Section 2.2.4) of the annealed PCR 
product, it was ligated (Section 2.2.4) into the target vector used for preparing the 
chimeric construct. The presence of insert was verified by colony PCR (Section 
2.3.2.4) and by DNA sequencing (Section 2.2.6).  
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2.2.2.3       Site-directed mutagenesis 
An inverse PCR technique was used to introduce site-directed point mutations. 
A forward primer was designed such that the 5′ end of the primer encoded the desired 
mutant amino acid, followed by 20–25 bp corresponding to the template sequence. 
The reverse primer contained 20–25 bp of template sequence, with the 3′-most three 
base pairs corresponding to the desired mutant amino acid sequence. After designing 
the primers, the PCR assay was carried out according to Table 2.8. 
Table 2.8: Mutagenesis PCR cycling parameters. 
TEMPRATURE TIME CYCLE 
98°C 2 min  
98°C 15 s  
72°C 1 kb/min 18 
72°C 7 min  
4°C Storage  
 
Following PCR, 2.5 µL of PCR product were used for ligation. Because the 
PCR produced blunt ends, 0.5 µL of T4 DNA kinase was added to the ligation 
mixture and incubated at 37°C for 1 h. The plasmid was isolated and the sequence 
containing the mutation was verified by sequencing. 
2.2.2.4       Colony PCR 
Colony PCR of Escherichia coli DH5α colonies produced as a result of 
ligation and transformation was used to check for the presence and correct size of the 
insert within the plasmid of interest. Using aseptic technique, each colony was picked 
from an LB agar plate using an autoclaved toothpick and resuspended in 20 µL of 
sterile MQ water. Up to 10 colonies per plate were randomly picked and screened for 
the correct insert. PCR amplification was performed using GoTaq® Green Master 
Mix (Promega Corporation, Madison, WI, USA) in reactions set up according to 
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Table 2.9. 
Table 2.9: Colony PCR reaction set up. 
PCR components Volume 
Resuspended colony 2 µL 
Forward primer 0.5 µL 
Reverse primer 0.5 µL 
GoTaq® Green Master Mix 7.5 µL 
Autoclaved MQ water 4.5 µL 
Total Volume 15 µL 
 
PCR assays were carried out using a MultiGene™ PCR Thermal Cycler, 
according to the cycling parameters in Table 2.10. 
Table 2.10: Colony PCR reaction cycling parameters. 
STEP TIME TEMPERATURE CYCLES 
Initial denaturation  3 min 95°C 1 
Denaturation 45 s 95°C  
Annealing 15 s 53°C 30 
Extension 1.5 min 72°C  
Final extension 5 min 72°C  1 
 
Following the final cycle of PCR amplification, the reaction was maintained at 
4°C. PCR amplification products were analysed by DNA electrophoresis by loading 
the entire 15 µL colony PCR reaction mixture into wells of a 1% w/v agarose gel 
(Section 2.2.3). 
The remaining 18 µL of each resuspended colony were stored at 4°C. Colonies 
containing a plasmid with the correct sized DNA insert were added to 10 mL of sterile 
LB medium containing the appropriate antibiotic. Cells were cultured overnight at 
37°C, with shaking at 180 rpm, in a Minitron incubator prior to plasmid purification 
(Section 2.2.1). 
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2.2.3 Agarose gel analysis 
Agarose gels were prepared by adding 0.5 g of agarose to 50 mL of 1× Tris 
acetate EDTA (TAE) buffer (see recipe in Appendix), and microwaving the solution 
for approximately 2 min until the agarose was completely dissolved. SYBR® Safe 
DNA Gel Stain (3 µL; Invitrogen™) was added to the dissolved agarose solution and 
swirled to mix, to allow DNA visualisation following electrophoresis. The 1% 
agarose/TAE solution was then poured into a gel casting box, and a comb was 
inserted to form wells. The gel was allowed to set at room temperature. 
Once set, the agarose gel was removed from the gel casting box and placed in 
a Mini Gel Unit (Hoefer Inc., San Francisco, CA, USA), and 1× TAE buffer was 
added until the gel was covered. DNA loading dye was added to a final concentration 
of 1× (samples containing GoTaq® Green Master Mix (Promega Corporation) 
required no loading dye) and, once mixed, were loaded into wells. HyperLadder™ 1 
kb (3 µL; Bioline USA Inc., Taunton, MA, USA) was loaded into one of the wells as 
a molecular weight marker. DNA gels were run for 30 min at 160 V using a Bio-Rad 
PowerPac Basic (Bio-Rad Laboratories, Hercules, CA, USA). 
Following electrophoresis, DNA was visualised using a Chemi Genius 2 Bio 
Imaging System and GeneSnap software (SynGene, Cambridge, UK) using 
transilluminator darkroom lighting and the EtBr/UV filter. 
2.2.4 Restriction and ligation 
All of the restriction enzymes used in this thesis work were High-Fidelity® 
restriction enzymes from New England Biolabs (Ipswich, MA, USA). Reactions were 




Table 2.11: Restriction reaction composition. 
RESTRICTION COMPONENTS VOLUME 
Plasmid 5 µL 
Restriction enzyme I 1 µL 
Restriction enzyme II 1 µL 
CutSmart™ Buffer 2 µL 
Autoclaved MQ water  11 µL 
Total 20 µL 
 
Reaction mixtures were incubated for 1 h at 37°C, and the restriction enzyme 
was deactivated either by heating at 65°C or using a PCR product clean up kit 
(Qiagen, Hilden, Germany).  
Ligations were performed using DNA Ligation Kit Mighty Mix (Takara 
Clontech Laboratories, Mountain View, CA, USA). Reactions were set up as shown 
in Table 2.12. 
Table 2.12: Ligation reaction composition. 
LIGATION COMPONENTS VOLUME 
Vector 1 µL 
Insert 1.5 µL 
Ligase 2.5 µL 
Total 5 µL 
 
The reaction mixture was incubated for 15–20 min at room temperature, and 
then the entire mixture was transformed into chemically competent cells (Section 
2.2.5). 
2.2.5 Competent cell preparation 
A 10-mL starter culture (SOC medium) was grown overnight at 37°C with 
shaking at 180 rpm. This starter culture was used to inoculate 300 mL of LB medium 
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without antibiotics. The culture was incubated at 37°C, with shaking at 180 rpm, until 
the optical density at 600 nm (OD600) reached 0.6. The cells were centrifuged at 6000 
rpm for 10 min at 4°C, and the supernatant was discarded. The cells were resuspended 
in 30 mL (1/10 of the culture volume) of ice-cold 0.1 M CaCl2 and incubated on ice 
for 4 h. The CaCl2 was removed by centrifuging the cell suspension at 6000 rpm for 
10 min at 4°C and discarding the supernatant. The cells were again resuspended in 7.5 
mL (1/40 of culture volume) of 0.085 M CaCl2/15% glycerol solution. Aliquots of 50 
µL were prepared and were either used immediately or snap frozen in liquid nitrogen 
and stored at −80°C. 
2.2.6 DNA sequencing 
DNA sequencing was performed by Macrogen (Seoul, Korea) using purified 
plasmid DNA samples and sequencing primers. 
2.3 Protein expression 
2.3.1 Transformation of plasmid 
Vectors containing the autophagy-related genes were transformed into 
competent cells (Section 2.2.5) using the heat shock technique. Plasmid DNA (2 µL 
of 100 ng/µL stock) was added to a thawed 50-µL aliquot of competent cells and 
incubated on ice for 30 min. The cells were heat shocked in a digital heat block at 
42°C for 35 s, after which they were immediately transferred to ice. SOC medium 
(250 µL) was added, and the mixture was incubated at 37°C for 60 min with shaking 
at 140 rpm. A 50-µL aliquot of cells was spread on a pre-warmed LB agar plate 
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containing appropriate antibiotics and incubated at 37°C for 12–16 h. Resulting 
colonies were used to prepare glycerol stocks or for subsequent plasmid preparation.  
2.3.2 Small-scale expression 
Small-scale expression trials were performed to determine the optimum 
incubation time and temperature for protein expression. Two methods of induction 
were trialled: isopropyl β-D-1-thiogalactopyranoside (IPTG) and auto-induction 
(Baneyx, 1999). 
2.3.2.1 Bacterial expression 
 
2.3.2.1.1 IPTG-induced protein expression  
Colonies from LB agar plates were used to inoculate LB medium (10 mL) 
containing appropriate antibiotics. Suspension cultures were grown in centrifuge 
tubes (50 mL) to an OD600 of 0.4–0.6 before IPTG was added (final concentration 0.2 
mM or 1 mM). To assess the effect of temperature on protein expression, the cultures 
were incubated at either 26°C or 37°C, with shaking at 180 rpm. Samples (500 µL) 
were taken at various time points, centrifuged (12,000 rpm, 5 min), and the 
supernatant was removed. SDS-PAGE buffer (80 µL) was added to the pellets, which 
were subsequently boiled for 5 min to lyse the cells, and 10 µL were loaded onto an 
SDS-PAGE gel. 
2.3.2.1.2 Protein expression by auto-induction 
Similar to the IPTG induction protocol, colonies from LB agar plates were 
used to inoculate auto-induction medium (10 mL) containing antibiotics, and 
incubated at 26°C and 37°C with shaking at 180 rpm. Samples were collected as 
described above. 
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2.3.2.2 Mammalian expression 
Small-scale mammalian expression trials were performed using the 
FreeStyle™ 293 Expression System (Thermo Fisher Scientific) following the 
manufacturer’s protocol. FreeStyle™ 293-F cells, derived from human embryonic 
kidney (HEK) cells, were thawed in a 37°C water bath and transferred into a 
disposable 125-mL polycarbonate Erlenmeyer shaker flask containing 17 mL of pre-
warmed FreeStyle™ 293 Expression medium. The cells were incubated at 37°C in a 
humidified atmosphere of 8% CO2 in air. The cap of the flask was loosened to allow 
aeration, and the flask was shaken at 125 rpm. The cells were subsequently 
subcultured until transfection. 
Lipid-DNA transfection complexes were prepared by adding 30 µg of plasmid 
DNA to Opti-MEM®I medium in a total volume of 1 mL, and by adding 60 µL of 
293fectin™ transfection reagent to 940 µL of Opti-MEM®I, incubating both 
solutions for 5 min, then mixing them together. The mixture was incubated for 30 min 
at room temperature to allow the formation of DNA-293fectin™ complexes. 
Cells were diluted into a fresh flask with FreeStyle™ 293 Expression medium 
to obtain a suspension containing 3 × 107 cells in a volume of 28 mL. The DNA-
293fectin™ complex was added to the flask to obtain a total volume of 30 mL, with 
approximately 1 × 106 viable cells/mL. The cells were incubated as above until they 
were harvested approximately 48 h post-transfection. Protein expression was checked 
by SDS-PAGE (Section 2.5.3).  
2.3.3 Large-scale expression 
For large-scale production of recombinant proteins, BL21 (DE3) cells 
containing the vector with gene of interest were streaked on LB agar plates containing 
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appropriate antibiotics and incubated overnight at 37°C. A single colony was used to 
inoculate 10 mL of LB broth (with antibiotics) and incubated overnight (37°C, 180 
rpm) as a starter culture. 
The starter culture was used to inoculate 200–400 mL of LB medium in a 2-L 
baffled flask. The culture was incubated at 37°C with shaking at 180 rpm until the 
OD600 reached 0.4–0.6, and then protein expression was induced with 0.2 mM IPTG. 
The culture was then incubated overnight at 26°C with shaking at 180 rpm. Cells 
were harvested by centrifugation at 4000 rpm for 10 min, and then resuspended in 20 
mL of buffer B. The cell suspension was either used to purify the recombinant protein 
or snap frozen in liquid nitrogen and stored at −80°C. 
2.4 Protein purification 
2.4.1 Protein extraction 
2.4.1.1 Sonication 
Sonication uses a small metal probe oscillating at ultrasonic frequency to 
generate localised low pressure and membrane disruption through cavitation. Cells 
were lysed using a Sonicator 3000 (Misonix, Farmingdale, NY, USA) equipped with 
a microprobe (Misonix) for volumes less than 5 mL, and a standard probe for larger 
volumes (30 mL). Cell suspensions were prepared in a 50-mL plastic beaker and 
placed in an ice slurry to prevent excessive heating of the sample. The cells were 
sonicated at 60% amplitude with a pulse interval of 3 s on and 10 s off for 20 min. 
2.4.1.2 High pressure homogenisation 
Cells can be lysed by homogenisation by passing a sample through a needle 
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valve at high pressure, causing cell disruption by shear stresses and decompression as 
cells return to normal atmospheric pressure. Volumes larger than 30 mL were lysed 
by passing the sample through a Microfluidics M-110P cell disruptor (Newton, MA, 
USA) at 17,000 psi and 4°C. The cycle was repeated three times to ensure complete 
lysis.  
The cell debris from the lysed samples was cleared by centrifugation at 15,000 
rpm for 25 min at 4°C. The supernatant, containing the soluble recombinant protein, 
was then purified by chromatography steps, as described in the following sections. 
2.4.2 IMAC for His6-tagged proteins  
IMAC was used to purify His6-tagged proteins. Both Ni-NTA sepharose resins 
(GE Healthcare) and pre-packed columns (Section 2.2.4) were used. The Ni-NTA 
resin was prepared by centrifugation at 600 rpm for 2 min. The storage buffer was 
removed by decanting the supernatant, and the resin was equilibrated by resuspending 
the pelleted resin in lysis buffer. To ensure proper equilibration, this centrifugation 
and resuspension process was repeated three times. The clarified cell lysate (Section 
2.4.1) was filtered through a 0.22-µm syringe filter and mixed with 2 mL of Ni-NTA 
resin for 1 h at 4°C. The slurry was gently transferred to a PD-10 gravity column (GE 
Healthcare), and the unbound lysate was allowed to flow through the column. The 
resin containing bound protein was washed with 10 bed volumes (BV) of lysis buffer 
containing 1% Triton X-100. To remove all the unbound protein from the resin, the 
resin was washed with 10 BV of lysis buffer containing 1 M NaCl. Finally, the resin 
was washed with 20 BV of lysis buffer to remove the high-salt buffer. The resin was 
then resuspended with three BV of elution buffer, and the flow through containing the 
purified protein was collected. To elute protein without the His6-tag, the resin was 
resuspended in 1 BV of lysis buffer, and 50 µL of 1 U/µL thrombin was added. The 
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mixture was incubated overnight at room temperature, then the purified protein 
without a His6-tag was collected. 
For purification using a pre-packed column, the clarified lysate was filtered 
through a 0.22-µm syringe filter and applied to a 1-mL Hi-Trap Chelating column 
pre-equilibrated in buffer B (10 column volumes (CV)) using a Gilson peristaltic 
pump. Where appropriate, a HisTrap column (GE Healthcare) was used with the same 
protocol. The column was washed with 10 CV of lysis buffer to remove any unbound 
protein. Purified protein was eluted with a gradient set to 100% elution buffer on an 
ӒKTApurifier system (GE Healthcare), and the eluted fractions were stored at 4°C or 
snap frozen in liquid nitrogen and stored at −80°C for later use. All flow rates were 
maintained at 1 mL/min. Different transition metals were studied to determine the 
maximum affinity of the proteins for purification. The Hi-Trap Chelating column was 
charged with either 100 mM CoSO4, 100 mM ZnSO4, 100 mM NiSO4 or 100 mM 
CuSO4 for each trial, and the sample fractions were assessed by SDS-PAGE. 
2.4.3 Purification using glutathione Sepharose for glutathione-S-
transferase (GST)-tagged proteins. 
Batch purification was used to purify the GST-tagged proteins. The binding of 
GST-tagged proteins depends on the size, conformation and concentration of the 
protein in the sample being loaded. Binding of GST to glutathione is also flow-
dependent, and lower flow rates often increase binding capacity. Therefore, the 
increased incubation time in a batch purification mode increases the binding of the 
recombinant protein to the matrix for efficient separation from other soluble proteins 
in the cell lysate. 
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Glutathione Sepharose 4B (GE Healthcare) was prepared by centrifugation at 
600 rpm for 2 min, and the storage buffer was removed by decanting the supernatant. 
The resin was equilibrated by resuspension in PBS buffer, then re-pelleting by 
centrifugation, as above, an additional three times. Approximately 2 mL of the 
prepared slurry was incubated with soluble lysate, extracted from 400 mL of bacterial 
culture (Section 2.5.1), for 90 min at room temperature with gentle shaking. The 
slurry was then centrifuged at 600 rpm for 5 min to pellet the resin with bound 
protein. The supernatant was discarded, and the pelleted resin was gently transferred 
to a PD-10 gravity column (GE Healthcare). Unbound protein was removed by 
washing with PBS + 1% Triton X-100 and with PBS + 1 M NaCl (five CV of each). 
The slurry was equilibrated with PBS before adding 80 µL of thrombin (1 U) and 
incubating for 16 h at room temperature. The cleaved protein was eluted in PBS (three 
CV). Generally, the eluted proteins were further purified by preparative SEC (Section 
2.4.4). 
2.4.4 SEC 
SEC was performed as an additional purification step to separate proteins by 
size to remove unwanted proteins that co-eluted with target protein in the initial 
IMAC or GST purification steps. A prepacked 24-mL Superdex 200 gel filtration 
column (GE Healthcare Life Sciences) was connected to an AKTAxpress 
chromatography system (GE Healthcare Life Sciences) and washed with three CV of 
MQ water before being equilibrated with 75 mL of SEC buffer at a flow rate of 0.3 
mL/min. The concentrated protein sample was then loaded onto the column and run at 
a flow rate of 0.25 mL/min at 4°C for a total buffer volume of 30 mL, then 1-mL 
fractions were collected in a 96-well plate. Fractions that corresponded to the A280 
peak on the chromatograph (UniCorn 5.11 Workstation, GE Healthcare Life 
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Sciences) were analysed by SDS-PAGE (Section 2.5.3), and fractions containing pure 
target protein were pooled and concentrated using a Vivaspin® 6 10,000 Da 
molecular weight cut-off (MWCO) polyethersulfone spin concentrator (Sartorius, 
Goettingen, Germany). Pure protein was snap frozen in liquid nitrogen and stored at 
−80°C. 
2.5 Protein analysis 
2.5.1 Protein concentration 
Purified protein concentration was determined by measuring absorption at 280 
nm (A280) on a NanoDrop 2000 spectrophotometer. Extinction coefficients of the 
specific proteins were calculated from their amino acid sequence using the ExPasy 
server (Gasteiger et al., 2005), and were used to determine protein concentration 
using the equation: 
Concentration = (A280/ε280) × l 
Where A280 is the absorption at 280 nm in AU, ε280 is the extinction coefficient at 280 
nm (M-1.cm-1), and l is the path length. 
2.5.2 Buffer exchange 
(i) Buffer exchange by dialysis 
Protein samples were transferred into dialysis tubing (10,000 MWCO), and 
dialysed against the required buffer. Sample to dialysis buffer ratios were typically 
1:2000. Dialysis was performed at 4°C with stirring to increase the rate of exchange. 
Typically, this was repeated to ensure complete exchange. 
(ii) Buffer exchange by chromatography  
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HiTrap Desalting (5 mL) columns (GE Healthcare) were pre-packed with 
Sephadex G-25 Superfine cross-linked dextran. These employ the same principles as 
gel filtration to separate molecules with a mass larger than 1 kDa from those with a 
mass below 5 kDa, thereby separating proteins from buffer salts. The column was 
connected to an ӒKTApurifier system, and equilibrated with three CV of the required 
buffer at 2 mL/min. A maximum of 1 mL of sample was loaded onto the column. 
Protein was eluted at 2 mL/min using the required buffer, 0.5 mL fractions were 
collected and protein elution was monitored at A280. 
(iii) Buffer exchange by dialysis devices  
Slide-A-Lyzer dialysis devices (Thermo Fisher Scientific) with a 7,000 
MWCO were used for faster buffer exchange of smaller volumes of sample (<1 mL). 
Protein sample (100–500 µL) was pipetted into the dialysis cup and partially 
submerged in the appropriate buffer. Dialysis was performed at room temperature or 
4°C, with stirring to increase the rate of exchange. 
2.5.3 SDS-PAGE  
SDS-PAGE is the most common technique to check the purity of protein 
samples. It completely denatures proteins in the presence of SDS, an ionic detergent, 
which breaks hydrogen bonds and coats the entire protein to give it a negative charge. 
This means protein migrates through the gel in a molecular weight-dependent manner. 
In the presence of reducing agents, such as dithiothreitol or β-mercaptopethanol, any 
disulfide bonds are reduced, thus denaturing the protein molecule.  
NuPAGE® 4–12% Bis-Tris gels were run according to the manufacturer’s 
recommendations in a NuPAGE® gel electrophoresis box at room temperature. 
Novex® Sharp protein ladder (3 µL; Life Technologies) was used as a molecular 
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weight marker. Protein samples were mixed with reducing agent and 4× lithium 
dodecyl sulphate (LDS) sample buffer or 2× Tris-Gly sample buffer, depending on 
the nature of the gel being run. Protein samples were typically denatured at 70–90°C 
for 5 min in SDS-PAGE buffer before loading onto the gel. After electrophoresis, gels 
were placed in distilled water and microwaved for 20 s to remove the SDS present in 
the running buffer. They were then placed in Simply Blue stain for 1 h, or until 
protein bands appeared, and subsequently destained in distilled water for 1 h. 
Table 2.13: Solutions used for SDS-PAGE. 
Solution Content 
MES running buffer  50 mM Tris-MES (pH 7.6) 0.1% SDS, 1 mM EDTA.  
LDS loading dye  564 mM Tris base, 424 mM Tris-HCl, 40% glycerol, 8% LDS, 
2.04 mM EDTA, 0.88 mM Coomassie Blue G-250, 0.7 mM 
phenol red (pH 8.5).  
Reducing agent  1 M β-mercaptoethanol.  
Tris-Gly loading dye  126 mM Tris-HCl (pH 6.8), 20% glycerol, 0.005% bromophenol 
blue.  
Simply Blue stain  80 mg/L Coomassie Brilliant Blue in 35 mM HCl.  
2.5.4 Differential scanning fluorimetry (DSF) 
The thermal stability of a protein can be determined using DSF. Pure protein 
samples were incubated with the fluorescent dye SYPRO® Orange (Invitrogen) in 
clear, thin-walled 96-well PCR plates. The samples were then heated using an IQ™ 5 
Real-time PCR Detection System (Bio-Rad), which measures fluorescence. Heating 
of the protein sample unfolds it and subsequently exposes its hydrophobic regions, 
which then bind the fluorescent dye, and this increase in fluorescence is measured as 
the temperature increases. SYPRO® Orange was excited at 490 nm, and its emission 
was measured at 595 nm. A stock solution containing 1 µL of SYPRO® Orange, with 
protein and buffer added up to a final volume of 100 µL, was prepared. Stock solution 
(25 µL) was added to each well, and assays were performed in triplicate. 
Themostability curves were obtained by heating the samples from 20°C to 100°C in 
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0.5°C increments, with a 10-s dwell time at each temperature. Data was processed and 
analysed using IQ™ 5 software (Bio-Rad). 
2.5.5 SEC-multi-angle light scattering  
Static light scattering (SLS) is a technique for determining the absolute 
molecular mass of a protein sample in solution through exposure to a low intensity 
laser. The intensity of the scattered light is measured as a function of angle, and the 
data are analysed to calculate the molecular mass. In addition to its use for quality 
control of proteins, SLS is a precise method for determining the oligomeric state of a 
protein. Because light scattering and concentration are measured for each of the 
eluting fractions, the mass and size can be determined independent of the elution 
position. This is particularly important for novel protein architectures that may elute 
at positions distant from those predicted by the calibration for the SEC column. 









KRI and KLS are instrument calibration constants, LS is the light scattering signal, RI 
is the refractive index signal and dn|dc is the refractive index increment, which is 
defined as 0.186 mL/g for globular proteins (Wen et al., 1996). 
A Superdex 200 GL 10/300 column (GE Healthcare) was connected to a 
Viscotek 302-040 Triple Detector GPC/SEC system (Malvern Instruments Ltd., 
Malvern, UK), operated at 28°C, and equilibrated with appropriate buffer at 0.4 
 52 
mL/min for a minimum of three CV until a stable baseline was observed. Protein 
samples (110 µL) were loaded onto the column. Absolute molecular weight, radius of 
hydration and size distributions were calculated using the refractive index (RI), 
intrinsic viscosity, and right-angle light scattering (RALS) measurements calibrated 
against bovine serum albumin (66.5 kDa; Sigma-Aldrich), which was run at the 
beginning and end of each sample sequence. Analysis was performed using OmniSEC 
software (Malvern Instruments) as per the manufacturer’s instructions. 
2.5.6 Pull-down assay 
Pull-down assays can verify the interaction between two proteins. It is a 
simple affinity purification technique in which a “bait” protein, expressed with a tag, 
is immobilised to beads and incubated with a solution containing the “prey” protein.  
 
Figure 2.1: Graphical representation of the pull-down assay procedure where the bait (blue) 
protein, expressed with a tag and bound to the resin, captures prey (yellow) protein. The 
interaction is verified using SDS-PAGE. 
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In this study, the bait protein was expressed with a GST-tag and was bound to 
glutathione Sepharose 4B resin (GE Healthcare). Glutathione Sepharose 4B resin (20 
µL) was added to a 1.5-mL microcentrifuge tube and washed twice with 500 µL of 
PBS buffer by centrifuging and discarding the supernatant. Prey protein (100 µL) was 
added to the washed glutathione Sepharose 4B resin, and incubated for 1 h at 4°C. 
Following incubation, the beads were washed twice with 500 µL of PBS + 0.1% 
Triton X-100 buffer, then the resin was washed twice with PBS (without Triton X-
100). SDS-PAGE loading dye was added to the resins, and the results were analysed 
on an SDS-PAGE gel. 
2.5.7 X-ray crystallography 
2.5.7.1 Crystallisation 
The PLEKHM1-LC3A, PLEKHM1-GABARAP and PLEKHM1-
GABARAPL1 chimeric proteins were purified and crystallised as chimeric LIR-
fusion proteins, whereas the LC3C8–125 region was co-crystallised with the 
PLEKHM1 LIR peptide (629–PQQEDEWVNVQYPD–642). Initial crystallisation 
trials were performed using the following crystallisation screens: Crystal Screen, 
Crystal Screen Cryo, Index, PEG/Ion (all acquired from Hampton Research, Alisa 
Viejo, CA, USA), JCSG+, Midas, Morpheus, PACT, Clear Screen Strategy I and 
Clear Screen Strategy II(all acquired from Molecular Dimensions, Suffolk, UK). In 
all cases, the drops included 400 nL of protein (concentrations listed below) and 400 
nL of mother liquor. All crystallisation experiments were set up and stored at 4°C. 
PLEKHM1-LC3A (10 mg/mL) crystals were grown in JCSG+ screen 
condition H7 (0.2 M ammonium acetate, 0.1 M Bis-Tris (pH 5.5), 25% w/v 
polyethlene glycol 3,350). Crystals for PLEKHM1-GABARAP (9.1 mg/mL) were 
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grown in PEG/Ion screen condition F5 (4% v/v Tacsimate (pH 8.0), 12% w/v 
polyethylene glycol 3,350). Crystals for the PLEKHM1-GABARAPL1 protein (7.5 
mg/mL) were grown in PEG/Ion screen condition A6 (20% w/v polyethylene glycol 
3,350, 0.2 M NaCl, 8% 2-methyl-2,4-pentanediol (pH 7.2)). The LC3C8–125 protein 
(9.2 mg/mL) was mixed with the PLEKHM1 peptide (2.4 mg/mL) in equal volumes 
and incubated for 3 h at 4°C, prior to setting up the crystallisation trays. Crystals were 
grown in PEG/Ion screen condition D5 (0.2 M potassium phosphate monobasic, 20% 
w/v polyethylene glycol 3,350). The crystals were frozen in liquid N2 prior to data 
collection. 
The ULK1-GABARAP chimeric protein was purified and crystallised as a 
chimeric LIR fusion protein. Initial crystallisation trials were performed using the 
following screens: Crystal Screen, Crystal Screen Cryo, Index and PEG/Ion 
(Hampton Research), JCSG+, Midas, Morpheus, PACT, Clear Screen Strategy 1 and 
Clear Screen Strategy 1 (Molecular Dimensions). The drops included 400 nL of 
protein (concentration listed below) and 400 nL of mother liquor. All crystallisation 
experiments were set up at 4°C and room temperature. The ULK1-GABARAP (10 
mg/mL) crystals were grown in Crystal Screen Cryo Screen condition G6 at room 
temperature (0.08 M HEPES (pH 7.5), 8% w/v polyethylene glycol 6,000, 4% v/v 
(+/−)-2-ethyl-2,4-pentanediol, 20% v/v glycerol). 
2.5.7.2 Data collection and processing 
X-ray diffraction data was collected on the MX2 micro-crystallography 
beamline at the Australian Synchrotron (Melbourne, Australia). The data were 
integrated using XDS (Kabsch, 2010a, b) and scaled using Aimless (Evans & 
Murshudov, 2013). The structures were solved by molecular replacement using 
MOLREP (Vagin & Teplyakov, 1997), and phases for the co-crystal structure were 
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estimated using PHASER (McCoy et al., 2007). The solved structures were refined 
using PHENIX.REFINE (Adams et al., 2010), and model building was performed 
using COOT (Emsley et al., 2010). Images were generated using PyMOL (The 
PyMOL Molecular Graphics System, Version 1.5.0.4 Schrödinger, LLC.). 
2.5.8 Surface plasmon resonance (SPR) 
All SPR experiments were performed on a ProteOn™ XPR36 Protein 
Interaction Array System using ProteOn™ GLC Sensor Chips at 25°C and ProteOn™ 
0.35-mL or 2-mL deep-well 96-well plates (all purchased from Bio-Rad). Following 
optimisation of ligand immobilisation levels, buffer conditions, analyte 
concentrations, injection parameters and regeneration conditions, SPR experiments 
were performed as described below. 
2.5.8.1 Buffer and protein solution preparation 
All buffers and solutions used for SPR were prepared fresh, and then filtered 
using 0.2-µm syringe-driven or vacuum-driven filters, before being sonicated for 20 
min (Digitech Ultrasonic Cleaner, Digitech Systems, Kolkata, India) to degas and 
disperse any remaining particulate in solution. Activation and deactivation solutions 
for amine coupling were supplied as part of the ProteOn™ amine coupling kit (Bio-
Rad). All protein samples were centrifuged at 4°C for 5 min at 12,000 rpm to pellet 
any aggregate that may have been present in the sample, prior to the concentration 
being checked in triplicate as described in Section 2.5.1. PBS with 0.05% Tween-20 
(PBST) was used as the running buffer in all experiments and in the blank buffer 
injections. 
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2.5.8.2 Sensor chip initialisation and pre-conditioning 
Each time a new or used sensor chip was inserted into the SPR machine, a wet 
initialisation step (50% v/v glycerol) was performed. Following several system 
flushes with running buffer, the sensor chip surface of a new chip was conditioned 
prior to any immobilisations with successive 30-µL pulses of 0.25% Tween-20, 50 
mM NaOH and 100 mM HCl for 60 s each at a flow rate of 30 µL/min, first in the 
vertical direction (ligand), followed by the horizontal direction (analyte). Blank buffer 
runs (eight in the analyte direction then eight in the ligand direction) were performed 
to remove all traces of the pre-conditioning solutions and to equilibrate the chip 
surface (100 µL of PBST at a flow rate of 100 µL/min for 60 s). 
2.5.8.3 Interaction of the ULK1 LIR with LC3A and GABARAP wild type 
and mutant proteins 
Two approaches were used to investigate the interaction between LC3A, 
LC3A-R70L, LC3A-F52Y, GABARAP, GABARAP-R67L and GABARAP-Y49F 
with the ULK1 LIR. In the first approach, an anti-GST polyclonal antibody was 
immobilised on the chip surface in all six ligand directions, and the recombinant 
GST-tagged ULK1 LIR protein was allowed to interact with the antibody. The LC3A 
and GABARAP proteins were injected in the analyte direction to measure the 
interaction of the ULK1 LIR with LC3A and GABARAP. 
In the second approach, the ULK1 LIR peptide (KSCDTDDFVMVPAQ) and 
a scrambled ULK1 LIR control peptide (KVSFPQACDMDTVD) were immobilised 
on the surface of a GLC chip (Bio-Rad) in channels L2 and L5 (control), and L3 and 
L6 (ULK1 LIR), by amine coupling (Fischer, 2010). After optimising peptide 
concentrations and activation and deactivation strategies to ensure a meaningful 
response from the interaction, the ligand was immobilised on the chip surface. The 
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LC3A and GABARAP proteins were injected in the analyte direction to measure the 
interaction of the ULK1 LIR with LC3A and GABARAP. 
2.5.8.3.1 Immobilisation  
The carboxymethyl dextran on the sensor chip surface was activated to 
produce reactive succinimide esters on the ligand channels of the sensor chip surface 
by injecting 150 µL of a 1:1 mixture of 0.4 M 1-ethyl-3-(3-
dimethylaminopropyl)carbodiimide and 0.1 M N-hydroxysuccinimide (NHS) at a 
flow rate of 30 µL/min for 300 s. Ligand was then immobilised on each channel by 
injecting 150 µL of 0.75 µg/mL antibody (in 10 mM sodium acetate buffer (pH 4)) for 
300 s at a flow rate of 30 µL/min. Ligand channel 1 (L1, activation and deactivation 
only) was used as a reference channel, and ligand channel 4 (L4, no activation or 
deactivation) was used as a blank channel. The ULK1 LIR peptide was immobilised 
in L3 and L6, while the control peptide was immobilised in L2 and L5. Ligand 
immobilisation was directly followed by deactivation of unreacted succinimide esters 
with 1 M ethanolamine HCl (pH 8) at a flow rate of 30 µL/min for 300 s. 
Following two blank buffer injections, four stabilisation steps were performed 
in the ligand direction to stabilise the ligand surface and remove any weakly bound 
ligand molecules. Two 30-µL pulses of 10 mM sodium acetate (pH 3.0) were 
followed by two 30-µL pulses of 10 mM glycine HCl (pH 2.0), with each 18-s 
injection having a flow rate of 100 µL/min. Multiple blank buffer injections, first in 
the ligand direction and then the analyte direction, were performed until a stable 
baseline was achieved across all channels. 
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2.5.8.3.2 Interaction of LC3A wild type, LC3A-R70L and LC3A-F52Y with 
the ULK1 LIR 
LC3A-wt, LC3A-R70L and LC3A-F52Y were injected in the analyte direction 
at six different concentrations: 25 µM, 12.5 µM, 6.25 µM, 3.125 µM, 1.56 µM and 
0.78 µM. A 275-µL volume of each concentration was injected across the chip at a 
flow rate of 60 µL/min and allowed to associate with the ULK1 LIR, followed by 
dissociation for 600 s and flow stabilisation for 20 s. The ligand surface was then 
regenerated with a 30-µL pulse of glycine HCl (pH 1.0) for 18 s at a flow rate of 100 
µL/min to remove any undissociated analyte. At least four blank buffer injections 
were performed to allow the ligand to recover and re-establish a stable baseline. The 
interaction for each analyte was repeated three times. 
 
2.5.8.3.3 Interaction of GABARAP wildtype, GABARAP-R67L and 
GABARAP-Y49F with the ULK1 LIR 
GABARAP-wt, GABARAP-R67L and GABARAP-Y49F were injected in the 
analyte direction at six different concentrations: 1.56 µM, 0.78 µM, 0.39 µM, 0.195 
µM, 0.097 µM and 0.048 µM. Experimental conditions were as described in Section 
2.5.8.3.2. The data was processed using Scrubber and ClampXP software to obtain the 
kinetics and binding affinity. 
2.5.9 Molecular dynamics simulation 
Molecular dynamics simulations were performed using GROMACS (version 
4.6.3) (Berendsen et al., 1995, Lindahl et al., 2001, Van Der Spoel et al., 2005, Hess 
et al., 2008). Simulations were performed with coordinates extracted from the 
structures of LC3A (PDB: 3WAL), GABARAP (PDB: 1GNU), the Atg13 LIR fused 
to LC3A (PDB: 3WAN) and the ULK1 LIR fused to GABARAP (solved in this 
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study). The Atg13 LIR amino acid sequence (FVMI) was modified to the ULK1 LIR 
sequence (FVMV) using COOT model building software (Emsley et al., 2010). 
Simulations were performed using the workflow below: 
 
The topology file was generated using the pdb2gmx command with the 
coordinate file as the input. The topology file contains information about the atoms, 
such as bond length and bond angles. The force field GROMOS96 54a7 (Schmid et 
al., 2011) was chosen because it is a general-purpose simulation package for 
biomolecules, and the simple point charge water model was selected during the 
generation of the topology file, as recommended by the GROMACS instructions. 
Next, the simulation box was defined using the editconf, genbox and grompp 
commands, where “cubic” was selected as the box type and the molecule was centred 
in the box. The distance between the molecule and the box was assigned as 0.9 nm. 
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The system was set up in a water environment neutralised with 0.15 M NaCl using the 
genion command.  
Addition of solvents and hydrogens causes interference with the structure. 
Therefore, energy minimisation was performed to bring the system to a relaxed state. 
The system was prepared for energy minimisation using grompp, followed by an 
mdrun of 50,000 energy-minimisation steps. Energy minimisation was performed 
until a maximum force of less than 1000 kJ/mol/nm was achieved. A group cut-off of 
1.4 nm was implemented for the van der Waals (vdw) settings. 
Position-restrained molecular dynamics (MD) was performed after energy 
minimisation. During this process, the atom positions are restrained and the solvent is 
allowed to move freely through the structure and create a proper environment such 
that the structure is properly immersed (or soaked) in the water. Position-restrained 
MD was performed for 1,500,000 steps (3 ns) using a group vdw cut-off of 1.4 nm. 
V-rescale thermostat was used to perform the simulation at fixed temperature. 
Finally, the main MD simulations were calculated for 100 ns (50,000,000 
steps) at 300 K using computer clusters. After the simulation, the molecule was 
placed at the centre of the box using the trjconv command. The root mean square 
deviation (RMSD) and the root mean square fluctuation (RMSF) were calculated 
using the trajectory file obtained from the simulation as the input file, with the gmx 
rms and gmx rmsf commands, respectively. The bond distances between the atoms 
over 5000 frames were calculated using Visual Molecular Dynamics (VMD) 
(Humphrey et al., 1996). The frame simulations were visualised using VMD, and 
important frames that displayed interesting interactions were saved as pdb files. 
Images from the frames saved in pdb format were prepared using PyMOL. 
 
 61 
Chapter 3.  CLONING, EXPRESSION, PURIFICATION 
AND INTERACTION STUDIES ON FIP200 AND ATG13 
3.1 Introduction 
The aim of this thesis was to study the interactions between the proteins 
involved in the autophagic pathway. In this chapter, the region of autophagy-related 
protein 13 (Atg13) that interacts with focal adhesion kinase family interacting protein 
of 200 kDa (FIP200) was studied. Atg13 and FIP200 are part of the human autophagy 
initiation complex, called the UNC51-like Kinase 1 (ULK1) complex (Hara et al., 
2008, Hosokawa et al., 2009). During starvation, inhibition of mammalian target of 
rapamycin (mTOR) dephosphorylates ULK1 and Atg13, which activates the ULK1 
kinase activity to phosphorylate FIP200 (Metcalf et al., 2012). FIP200 interacts with 
the C-terminus of Atg13, but the region of FIP200 that interacts with Atg13 is 
unknown (Hosokawa et al., 2009). To identify this, studies of the interaction between 
the C-terminus of Atg13 and fragments of FIP200 were attempted. 
Unlike the yeast initiation complex (the Atg1 complex), the members of the 
ULK1 complex (ULK1, FIP200, Atg13 and Atg101) remain stably associated in both 
the active and inactive states (Hara et al., 2008, Hosokawa et al., 2009). Interestingly, 
Atg13 keeps the entire ULK1 complex stably associated by mediating the interaction 
between ULK1 and FIP200, and also mediates the phosphorylation of FIP200 
(Hosokawa et al., 2009, Jung Ch Fau - Jun et al., 2009, Metcalf et al., 2012). 
Therefore, studying the interaction between FIP200 and Atg13 provides a starting 
point for studying the full ULK1 complex, and is an initial step towards 
understanding the mechanism of ULK1 complex interaction.  
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In addition to their role in the initiation of starvation-induced autophagy, 
FIP200 and Atg13 are functionally important proteins. FIP200 is a multifunctional 
protein that is involved in various cellular activities, such as cell proliferation, cell 
migration, cell size regulation, cell death and tumour suppression (Chano et al., 2002, 
Gan et al., 2005, Gan et al., 2006, Melkoumian et al., 2005). Silencing of either 
FIP200 or Atg13 inhibits autophagosome formation, thereby making these proteins 
important targets for understanding diseases related to autophagy (Hara et al., 2008, 
Hosokawa et al., 2009, Klionsky et al., 2007, Rubinsztein, 2006, Rubinsztein et al., 
2012, Rubinsztein et al., 2011). 
 
Figure 3.1: Schematic representation of the strategy used to study the interaction between 
FIP200 and Atg13. The FIP200 gene was truncated into six fragments (labelled P1–P6 and 
shown in yellow). Each of the six fragments was cloned into the pCold™ TF vector, which 
encodes an N-terminal His6 tag, followed by the sequence of the chaperone trigger factor, in 
front of the gene of interest. The proteins expressed by these six constructs were used as 
“prey” in a pull-down assay. The C-terminal of Atg13 (380–517), shown in blue, was cloned 
into vector pGEX-4T-1 with a GST tag, and the expressed protein was used as “bait” in the 
pull-down assay. 
In this chapter, the FIP200 gene was divided into six equal-sized truncated 
regions to map the Atg13-interacting region in FIP200 (Figure 3.1). This strategy was 
used because of the ease of identifying the binding region from a smaller sequence 
range, and because the relatively large size of the full-length protein (180 kDa) 
reduces the probability of successful expression in bacterial cells. The six FIP200 
constructs were expressed with N-terminal His6-trigger factor (TF) sequences. TF is a 
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ribosome-associated protein chaperone found in prokaryotes that promotes folding of 
newly-expressed polypeptides (source: Takara Bio Inc., Shiga, Japan). The C-terminal 
Atg13 region was expressed with a GST-tag (Figure 1.1). Despite performing a pull-
down assay to identify the FIP200 construct that interacted with the C-terminal 
ATG13 construct, the C-terminal Atg13 construct did not bind any of the six FIP200 
constructs.   
3.2 Results 
3.2.1 Cloning and expression of full-length Atg13  
A high level of expression of correctly folded and stable Atg13 was required 
to study the interaction between Atg13 and FIP200, and to study the crystal structure 
of full-length Atg13. Full-length Atg13 (517 amino acids) is a challenging protein to 
express using a simple expression system like E. coli because it is a complex 
eukaryotic protein, with nine cysteine residues that require chaperones for proper 
folding, and undergoes heavy post-translational modification. Therefore, a 
mammalian expression system was chosen for expression of full-length Atg13. 
The full-length human ATG13 gene was cloned into a pCMV-Fc fusion vector 
to express the ATG13 protein fused to an immunoglobulin Fc domain in Freestyle 
human embryonic kidney 293 (HEK293) cells. PCR amplification of the full-length 
human ATG13 gene generated a single 1557-bp DNA fragment (Figure 3.2A). 
Screening by colony PCR (Figure 3.2B), followed by DNA sequencing of the plasmid 
DNA from the colonies with correct-sized inserts, showed that a fragment with the 





Figure 3.2: A. DNA agarose gel showing the amplified PCR products (gene encoding full-
length ATG13) as distinct bands (marked with white box) that were cut from the gel for 
purification. Migration of a band at approximately 1500 bp suggests that the correct-sized 
fragment was amplified. B. Agarose gel showing colony PCR analysis, confirming that the 
gene encoding full-length ATG13 was successfully ligated into pGEX-4T-1 (observed as a 
band of ~1500–2000 bp). Plasmids from colonies with bands of the correct size were 
sequenced to verify ligation of the correct DNA sequence.  
The expression of full-length ATG13 in HEK293 cells was unsuccessful. The 
pCMV-Fc fusion vector has a secretion signal that allows secretion of the expressed 
protein through endoplasmic reticulum/Golgi system into the culture medium. Human 
ATG13 is an intracellular protein, so there was a risk that the protein would be 
incompatible with the secretion and processing pathways, leading to its degradation. 
Therefore, removing the secretion signal and attempting to express full-length ATG13 
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as an intracellular protein may be successful. However, because of the time 
constraints and the high cost involved, this optimisation could not be performed in the 
current study. 
3.2.2 Cloning, expression and purification of the C-terminal of ATG13 
(380–517) 
DNA encoding the region of ATG13 that binds FIP200 (amino acids 380–517) 
(Hosokawa et al., 2009) was successfully cloned into pGEX-4T-1. PCR amplification 
generated a 411-bp product with BamHI and EcoRI restriction sites on either end. The 




Figure 3.3: A. Agarose gel showing amplified PCR products (region encoding ATG13 
residues 380–517) as distinct bands (marked with white box) that were cut from the gel for 
purification. No amplicon was obtained at the calculated annealing temperature, therefore 
temperature-gradient PCR was performed. Migration of a band at ~400 bp suggested that the 
correct-sized DNA fragment was amplified. B. Agarose gel analysis of colony PCR samples 
suggested that the region encoding ATG13 380–517 was successfully ligated into pGEX-4T-
1, as demonstrated by a band of 400–600 bp (bands marked in white box). Plasmids from 
colonies producing the correct-sized bands were sequenced to verify ligation of the correct 
DNA sequence.  
Colony PCR screening (Figure 3.3B) and subsequent sequencing of plasmids 
confirmed the presence of the correct sequence in the correct frame for expression. 
Therefore, the region of ATG13 that binds FIP200 was successfully cloned into 
vector pGEX-4T-1 for expression and interaction analysis. 
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Rosetta (DE3) cells, which contain the pRARE plasmid to supply tRNAs for 
rare codons, were used to achieve high-level expression of ATG13 amino acids 380–
517. SDS-PAGE analysis of small-scale expression trials with the pGEX-4T-1 
ATG13 expression vector showed a band at the expected size of 40 kDa. Despite this, 
the expression level was low compared with the FIP200 protein fragments (Figure 
3.4A). Optimisation trials were performed to increase the expression level, with 
parameters including growth temperature, expression time, growth medium and IPTG 
concentration (Figure 3.4B), but these did not improve the expression level of the 
ATG13 (380–517) protein. Large-scale expression was performed with optimised 
conditions, and low levels of expression of the ATG13 (380–517) protein with a GST 




Figure 3.4: A. Samples from small-scale expression were analysed by SDS-PAGE, which 
demonstrated that the six FIP200 constructs and the ATG13 (380–517) construct were 
successfully expressed in E. coli. Lanes 1–6: crude cell lysate from BL21 (DE3) cells 
expressing FIP200 P1–P6, lane 7: cell lysate from Rosetta (DE3) cells expressing ATG13 
(380–517), lane 8: cell lysate of BL21 (DE3) cells expressing ATG13 (380–517). B. To identify 
the ideal IPTG concentration for the induction of ATG13 (380–517), the cells were induced 
with different concentrations of IPTG. SDS-PAGE analysis showed that varying IPTG 
concentration did not affect the expression levels of ATG13 (380–517). Lanes 1–8: cell 
lysates from cultures induced with IPTG at the following concentrations: 0.1 mM, 0.2 mM, 0.3 
mM, 0.4 mM, 0.5 mM, 0.6 mM, 0.8 mM and 1 mM. C. Samples from large-scale (1-L culture) 
expression were analysed by SDS-PAGE. SDS-PAGE analysis demonstrated that the six 
FIP200 constructs expressed well, whereas the ATG13 (380–517) construct showed low-level 
expression. Lanes 1 & 2: crude cell lysate from ATG13 (380–517), lanes 3–8: cell lysate from 
FIP200 P1–P6. D. SDS-PAGE gel showing samples from affinity chromatography purification. 
SDS-PAGE analysis showed that ATG13 protein expressed using Rosetta (DE3) was 
successfully purified, although the expression level was relatively low. All six FIP200 
constructs were purified successfully. Lane 1: ATG13 (380–517) expressed using Rosetta 
(DE3) cells that were purified using glutathione Sepharose resin, lane 2: ATG13 (380–517) 
expressed using BL21 (DE3) cells that were purified using glutathione Sepharose resin, lanes 
3-8: FIP200 (P1–P6) purified using Ni-NTA resins. 
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3.2.3 Strategy for cloning, expression and purification of FIP200 constructs 
After careful analysis of secondary structures using XtalPred, the 4773-bp 
human FIP200 gene was truncated into six DNA fragments of around 800 bp each 
(exact size summarised in Table 2) to map the region of ATG13 that interacts with 
FIP200. The six FIP200 fragments expressed as polypeptides without a proper tertiary 
structure have the risk of becoming insoluble protein. Therefore, a chaperone-like TF 
tag was included to assist the folding of the polypeptide and obtain soluble protein. To 
achieve this, the six FIP200 DNA fragments were cloned into pCold™ TF, which is a 
cold-shock fusion vector that expresses the protein of interest as a TF (48 kDa) 
chaperone fusion. As TF is derived from E. coli, it is expressed highly in E. coli 
expression systems. The pCold™ TF vector also has a His6 tag sequence before the 
TF sequence and a thrombin cleavage site, for potential TF removal, between the TF 
domain and the multiple cloning sites.  
The amplified DNA fragments were verified on an agarose gel, which showed 
the 800-bp PCR product as a discrete band (Figure 3.5A and B). Colony PCR was 
performed to identify transformants containing plasmids with correct-sized inserts, 
and the resulting products were verified by agarose gel electrophoresis (Figure 3.6). 
Plasmids containing the correct insert produced a discrete 1000-bp band, including 
the multiple cloning site regions. Sequencing of the plasmid samples purified from the 
selected colonies confirmed the presence of the target gene, and showed that the 





Figure 3.5: A. Typical agarose gel showing the amplified PCR products (FIP200 P1, P2, P3, 
P4 and P6) as distinct bands (marked with white box). The bands were cut from the gel to 
purify the amplified PCR product. The migration of the product to approximately 800 bp 
suggested that the correct DNA fragment was amplified for FIP200 P1, P2, P3, P4 and P6. 
The FIP200 P5 fragment did not amplify using the calculated annealing temperature; 
therefore, a temperature-gradient PCR was performed. A product of the expected size for 
FIP200 P5 was then observed as a distinct band, as shown in panel B. 
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Figure 3.6: Agarose gels showing the results from the colony PCR used to identify plasmids 
containing the correct 800–1000 bp inserts corresponding to FIP200 (P1–P6). The plasmids 
from the colonies corresponding to the correct-sized bands were sequenced to verify ligation 
of correct DNA sequence. 
Extensive expression trials were performed to identify the optimum conditions 
required for overexpression. After trying several E. coli strains, the six FIP200 
constructs cloned into pCold™ TF expressed well as His6-TF fusion proteins in BL21 
(DE3) cells. Expression was verified on an SDS-PAGE gel, which showed discrete 
bands for the FIP200 constructs (P1–P6) at around 80 kDa, as expected for the His6-
TF-protein fragment fusions (Figure 3.4A). Large-scale expression was carried out 
using the optimised conditions, and SDS-PAGE analysis of His6-TF-FIP200 
fragments showed good expression levels (Figure 3.4C). 
The His6-TF-FIP200 (P1–P6) proteins were purified successfully by affinity 
chromatography using Ni-NTA resin following large-scale (1 L) expression. Removal 
of the His6-TF region from the FIP200 fragments by thrombin cleavage resulted in the 
precipitation of the protein. Therefore, all the FIP200 fragments were used as His6-TF 
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fusions for further studies. The protein purified using Ni-NTA resin was analysed on 
an SDS-PAGE gel (Figure 3.4D), which confirmed the purity of the protein samples 
obtained from all six FIP200 constructs. 
 
Figure 3.7: A–F. Chromatograms from SEC purification of the six FIP200 (P1–P6) fragments 
show more than one peak, suggesting that the proteins were not of sufficient purity for 
crystallisation. His6-TF-FIP200 (P1–P6) constructs were purified, but were difficult to separate 
because of the unstable nature of the FIP200 (P1–P6) constructs. G. SDS-PAGE gel showing 
the fraction that had the FIP200 P1–P6 constructs. Results suggested that, despite observing 
bands of the correct size, the samples were not pure and were degraded, which was evident 
from the ladder-like bands in each lane. Lanes 1–6: FIP200 P1–P6. 
To obtain pure protein samples for the crystallisation experiments, size 
exclusion chromatography was used as a final purification step after elution of all six 
His6-TF-FIP200 fragments from the Ni-NTA resin. The fractions were collected in 1-
mL volumes, and SDS-PAGE analysis (Figure 3.7G) showed peaks corresponding to 
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the FIP200 fragments. Several peaks were observed during purification by SEC 
(Figure 3.7A–F), but it was difficult to separate and purify the protein samples 
because of the unstable nature of the FIP200 fragments. 
3.2.4 Pull-down assay demonstrated no binding between the ATG13 (380–
517) construct and the FIP200 (P1–P6) constructs 
Pull-down assays did not show the binding region of C-terminal ATG13 in 
FIP200. To identify the FIP200 (P1–P6) fragment that binds to the C-terminal of 
ATG13 (380–517), a GST pull-down assay was performed. The ATG13 (380–517)-
GST fusion protein was used as “bait” by attaching it to glutathione Sepharose resin. 
The six His6-TF-FIP200 (P1–P6) fragments were used as “prey” (refer to Section 
2.5.6 and Figure 2.1). All six His6-TF-FIP200 (P1–P6) fusion proteins were eluted 
from the Ni-NTA resin, and were then incubated with ATG13 (380–517)-GST 
attached to the glutathione Sepharose resin. After several rounds of washing, the 
incubated samples were loaded onto an SDS-PAGE gel to observe the binding. GST 
without any fusion protein was used as a control to ensure that any observed 




Figure 3.8: SDS-PAGE analysis of the pull-down assay demonstrated that there was no 
binding between ATG13 (380–517)-GST and the six His6-TF-FIP200 (P1–P6) fragments. 
Molecular weight marker (Novex® Sharp Prestained Protein Standard) was loaded in lane 1. 
The GST control protein was run in lane 2, and ATG13 (380–517)-GST was run in lane 3. 
His6-TF-FIP200 (P1–P6) fragments incubated with the GST control protein were run in lanes 
4, 6, 8, 10, 12 and 14. His6-TF-FIP200 (P1–P6) fragments incubated with ATG13 (380–517)-
GST were run in lanes 5, 7, 9, 11, 13 and 15. 
Interaction between Atg13 and FIP200 would be expected to show as bands 
on the SDS-PAGE gel at 80 kDa for FIP200 fragments and 40 kDa for ATG13 in the 
P1A–P6A lanes (Figure 3.8 shown in blue arrows). However, it was observed that all 
six His6-TF-FIP200 polypeptides (P1–P6) interacted with the GST control (lanes P1 
GST–P6 GST, shown as orange arrows in Figure 3.8). Therefore, it was difficult to 
distinguish whether the interaction of FIP200 polypeptides was with the ATG13 or 
with the GST region of the fusion protein. Another problem was the massive 
degradation of ATG13 (380–517)-GST attached to the GST resin, which occurred 
only upon binding of this protein to the GST resin, but not to sample eluted from the 
GST resin. Although interaction between FIP200 and Atg13 has been previously 
reported (Hosokawa et al., 2009), it was not possible to identify the region of FIP200 
that binds ATG13 using this pull-down assay because of the abovementioned reasons. 
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Extensive unsuccessful attempts were made to optimise the pull-down assay to avoid 
the false positive interaction of GST with FIP200 and overcome ATG13 (380–517)-
GST degradation. However, because of the repeated failure of these attempts, the 
experiment was not pursued further. 
3.2.5 Initial crystallisation trials on the FIP200 (P1–P6) constructs  
Initial crystallisation experiments for the six His6-TF-FIP200 (P1–P6) 
fragments did not result in any protein crystals. Protein samples from SEC 
purification were used for crystallisation experiments. Peak fractions corresponding to 
the expected size of the His6-TF-FIP200 (P1–P6) fragments were pooled and 
concentrated using 30,000 MWCO spin concentrators. Each fragment was 
concentrated to 10 mg/mL. Despite degradation of the protein samples and the 
samples not being sufficiently pure (Figure 3.7G) for crystallography experiments, 
initial crystallisation trials were still performed using Crystal Screen, Crystal Screen 
Cryo, Index and PEG/Ion (All from Hampton Research) and JCSG+, Midas, 
Morpheus, PACT, Clear Screen Strategy 1 and Clear Screen Strategy II (All from 
Molecular Dimensions). In all cases, the drops included 400 nL of protein and 400 nL 
of mother liquor. All crystallisation experiments were attempted at both room 
temperature and 4°C. No crystal hits were found in the initial trial, and further trials 
were not conducted due to the unstable nature of the proteins. 
3.3 Summary 
Although the region of ATG13 that binds to FIP200 is known, the ATG13-
binding region in FIP200 remains elusive. To map the ATG13-binding region of 
FIP200, the full length FIP200 gene was truncated into six fragments, and was 
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successfully cloned into pCold™ TF vector and expressed in E. coli BL21 (DE3) 
cells. The ATG13 DNA sequence encoding amino acids 380–517 was successfully 
cloned into pGEX-4T-1 vector and was expressed in Rosetta (DE3) cells.  
It was hypothesised that the previously reported C-terminal region of ATG13 
would bind to one the six fragments of FIP200 (P1–P6), and the amino acids of the 
interacting fragment that are involved in binding could be further mapped. However, 
because of the false positive interaction between FIP200 polypeptides and the GST 
tag, the pull-down assay did not provide any useful information that could be used to 
map the interaction region in FIP200. It is possible that the FIP200 polypeptides were 
not properly folded, which caused them to interact with the GST protein. Using a 
different fusion partner for ATG13, such as maltose binding protein, and 
experimenting with different FIP200 fragments may be viable future approaches to 
troubleshoot the abovementioned problems.  
In conclusion, despite the failure to map the region of FIP200 that interacts 
with ATG13, this chapter provided key information for the failure of the pull-down 
assay. Further optimisation based on the suggestions above may allow discovery of 




Chapter 4.  STRUCTURAL ANALYSIS OF THE LIR-
DEPENDENT INTERACTION BETWEEN THE 
PLEKHM1 LIR AND HUMAN ATG8-LIKE 
PROTEINS. 
4.1 Introduction 
In the previous chapter, the interaction between FIP200 and ATG13, which 
are part of the ULK1 complex, was studied using pull-down assays. Autophagy-
related protein 8 (Atg8) proteins are essential for the formation of the autophagosome 
(Nakatogawa et al., 2007, Weidberg et al., 2011, Xie et al., 2008). Atg8 proteins form 
a multifunctional family that act as scaffolds for large complexes, and as adaptors that 
link the cargo to be degraded to the autophagosome (Nakatogawa et al., 2007, Kirkin 
et al., 2009, Novak et al., 2010, Bjørkøy et al., 2005, Shvets et al., 2008). Although 
lower eukaryotes, such as yeast, express only one Atg8 protein (Lang et al., 1998, 
Kirisako et al., 1999), humans have six homologues that are subdivided into two 
families: the MAP1LC3 family (including LC3A, LC3B and LC3C), and the 
GABARAP family (including GABARAP, GABARAPL1 and GABARAPL2) 
(Shpilka et al., 2011). In this chapter, the interactions of human ATG8 family proteins 
with pleckstrin homology domain-containing protein family member 1 (PLEKHM1) 
are studied. 
PLEKHM1 is a multivalent adaptor protein that regulates the degradation of 
protein aggregates through either the selective or the non-selective autophagic 
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pathways. It facilitates fusion of the autophagosome with the lysosome, with the help 
of Atg8 family proteins (McEwan et al., 2015). PLEKHM1 interacts with all 
members of the human ATG8 protein family, but with varying binding affinities (data 
not published, Table 4.1). In this chapter, X-ray crystallographic experiments were 
performed to rationalise the differences in binding affinities of members of the LC3 
and GABARAP families of human ATG8 proteins with PLEKHM1, and to probe the 
mechanism of interaction. 
PLEKHM1 regulates the selective degradation of defective ribosomal 
products and the removal of puromycin-induced aggresome-like induced structures in 
an LIR-dependent manner (Szeto et al., 2006). PLEKHM1 mutations cause 
osteoporosis (Van Wesenbeeck et al., 2007) as a result of dysfunctional ruffled border 
formation, which is a specialised process that requires lysosome fusion and facilitates 
degradation of the bone matrix (Van Wesenbeeck et al., 2007, Zhao et al., 2001, 
DeSelm et al., 2011). Understanding the interaction mechanism of PLEKHM1 could 
provide information about the cause of this disease. 
The interaction of PLEKHM1 with mammalian Atg8 (mAtg8) is mediated 
through the LC3-interacting region (LIR) motif (Alemu et al., 2012). A typical LIR 
motif sequence is W/Y/FxxL/I/V, where the first residue is an aromatic amino acid, 
followed by acidic residues (shown as “x”), with a hydrophobic residue at the end. 
Tryptophan and phenylalanine are the most common aromatic residues in LIR motifs, 
especially in the selective autophagy adaptors (Alemu et al., 2012). The PLEKHM1 
LIR has the sequence 634-EWVNV-638, with a tryptophan in the “W-site” and valine 
in the “L-site” (McEwan et al., 2015). To date, the structures of various selective 
adaptors with mammalian Atg8 proteins (NDP52-LC3C, OPTN-LC3B, p62-LC3B, 
NBR1-GABARAPL1) have been solved (Ichimura, Kumanomidou, et al., 2008, 
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Kirkin et al., 2009, Novak et al., 2010, Pankiv et al., 2007, Suzuki et al., 2014, 
Thurston et al., 2009, von Muhlinen et al., 2012a). Although, considerable effort has 
gone into understanding the LIR-dependent interaction between the adaptors and 
various human ATG8 modifiers, there are no crystal structures of a single LIR with 
all of the members of human ATG8 proteins, which could be used to explore how the 
LIR interactions differ between LC3 and GABARAP proteins.  
The LC3 and GABARAP family proteins have similar crystal structures. Both 
have two domains: an N-terminal domain that consists of the α1 and α2 helices, and 
the C-terminal domain that has a ubiquitin-like form with a β-grasp fold (Figure 4.1A) 
(Sugawara et al., 2004, Bavro et al., 2002, Knight et al., 2002). The same domain 
architecture was found in all five crystal structures of human ATG8 proteins in 
complex with the PLEKHM1 LIR (Figure 4.1A). Both the LC3 and GABARAP 
family proteins have two hydrophobic pockets: the “W-site” and the “L-site” (Figure 
4.1B). In the interaction between the PLEKHM1 LIR and the LC3 and GABARAP 
family proteins, Trp635 docks into the “W-site” and Val638 docks into the “L-site” 




Figure 4.1: A. Structural overlay of PLEKHM1 LIR-LC3A (yellow), PLEKHM1 LIR-LC3B 
(orange), PLEKHM1 LIR-GABARAP (green) and PLEKHM1 LIR-GABARAPL1 (cyan) 
demonstrates that the domain architecture of the four human ATG8 protein structures is very 
similar. The PLEKHM1 LIR (shown in magenta) interacts with all of the human ATG8 
structures in a similar orientation. The hydrophobic amino acids Trp635 and Val638, with the 
“W-site” and “L-site” hydrophobic surfaces, are shown as dot surface representations. B. The 
interaction of Trp635 from the PLEKHM1 LIR with the “W-site” hydrophobic surface (show as 
yellow surface representation) shows subtle differences in the orientation of Trp635 between 
the ATG8-family members, whereas there is no noticeable difference in the orientation of 
Val636 at the “L-site”. 
A recent report (McEwan et al., 2015) demonstrated that the PLEKHM1 LIR 
binds all members of the human ATG8 protein family, but whether the PLEKHM1 
LIR has a preference for a particular member of this protein family is unknown. To 
investigate this, the binding affinities of the PLEKHM1 LIR with all human ATG8 
family proteins were determined using isothermal titration calorimetry (ITC) in 
Professor Ivan Dikic’s laboratory. ITC data was kindly provided by Vladmir Rogov 
(Table 4.1).  
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Table 4.1: Thermodynamic parameters of the interaction between ATG8 family proteins and 


















LC3A −7±0.2 +1.17 −0.35 −7.33 0.24±0.02 4.22 0.98±0.02 
LC3B −5.8±0.2 +4.27 −1.27 −7.09 0.16±0.01 6.33 1.06±0.01 
LC3C −8.3±0.2 −2.83 +0.84 −7.48 0.29±0.02 3.45 0.99±0.02 
GABARAP −10.6±0.06 −6.92 +2.06 −8.54 1.8±0.1 0.55 1.00±0.01 
GABARAP L1 −7.8±0.1 +1.94 −0.58 −8.35 1.3±0.1 0.77 1.00±0.01 
GABARAP L2 −6.14±0.03 +7.00 −2.09 −8.23 1.07±0.03 0.93 1.05±0.01 
 
These results show that GABARAP family proteins have higher binding 
affinity towards the PLEKHM1 LIR than LC3 family proteins. GABARAP (KD = 
0.55 µM) has the highest binding affinity towards the PLEKHM1 LIR, and LC3B (KD 
= 6.3 µM) has the lowest binding affinity, a 12-fold difference. The difference in 
binding affinity between LC3C (KD = 3.45 µM), which has the highest binding 
affinity among LC3 family proteins, and GABARAPL2 (KD = 0.93 µM), which has 
the lowest binding affinity among GABARAP family proteins, is four-fold, indicating 
that all GABARAP family proteins have higher binding affinity towards the 
PLEKHM1 LIR than the LC3 family proteins.  
A more detailed analysis of the interaction between the PLEKHM1 LIR and 
ATG8 family proteins may explain the differences in binding affinity. However, there 
is no structural information on a single LIR motif interacting with all members of 
both the LC3 and GABARAP family proteins. In this chapter, the crystal structures of 
the PLEKHM1 LIR peptide in complex with LC3A, LC3C, GABARAP and 
GABARPL1 were determined using X-ray crystallography. The structures were then 
compared to understand the structural basis of the differences in binding affinity 
observed using ITC. The results suggest that small differences in the interaction of the 




4.2.1 Purification and crystallisation of the PLEKHM1 LIR-human ATG8 
complexes. 
To shed light on the differences in binding affinities between human ATG8 
proteins and the PLEKHM1 LIR, crystal structures of human ATG8 proteins in 
complex with the PLEKHM1 LIR peptide were determined. Pure protein samples 
were required for crystallisation experiments. To achieve this, genes for each of the 
ATG8 proteins were cloned into the pET30ΔSE vector as chimeric constructs to 
express His6-tagged PLEKHM LIR-ATG8 family fusion proteins. Proteins were 
expressed in E. coli BL21(DE3) cells. Following IMAC, SEC resulted in purification 
of the target protein samples, as shown by the sharp peaks in the chromatograms and 





Figure 4.2: Purification of His6-PLEKHM1-ATG8 family chimeric proteins by SEC. Peaks 
containing protein that was used for crystallisation are marked with red boxes. Inset: SDS-
PAGE gels show purity of the samples obtained following SEC, and bands marked with red 
boxes show that the target protein separated at the correct size. 
Full-length LC3C was unstable and was difficult to obtain in concentrations 
high enough for crystallisation. Thus, a truncated version of LC3C (8–128) was 
expressed with a His6 tag. Vladmir Rogov encountered a similar problem, and 
expressed a truncated LC3C region (11–125) that was used in ITC experiments 
(Personal communication). LC3C (8–128) was purified using the same procedure as 
that used for the chimeric protein samples, except that the entire purification 
procedure was performed at 4°C, including the overnight thrombin cleavage for 
removal of the His6 tag. Ultimately, pure target protein samples were successfully 
obtained and crystallised (Section 2.5.7.1). 
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4.2.2 Structural characterisation of the PLEKHM1 LIR in complex with 
members of the human ATG8 protein family demonstrates subtle 
differences in the crystal structures. 
Given the very similar structure and high sequence similarity between 
members of the human ATG8 protein family, it was unclear why the PLEKHM1 LIR 
peptide interacts with the different proteins with different binding affinities. To 
understand this, the interactions between these proteins and the PLEKHM1 LIR were 
examined in atomic detail. The crystal structures of LC3A, LC3C, GABARAP and 
GABARAPL1 in complex with the PLEKHM1 LIR were determined, as described in 
Section 2.5.7. The chimeric protein crystals diffracted at 2.5 Å for PLEKHM1-LC3A, 
2.0 Å for PLEKHM1-GABARAP and 2.9 Å for PLEKHM1-GABARAPL1. The 
LC3C (8–128) protein was co-crystallised with the PLEKHM1 LIR (629–642) 
peptide, and diffracted to 2.19-Å resolution. The crystal structure of the PLEKHM1-
LC3B complex (PDB code: 3X0W) was recently solved (McEwan et al., 2015), and 
was included for structural comparison. The data collection statistics and refinement 



















Space group P31 P3221 P21  
Cell parameters  
a, b, c (Å); α, β, γ (º) 
73.8, 73.8, 74.5; 
90, 90, 120 
84.8, 84.8, 
105.4; 90, 90, 
120 
62.7, 63.1, 
84.9; 90, 100.9, 
90 
 
Wavelength (Å) 0.9537 0.9537 0.9537  







RMerge 0.196 (3.387) 0.148 (2.352) 0.113 (0.614)  
Rp.i.m. 0.060 (1.066) 0.048 (0.735) 0.068 (0.366)  
Rmeas. 0.205 (3.652) 0.156 (2.466) 0.132(0.716)  
I/σI 10.3 (1.5) 10.6 (1.4) 7.1 (2.1)  
Completeness 99.2 (98.6) 99.9 (99.5) 100 (100)  
CC(1/2) 0.998 (0.651) 0.991 (0.581) 0.928 (0.754)  
Redundancy 11.6 (11.6) 10.9 (11.0) 3.8 (3.8)  
Total reflections (unique) 353,770 
(26,146) 
110,277 (17,825) 22,780 (2,562)  
Refinement statistics 
RWork/RFree (%) 18.4/22.3 21.4/26.0 21.8/26.1  
Number of atoms     
  Protein 2,990 1,949 4,086  
  Water 177 0 42  
Temperature factors     
  Main chain 34.4 100.8 54.7  
  Side chain 37.1 103.4 64.2  
  LIR peptide 30.6 110.4 50.7  
  Solvent 37.5 - 37.6  
Ramachandran plot     
Allowed regions 100.0 99.6 99.4  
Outliers 0.0 0.41 0.61  
R.m.s.d from ideality     
  Bond lengths (Å) 0.008 0.003 0.006  
  Planarity (°) 0.005 0.004 0.005  



















Space group P1 P21   
Cell parameters  
a, b, c (Å); α, β, γ (º) 







Wavelength (Å) 0.9537 0.9537   





RMerge 0.074 (0.875) 0.053 (0.353)   
Rp.i.m. 0.048 (0.573) 0.021 (0.138)   
Rmeas. 0.089 (1.063) 0.056 (0.379)   
I/σI 13.4 (1.9) 22.3 (5.2)   
Completeness 98.6 (97.8) 99.8 (99.2)   
CC(1/2) 0.999 (0.824) 0.999 (0.974)   
Redundancy 6.6 (6.6) 7.5 (7.5)   






RWork/RFree (%) 20.0/24.6 23.0/30.78   
Number of atoms     
  Protein 8,300 4,109   
  Water 170 143   
Temperature factors     
  Main chain 49.8 46.34   
  Side chain 58.4 60.27   
  LIR peptide 62.4 64.75   
  Solvent 40.2 44.89   
Ramachandran plot     
Allowed regions 99.1 98.92   
Outliers 0.9 1.08   
R.m.s.d from ideality     
  Bond lengths (Å) 0.004 0.015   
  Planarity (°) 0.004 0.009   
  Angles (°) 0.732 1.334   
 
The crystal structure of PLEKHM1-GABARAP was solved in the trigonal 
crystal system P31, and had three molecules in an asymmetric unit (Figure 4.3A). 
Each molecule interacted with the PLEKHM1 LIR region of a symmetry-related 
molecule (i.e. the LIR region of molecule A interacts with the symmetry-related 
molecule A). The PLEKHM1-GABARAPL1 structure was solved in a trigonal crystal 
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system, P3221. Instead of three molecules, the PLEKHM1-GABARAPL1 crystal 
structure had two molecules in the asymmetric unit (Figure 4.3B). Unlike PLEKHM1-
GABARAP, the LIR region in PLEKHM1-GABARAPLI of molecule A interacted 
with molecule B within the asymmetric unit, and the LIR region of molecule B 
interacted with symmetry-related molecule A (Figure 4.3B). The typical LIR 
hydrophobic residues Trp635, Val636 and Val638 of the PLEKHM1 LIR, which 
interact with the GABARAP and GABARAPL1 proteins, were clearly visible in the 








Figure 4.3: A. Left panel shows three monomers of PLEKHM1 LIR-GABARAP (labelled as A, 
B and C, and coloured by chains) found in an asymmetric unit, represented as a cartoon 
structure. Middle panel shows the OMIT map of the PLEKHM1 LIR. Right panel shows the 
2Fo-2Fc map (blue) at 1 σ, the Fo-Fc map (green) at 3 σ and the Fo-Fc map (red) at −3 σ of 
the PLEKHM1 LIR, as was manually modelled. Clear density around the hydrophobic 
residues Trp635 and Val636, which are involved with the “W-site” and “L-site” hydrophobic 
surfaces, is also shown. B. Left panel shows two monomers of PLEKHM1 LIR-GABARAPL1 
(labelled as A and B, and coloured by chains) found in an asymmetric unit, represented as a 
cartoon structure. Middle panel shows the OMIT map of the PLEKHM1 LIR. Right panel 
shows the 2Fo-2Fc map (blue) at 1 σ, the Fo-Fc map (green) at 3 σ and the Fo-Fc map (red) 
at −3 σ of the PLEKHM1 LIR, as was manually modelled. Clear density is also shown around 
residues Trp635 and Val636. 
The crystal structure of PLEKHM1-LC3A was solved in the monoclinic 
crystal system P21, with four molecules in an asymmetric unit (Figure 4.5A). Unlike 
the LIR interactions observed in the PLEKHM1-GABARP and PLEKHM1-
GABARAPL1 crystal systems, in the PLEKHM1-LC3A system, the LIR region of 
molecules A and B interacted with the symmetry-related molecules A and B, 
respectively, whereas the LIR region of molecule C interacted with symmetry-related 
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molecule D, and the LIR region of molecule D interacted with symmetry-related 
molecule C. 
PLEKHM1-LC3C was integrated in space group P21, but refinement was 
unsuccessful because of the presence of translational pseudo-symmetry. The 
processed data set from XDS was scaled using AIMLESS (Evans, 2006) from the 
CCP4 software package. Analysis of systematically absent reflections determined 21 
screw axes along b, confirming the P21 space group (Figure 4.4A). Therefore, the data 
was processed in space group P21, and a diagnostic test for translational pseudo-
symmetry was performed using phenix.xtriage from the PHENIX suite (Adams et al., 
2010). Data were analysed from 10.00 Å to 2.84 Å resolution, and the intensity 
statistics suggested translational pseudo-symmetry with a value for (I2)/(I)2 of 2.667, 
which is not consistent with the theoretical value of 2. Additionally, the intensity 
probability distribution produced an abnormal curve, suggesting the presence of 
translational pseudo-symmetry (Figure 4.4B). However, the L-test did not show any 
twinning in the dataset (Figure 4.3C). Therefore, the data was solved and refined in 
the P1 space group (Table 4.3), and this model was used for molecular replacement. 
After iterative refinement and model building, the Rfree did not go below 30%, and the 
difference between Rfree and Rwork remained high at 7% (Table 4.3). Therefore, the 




Figure 4.4: A. Axial reflection along the b axis with no violations from 40 measurements, 
suggesting a clear 21 screw axes along the b axis. B. Traditional cumulative intensity 
distribution normalised in resolution shells. The acentric observed and untwinned are shown 
in blue and green curves. The centric observed and untwinned are shown in red and blue 
curves. The abnormal distribution of the curves shows a clear translational pseudo-symmetry. 
C. The cumulative probability distribution of the local intensity statistics is shown, where the 
acentric theory (green) and the observed (blue) are compared with perfectly twinned data 
(red). The dataset shows no twinning.  
The asymmetric unit (P1 space group) had eight monomers (Figure 4.5B), and 
each monomer had one molecule of LC3C interacting with one molecule of the 
PLEKHM1 LIR peptide. The electron density for the PLEKHM1 LIR peptide was 
clearly visible, and the amino acids were assigned according to the PLEKHM1 LIR 
peptide sequence (Fig 4.5C and 4.5D). Overall the data collection statistics and the 
refinement statistics of all four crystal structures suggest that the models are reliable, 




Figure 4.5: A. Left panel shows four monomers of PLEKHM1 LIR-LC3A (coloured by chains) 
found in an asymmetric unit, represented as a cartoon structure. Middle panel shows the 
OMIT map of the PLEKHM1 LIR. Right panel shows the 2Fo-2Fc (blue) at 1 σ, Fo-Fc (green) 
at 3 σ and Fo-Fc (red) at −3 σ maps of the PLEKHM1 LIR, which was manually modelled. It 
also shows clear density around the hydrophobic residues Trp635 and Val636, which are 
involved with the “W-site” and “L-site” hydrophobic surfaces. B. Left panel shows two 
monomers of PLEKHM1 LC3C (coloured by chains) found in an asymmetric unit, represented 
as a cartoon structure. Middle panel shows the OMIT map of the PLEKHM1 LIR. Right panel 
shows the 2Fo-2Fc (blue) at 1 σ, Fo-Fc (green) at 3 σ and Fo-Fc (red) at −3 σ maps of the 
PLEKHM1 LIR, which was manually modelled. It also shows clear density around the 
hydrophobic residues Trp635 and Val636. 
The monomers in an asymmetric unit of each crystal structure were 
overlaid/aligned (Figures 4.6A, B, C & D) to explore the binding heterogeneity. The 
overlays show that the LIR region (EWVNV) of the PLEKHM1 LIR peptide was in 
largely the same orientation across all the monomers in all five crystal structures 
(including PLEKHM1-LC3B, PDB code: 3X0W, also included in the analysis). The 
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monomers in an asymmetric unit that contains the PLEKHM1 LIR fused at the N-
terminal were overlaid, and the root-mean-square deviation (RMSD) for the α-carbon 
was calculated. The monomers overlaid with RMSDs of 0.174 Å for PLEKHM1-
LC3A, 0.217 Å for PLEKHM1-LC3B, 0.167 Å for PLEKHM1-GABARAP and 
0.326 Å for PLEKHM1-GABARAPL1 (Figure 4.6A–E). For the PLEKHM1-LC3C 
complex, the LC3C molecule interacting with the PLEKHM1 peptide was taken as 
one monomer and was overlaid with the other seven monomers (LC3C in complex 
with PLEKHM1 peptide), and displayed a RMSD of 0.426 Å. The overlays of the 
PLEKHM1 LIR showed fluctuation in the amino acid residues present on either side 
of the PLEKHM1 core LIR region (WVNV), but these residues aligned well across 
all of the monomers (Figure 4.6F). This suggested strong binding between 
hydrophobic residues of the PLEKHM1 LIR and the “W-site” and “L-site” 
hydrophobic surfaces of human ATG8 proteins. The RMSD values suggest that the 
monomers overlay very well. Therefore, subsequent analyses, performed using 




Figure 4.6: A. Overlay of the four PLRKHM1-LC3A monomers in the asymmetric unit. The 
monomers overlay well, and the PLEKHM1 LIR, represented as sticks, is in the same 
orientation in all four monomers, with the key amino acid Trp635 aligned well. B–E. Overlay of 
monomers in an asymmetric unit for PLEKHM1-LC3B, PLEKHM1-LC3C, PLEKHM1-
GABARAP and PLEKHM1-GABARAPL1 structures, respectively. The monomers and the 
PLEKHM1 LIR overlay well. F. Overlay of all five human ATG8 protein structures. One of the 
monomers in each asymmetric unit from A–E was used for analysis The PLEKHM1 LIR is 
represented as red sticks.   
Crystal structures of LC3A, LC3B, LC3C, GABARAP and GABARAPL1 
displayed similar architecture to other ATG8 protein structures, with two domains (N-
terminal and C-terminal) (Fig 4.1A). A typical LIR interaction was observed between 
the PLEKHM1 LIR and the human ATG8 proteins, where Trp635 of the PLEKHM1 
LIR interacts with the hydrophobic surface at the “W-site” of the human ATG8 
family protein, and Val638 of the PLEKHM1 LIR interacts with the hydrophobic 
surface at the “L-site” (Fig 4.1B). As observed in the other LIR interactions, the main 
chains of Val636 and Val638 of the PLEKHM1 LIR form hydrogen bonds with 
Lys51 and Leu53 in LC3A and LC3B, Lys57 and Leu59 in LC3C and Lys48 and 
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Figure 4.7: Comparison of β2-strand hydrogen bond interaction with the PLEKHM1 LIR. The 
figure depicts the interaction of Val636 and Val638 (PLEKHM1 LIR shown in red) with the β2 
strand of ATG8 family proteins. A. Lys51 and Leu53 of LC3A, shown in green, make 
hydrogen bonds with Val636 and Val638 of the PLEKHM1 LIR, represented as red sticks. B–
E. LC3B residues are shown in magenta, GABARAP residues in cyan, LC3C residues in 
yellow and GABARAPL1 residues in blue.  
4.2.3 The interaction of human ATG8 proteins with Trp635 and Asn637 of 
the PLEKHM1 LIR suggests a tighter interaction of GABARAP and 
GABARAPL1 with the PLEKHM1 LIR. 
Two pairs of interactions observed in all five structures are summarised in 
Table 4.4. Structural analysis suggests that tighter interaction between Arg28 and 
Asn637, coupled with the hydrogen bond between Glu17 and Trp635, may contribute 
to the higher binding affinity of GABARAP and GABARAPL1 towards the 
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PLEKHM1 LIR, when compared with the members of LC3 protein. The distance 
between Asp19 and Trp635, and Lys30 and Asn637, in the PLEKHM1 LIR-LC3B 
complex suggests LC3B has the weakest interaction with the PLEKHM1 LIR among 
all the human ATG8 homologues, which is consistent with the ITC data. 















GABARAP 2.8 Å 3.6 Å 0.55 
GABARAPL1 3.1 Å 3.4 Å 0.77 
LC3C 3.1 Å No interaction 3.45 
LC3A No interaction 3.5 Å 4.22 
LC3B No interaction No interaction 6.33 
 
All five PLEKHM1-human ATG8 complexes had very similar structures, and 
the orientation of the PLEKHM1 LIR was similar in all cases. Given the differences 
in binding affinities for the PLEKHM1 LIR between the human ATG8 proteins, we 
hypothesized that subtle differences in the interaction between these molecules could 
contribute to the differences in binding affinity. To evaluate this hypothesis, the 
amino acids involved in the interactions of the PLEKHM1 LIR with ATG8 
homologues were carefully analysed. The analysis showed that a lysine residue was 
located in the β2-sheet region of LC3A (Lys30), LC3B (Lys30) and LC3C (Lys36), 
whereas Arg28 was observed at the same position in GABARAP and GABARAPL1 
(Figure 4.7).  
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Figure 4.8: Interaction of Trp635 and Asn637 with ATG8 family members. The residues in 
green represent the PLEKHM1 LIR bound state, and the residues in orange represent the 
unbound state. The PLEKHM1 LIR peptide is shown in red. A. Interaction of the PLEKHM1 
LIR with LC3A. Trp635 of PLEKHM1 interacts with Glu19 of LC3A (3.5 Å distance). Asn637 of 
PLEKHM1 interacts with Lys30 (3.9 Å distance). B. LC3B interacts in a similar way to LC3A, 
but the bond distances are higher (6.6 Å and 4.1 Å, respectively), suggesting a weaker 
interaction. C. LC3C also interacts in a similar way to LC3A, but forms a strong interaction 
between Asn637 and Lys36 (3.1 Å distance). D. Trp635 forms a strong interaction with Glu17 
in GABARAP (3.5 Å distance). Instead of Lys interacting with Asn637, GABARAP proteins 
interact through Arg28, which flips around 4 Å between bound and unbound states, and forms 
a tight interaction with Asn637 (2.8 Å distance). E. GABARAPL1 interacts in a similar way to 
GABARAP, with Asn637 interacting with Arg28 (3.1 Å distance). 
Asn637 in the PLEKHM1 LIR forms a hydrogen bond with Arg28 of 
GABARAP and GABARAPL1 (Figure 4.8D and E). A similar interaction at the same 
position was found in LC3C, between Lys36 and Asn637 of the PLEKHM1 LIR 
(Figure 4.7C), but the position of Lys30 in LC3A and LC3B made it difficult to 
interact with Asn637 (Figure 4.8A and B). In GABARAP and GABARAPL1, the 
comparison between the liganded and unliganded states shows that the side chain of 
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Arg28 undergoes a shift of 4 Å, and nitrogen (Nη2) of Arg28 forms a hydrogen bond 
with the oxygen (Oδ1) of Asn637 at a distance of 2.8 Å for GABARAP and 3.1 Å for 
GABARAPL1 (Figure 4.8D and E). In LC3C, comparison between the liganded and 
unliganded states shows that, unlike Arg28 in GABARAP and GABARAPL1, the 
side chain of Lys36 does not change with respect to its ideal position. Instead, the 
nitrogen (Nζ) forms a hydrogen bond with Oδ1 of Asn637 in the PLEKHM1 LIR at a 
distance of 3.1 Å (Figure 4.8 C). In LC3A and LC3B, comparison between the 
liganded and unliganded states shows that the side chain of Lys30 does not rearrange. 
Greater distances between Oδ1 of PLEKHM1 LIR Asn637 and Nζ of Lys30 in LC3A 
(3.9 Å) and LC3B (4.1 Å) suggest that hydrogen bond formation between these two 
residues was more difficult (Fig 4.8A and B). Therefore, this analysis suggests that 
the hydrogen bond formed between GABARAP and Asn637 of PLEKHM1 is the 
tightest among all five PLEKHM1 LIR-human ATG8 structures, followed by 
GABARAPL1 and LC3C. 
The second difference between the five PLEKHM1 LIR-human ATG8 
complex structures was the weak hydrogen bond formed between Oε2 of Glu17 in 
GABARAP and GABARAPL1 and Nε1 of Trp635 in the PLEKHM1 LIR (Figure 
4.8D and E). A similar interaction was found between Oε2 of Glu19 in LC3A and Nε1 
of Trp635 of the PLEKHM1 LIR (Figure 4.8A). In the PLEKHM1 LIR-LC3C 
complex, the distance between corresponding amino acid Glu25 and Trp635 was 4.5 
Å, which made hydrogen bond formation difficult (Figure 4.8C). Unlike other human 
ATG8 family proteins, the corresponding position in LC3B is an aspartic acid 
(Asp19), rather than a glutamic acid. Aspartic acid has a shorter side chain than 
glutamic acid, and therefore the distance between Asp19 of LC3B and Trp635 of the 
PLEKHM1 LIR (6.6 Å) is less suitable for hydrogen bond formation (Figure 4.8B). 
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Overall, these interactions provide a logical reason for the varying binding affinities 
between the PLEKHM1 LIR and human ATG8 family proteins. 
4.2.4 Analysis of the “W-site” and “L-site” hydrophobic pockets in 
GABARAP and LC3 proteins. 
The presence of the hydrophobic amino acids (W/Y/FxxL/I/V) in the LIR and 
their interaction with the “W-site” and “L-site” hydrophobic surfaces are considered 
the important features of a typical LIR. Comparison of the unliganded crystal 
structures of ATG8 family proteins demonstrates that GABARAP and GABARAPL1 
have deeper “W-site” and “L-site” hydrophobic pockets than LC3A, LC3B and LC3C 
(Figure 4.9), with the difference particularly pronounced for the former site. This 
suggests that the GABARAP family proteins have favourable architecture for 
accommodating LIRs with bulkier aromatic amino acids, such as tryptophan, more 
efficiently. This difference in the “W-site” and “L-site” hydrophobic pockets may 
explain the higher binding affinity of GABARAP proteins with the PLEKHM1 LIR. 
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Figure 4.9: Analysis of “W-site” and “L-site” hydrophobic pockets (yellow circles) of human 
ATG8 family proteins. There is a noticeable difference in the depth of the “W-site” and the “L-
site” hydrophobic pockets, with GABARAP proteins having deeper pockets than LC3 proteins. 
Surface representations of GABARAP and LC3 proteins are coloured based on 
hydrophobicity using the Kyte-Doolittle algorithm. The most hydrophobic and hydrophilic 
regions are shown in orange-red and blue, respectively. The figure was generated using 





4.3 Discussion  
The PLEKHM1 LIR peptide binds the GABARAP family proteins with higher 
affinity than LC3 family proteins, as demonstrated by ITC experiments. In addition to 
the large differences in binding affinity, GABARAP family proteins demonstrated 
entropy values that were negative, in contrast to those of LC3A and LC3B. 
The interaction of PLEKHM1 LIR with human ATG8 family members was 
studied by solving the crystal structures of the PLEKHM1 LIR in complex with 
LC3A, LC3C, GABARAP and GABARAPL1 using two approaches. In the first 
approach, the PLEKHM1 LIR was expressed as a chimeric fusion protein to produce 
the PLEKHM1 LIR-LC3A, PLEKHM1 LIR-GABARAP and PLEKHM1 LIR-
GABARAPL1 complexes. In the second approach, the PLEKHM1 LIR peptide was 
co-crystallised with LC3C. An overlay of monomers in each asymmetric unit 
demonstrated similar orientation of the PLEKHM1 LIR across all the monomers, 
suggesting that the LIR interaction observed in the crystal structure is conserved.    
Despite the similar interaction of the PLEKHM1 LIR across all five human 
ATG8 structures, subtle differences contribute to a tighter interaction between the 
PLEKHM1 LIR and GABARAP proteins, in comparison with LC3 proteins. 
Structural comparison of the PLEKHM1 LIR-human ATG8 complexes showed that 
the lysine and leucine residues located in the β2-sheet in all five human ATG8 
proteins form hydrogen bonds with the Val636 and Val638 of the PLEKHM1 LIR. 
However, the presence of arginine at position 28 in GABARAP, instead of the lysine 
residue found in the corresponding position in LC3 proteins, allows interaction with 
Asn637 in the PLEKHM1 LIR, similar to the interaction of Trp635 in the PLEKHM1 
LIR with Glu17 in GABARAP. 
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Given the importance of hydrophobic surfaces in a typical LIR interaction, it 
was noted that the “W-site” and “L-site” hydrophobic pockets were deeper in 
GABARAP proteins than in LC3 proteins. This suggests that the hydrophobic amino 
acids Trp635 and Val638 of the PLEKHM1 LIR are buried deeper in the “W-site” 
and “L-site” pockets of GABARAP proteins, when compared with LC3 proteins. 
In conclusion, the above discussion provides a rationale for the difference in 
binding affinity of the PLEKHM1 LIR with GABARAP proteins and LC3 proteins by 
analysing the crystal structures of PLEKHM1-human ATG8 family complexes. 
Comparison of amino acids in the α3-helix shows that GABARAP proteins have more 
hydrophobic residues than LC3 proteins. Therefore, in the next chapter, the effects of 
mutating single amino acid residues in the α3-helix on the binding affinity for the LIR 
will be studied. 
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Chapter 5.  THE “W-SITE” HYDROPHOBIC POCKET 
REGULATES THE INTERACTION OF THE LIR IN LC3A 
AND GABARAP IN DIFFERENT WAYS. 
5.1 Introduction 
In the previous chapter, it was suggested that the interaction between the 
Glu17 in GABARAP and Trp635 in the PLEKHM1 LIR, and the interaction between 
Arg28 in GABARAP and Asn637 in the PLEKHM1 LIR, contribute to the higher 
binding affinity of the PLEKHM1 LIR towards GABARAP than to LC3A. It was also 
shown that the “W-site” hydrophobic pocket of GABARAP proteins is noticeably 
deeper than LC3 family proteins. Together, the results suggested that there is a 
difference between GABARAP proteins and LC3 proteins in their mechanism of 
interaction with the LIR. In this chapter, two key questions are addressed. The first is 
how the “W-site” hydrophobic pocket mediates the LIR interaction differently 
between LC3A and GABARAP family proteins. The second question is what 
underlying mechanism regulates the “W-site” hydrophobic pocket differently between 
LC3A and GABARAP family proteins.  
To answer the above questions, the ULK1 LIR was used to study the 
differences in the LIR-dependent interactions of GABARAP and LC3A proteins. The 
rationale for switching from the PLEKHM1 LIR to the ULK1 LIR was to eliminate 
the hydrogen bonds formed by the side chains of Trp635 and Asn637 of the 
PLEKHM1 LIR with GABARAP proteins, but not with LC3 proteins, that contribute 
to the LIR interaction. The ULK1 LIR sequence (SCDTDDFVMVPA) does not make 
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electrostatic interactions with LC3A or GABARAP, and thus was chosen for further 
experiments. 
 
Figure 5.1: A. Structural overlay of LC3A (green), LC3B (magenta), LC3C (yellow), 
GABARAP (cyan), GABARAPL1 (blue) and yeast Atg8 (grey). The mammalian Atg8 family 
proteins have a similar ubiquitin-like fold to yeast Atg8. B. Multiple alignment of human ATG8 
family proteins showing a high sequence similarity (96%) between LC3 family proteins and 
GABARAP family proteins. Residues marked in red are identical and residues marked in 
yellow have high similarity. The residues involved in LIR interactions (Atg13, p62, PLEKHM1, 
Optinurin, Nix and ALFY) are shown by a red arrow, and all other interacting residues are 
identical, except for Phe52 in LC3 proteins and Tyr49 in GABARAP proteins. The sequence 




Mammalian Atg8 homologues have very similar structures, and interact with 
their binding partners in a similar fashion (Sugawara et al., 2004). They have a core 
ubiquitin-like fold, and their overall secondary and tertiary structures are similar to 
yeast Atg8 (Figure 5.1A) (Paz et al., 2000, Bavro et al., 2002, Sugawara et al., 2004). 
Not surprisingly, the human ATG8 homologues share high sequence similarity (96%) 
(Figure 5.1B). Despite their similar structures and sequences, the GABARAP and 
LC3 proteins interact with the LIRs with different binding affinities. This suggests 
that the mode of interaction with the LIR differs between GABARAP and LC3 
proteins.  
In this chapter, a combination of surface plasmon resonance (SPR), X-ray 
crystallography and molecular dynamics simulations were used to demonstrate that 
mutation of a single amino acid affects the “W-site” hydrophobic pocket of LC3A, 
reducing its binding affinity with the ULK1 LIR, whereas the corresponding mutation 
in GABARAP does not affect the binding affinity with the ULK1 LIR. This 
difference in binding mechanism at the “W-site” hydrophobic pocket suggests that 






5.2.1 Purification of LC3A and GABARAP.  
To study the crystal structures and perform SPR experiments, pure protein 
samples were required. To achieve this, DNA encoding LC3A (2–121) and 
GABARAP (2–117) was cloned into the pET30ΔSE vector, which expresses with a 
His6 tag. The modified pET30ΔSE vector, which has the serine and glutamic acid 
residues deleted from the linker region between the tag and cloning sites of pET30, 
was used to reduce the number of residues in the tagged protein that are not part of the 
protein of interest. Protein was expressed from these vectors in E. coli BL21(DE3). 
The His6-tagged LC3A and GABARAP proteins were isolated and purified from the 
cell lysate using Ni-NTA affinity chromatography. Following the removal of the His6 
tag by thrombin cleavage, the protein was purified by SEC, as shown by sharp peaks 
in the chromatograms (Figure 5.2A and 5.2B). Samples from the peak fractions were 
analysed on an SDS-PAGE gel (Figure 5.2C), which showed bands at ~15 kDa, 
corresponding to the molecular weights of LC3A (2–121) and GABARAP (2–117).  
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Figure 5.2: A&B: SEC chromatograms for the purification of LC3A and GABARAP, 
respectively. The purified proteins were visualised as a distinct peak in each of the 
chromatograms (red box). The samples from these fractions were analysed on an SDS-
PAGE gel (C), which shows bands for the purified LC3A and GABARAP at the expected size 
(~15 kDa). 
5.2.2 GABARAP has a higher binding affinity for the ULK1 LIR peptide 
than LC3A. 
Using SPR fitted to the 1:1 Langmuir isotherm model (Figure 5.3A–D), the 
binding affinity of LC3A and GABARAP with the ULK1 LIR peptide 
(KSCDTDDFVMVPAQ) was measured. To determine the association and 
dissociation constants, LC3A and GABARAP were injected as analytes, and the 
ULK1 LIR peptide was immobilised to the chip. GABARAP bound the ULK1 LIR 
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peptide with significantly higher affinity (KD = 0.3 ± 0.05 µM) than the LC3A protein 
(KD = 4.4 ± 0.5 µM). A scrambled version of the ULK1 LIR peptide 
(KVSFPQACDMDTVD) was used as a negative control, and did not bind to either 
LC3A or GABARAP. The data was consistent across the triplicate samples collected 
for both proteins (Figure 5.4). The kon and koff rates were very fast for both proteins, 
such that it was difficult to fit these with meaningful values (Figure 5.4).   
 
Figure 5.3: A & C. 1:1 Langmuir model for wild-type (wt) LC3A and GABARAP fitted for the 
triplicate data sets. The equilibrium-binding constant was calculated from the response vs. 
concentration curve. The KD value of GABARAP (KD = 0.3 ± 0.05 µM) showed it had a 12-fold 
higher binding affinity than LC3A (KD = 4.4 ± 0.6 µM) for the ULK1 LIR. B & D. Scatchard plot 
for the average from the triplicate data showed the relative binding affinity and the difference 
in binding affinity between LC3A and GABARAP. GABARAP had higher binding affinity and 
agreed with the 1:1 Langmuir model. 
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Figure 5.4: Triplicate SPR response data collected for wt LC3A and GABARAP. The 
response data is shown in black, and six concentrations of LC3A (25 µM, 12.5 µM, 6.25 µM, 
3.125 µM, 1.56 µM and 0.78 µM) and six concentrations of GABARAP (1.56 µM, 0.78 µM, 
0.39 µM, 0.195 µM, 0.097 µM and 0.048 µM) were injected. The data points from the region 
marked by the red box were averaged and used in the 1:1 Langmuir model to calculate the 
binding affinity. 
5.2.3 Crystal structure of the ULK1 LIR fused to GABARAP demonstrates 
that LIR interaction is similar in LC3A and GABARAP 
Given the close sequence and structural similarities of the unliganded 
GABARAP and LC3A proteins (Figure 5.1B), it was surprising that these proteins 
bind the ULK1 LIR peptide with different affinities. To address this at the molecular 
level, the crystal structure of GABARAP in complex with the ULK1 LIR was solved 
(to 2.09-Å resolution, data collection and refinement statistics in Table 5.1), and 
compared with the previously reported LC3A-ATG13 LIR structure ((Suzuki et al., 
2014), PDB code: 3WAN; ATG13 LIR sequence DDFVMI). The ULK1 LIR peptide 
(354–TDDFVMV–360) was fused at the N-terminus of GABARAP, generating a 
GABARAP-ULK1 LIR chimera. In the structure, the ULK1 LIR peptide interacted 
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with a symmetry-related GABARAP molecule in the crystal lattice (Figure 5.5A). 
The aromatic amino acid Phe357 of the ULK1 LIR docked into the “W-site” 
hydrophobic pocket, and Val360 interacted at the “L-site” hydrophobic pocket 
(Figure 5.5A). The main chains of Val358 and Val360 formed hydrogen bonds with 
the main chains of Leu50 and Lys48 in GABARAP. The main chain oxygen of 
Val360 also formed a hydrogen bond with side chain nitrogen of Arg28 at the (NH1) 
position (Figure 5.5B). 
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Figure 5.5: A. (Left panel) Cartoon representation of ULK1 LIR-GABARAP (cyan) showing the 
interaction of the ULK1 LIR (red sticks) with GABARAP, and (right panel) surface 
representation of “W-site” and “L-site” hydrophobic pockets (in red) of GABARAP showing the 
position at which Phe357 and Val360 of the ULK1 LIR interact with the hydrophobic pocket. 
B. Backbone of Val358 and Val360 in ULK1 LIR (red) forms hydrogen bonds with residues 
from GABARAP (cyan). C. Structural overlay of various LIRs interacting with GABARAP. All 
the LIRs examined interact with the ULK1 LIR in the same conformation. 
The binding conformation of the peptide against the GABARAP surface is 
similar to that of other ATG8-LIR complexes (Figure 5.5C) (Genau et al., 2015, 
Thielmann et al., 2009, Lystad et al., 2014). Structural comparison between LC3A-
ATG13 LIR ((Suzuki et al., 2014), PDB code 3WAN) and GABARAP-ULK1 LIR 
shows a similar orientation of the LIR peptide in both the LC3A and GABARAP 
proteins (Figure 5.6A). 
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Figure 5.6: A. Structural comparison of ATG13 LIR-LC3A residues (green) and ULK1 LIR-
GABARAP residues (cyan) with the ATG13 LIR peptide in orange, and the ULK1 LIR peptide 
in red. This demonstrated the presence of a tyrosine residue in GABARAP instead of 
phenylalanine in LC3A at the corresponding position. B. Structural comparison of GABARAP 
in liganded and unliganded forms. The residues in purple were in complex form, and the 
residues in cyan were in unliganded form. A 6.6-Å structural rearrangement of the Lys46 side 
chain was observed between the two forms.  
Structural comparison of the unliganded (PDB code; 1GNU) and the liganded 
forms of GABARAP (Figure 5.6B) demonstrated that Lys46 gates peptide binding at 
the “W-site” site, as recently demonstrated for LC3X (Suzuki et al., 2014). In this 
mechanism, the amino group of Lys46 moved 6.6 Å between its open and closed 
states. The most obvious sequence difference between LC3A and GABARAP at the 
“W-site” is the presence of Tyr49 in GABARAP, instead of Phe52 in LC3A (Figure 
5.6B). The sequence alignment between all human ATG8 proteins (Figure 5.1B) 
demonstrates that the residues involved in LIR interaction (marked with red arrows) 




Figure 5.7: A & B show a surface representation of LC3A in unliganded (A) and liganded 
forms (B) with the ATG13 LIR. The most hydrophobic and hydrophilic regions, as determined 
by the Kyte-Doolittle algorithm, are shown in orange-red and blue, respectively. The figure 
was generated using Chimera. The “W-site” hydrophobic pocket, marked with a yellow circle, 
shows a closed conformation in the unliganded form and an open conformation in the 
liganded form. C & D show a surface representation of GABARAP in unliganded (A) and 
liganded forms (B) with the ULK1 LIR. Colouring is as described in panels A and B. The “W-
site” hydrophobic pocket, marked with a yellow circle, shows an open conformation in both 
unliganded and liganded forms. 
Structural comparison of the unliganded (GABARAP PDB code: 1GNU; 
LC3A PDB code: 3WAL) and liganded (LC3A PDB code: 3WAN) forms of 
GABARAP and LC3A using surface representation (Figure 5.7) showed that the “W-
site” hydrophobic pocket in LC3A opens only in the liganded state, and remains 
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closed in the unliganded state (Figure 5.7A and B). However, in GABARAP, the “W-
site” hydrophobic pocket remains open regardless of the ligand-binding state (Figure 
5.7C and D). This clearly shows that the difference in the LIR-binding mechanisms of 
LC3A and GABARAP occurs at the “W-site” hydrophobic surface. 
5.2.4 Molecular dynamics simulations demonstrate that Arg70 in LC3A 
and Arg67 in GABARAP interact differently with the ULK1 LIR. 
Given that there is a noticeable structural difference at the “W-site” 
hydrophobic surface between liganded and unliganded structures of GABARAP and 
LC3A, the dynamics of the structures were investigated to verify: 1) whether LC3A is 
more dynamic than GABARAP; 2), whether Phe357 and Val360 of the ULK1 LIR 
interact differently with the “W-site” and the “L-site” of LC3A and GABARAP; and 
3) whether there are any other amino acids that play key roles in the interaction with 
the ULK1 LIR. To investigate these questions, a 100-ns molecular dynamics 
simulation was performed on the crystal structures of unliganded and liganded LC3A 
and GABARAP. The LIR sequence of ATG13 (FVMI) was modified to the 
ULK1LIR sequence (FVMV) in the ATG13 LIR-LC3A (3WAN) crystal structure and 
used as the initial coordinate file for the ULK1 LIR-LC3A simulation. 
The RMSD calculated for the α-carbon with the starting frame as the reference 
(Figure 5.8) showed that the LC3A structures were more dynamic than the 
GABARAP structures in both liganded and unliganded simulations. The RMSD of 
ULK1 LIR-GABARAP displayed a more stable simulation than unliganded 
GABARAP, suggesting that interaction with the ULK1 LIR may stabilise GABARAP 
(Figure 5.8A and D). However, no such differences were noticed in the RMSD of 
liganded and unliganded LC3A simulations (Figure 5.8B and E). Overall, the RMSD 
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also provided information about the quality of the simulation, and suggested that all 
six simulations were stable over a period of 100 ns (Figure 5.8A–F). To support the 
simulation data that suggested LC3A was more dynamic, thermostability assays were 
performed using differential scanning fluorimetry (DSF) (Figure 5.8G). The results 
correlated with the simulation data, as the less dynamic protein, GABARAP, had a 
higher melting point (55°C) than LC3A (47°C) (Figure 5.8G), indicating that it was 
more stable.  
 
Figure 5.8: Panels A–F show the RMSD of GABARAP, LC3A, LC3A-R70L, ULK1 LIR-
GABARAP, ULK1 LIR-LC3A and ULK1 LIR-LC3A-R70L, respectively. The RMSD was 
calculated for the α-carbon over the entire duration of the simulation (100 ns) using the gmx 
rms function of GROMACS and the starting frame as the reference frame. The plot 
demonstrates a more dynamic simulation for LC3A and ULK1 LIR-LC3A (around 0.3 nm) than 
for GABARAP and ULK1 LIR-GABARAP (≤0.2 nm). G. The DSF plot shows GABARAP has 
greater thermal stability (melting temperature: 55°C) than LC3A (melting temperature: 46°C). 
Next, the “W-site” and “L-site” hydrophobic pockets of LC3A and 
GABARAP were analysed using the simulation data. The crystal structure clearly 
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showed that the LC3A “W-site” hydrophobic pocket was more dynamic between its 
LIR-bound and -unbound states than GABARAP. Therefore, it was interesting to 
analyse the RMSD of ULK1 LIR amino acids Phe357, which interacts at the “W-
site”, and Val360, which interacts at the “L-site” (Figure 5.9). The RMSD for α-
carbons was calculated by aligning the ULK1 LIR peptide with the protein (LC3A or 
GABARAP). Consistent with the SPR data, which showed LC3A had lower binding 
affinity for the ULK1 LIR than GABARAP, LC3A had a more dynamic Phe357 at the 
“W-site” than GABARAP (Figure 5.9A). However, Val360 at the “L-site” did not 
show much dynamic difference between LC3A and GABARAP (Figure 5.9B). This 
result, consistent with both SPR data and structural comparison, clearly indicated that 
the weaker binding affinity of LC3A towards the ULK1 LIR is caused by the dynamic 
“W-site” hydrophobic pocket of LC3A, which does not make a strong hydrophobic 
interaction with Phe357 of the ULK1 LIR. 
 
Figure 5.9: A. Comparison of the RMSD of ULK1 LIR Phe357, which interacts with the “W-
site” in both LC3A (blue) and GABARAP (green), shows greater flexibility in LC3A, suggesting 
a weaker interaction of ULK1 LIR with LC3A compared with that of GABARAP. B. 
Comparison of RMSD of ULK1 LIR Val360, which interacts at the “L-site” in both LC3A (blue) 
and GABARAP (green), does not show much difference in the flexibility between the two 
proteins. 
Finally, the simulation data were used to identify the amino acids in LC3A 
and GABARAP that interacted differently with the ULK1 LIR. Considering the lower 
binding affinity of LC3A towards the ULK1 LIR, we were interested to determine 
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whether there were any additional interactions that supplemented the hydrophobic 
interaction in LC3A. A visual inspection of the frames from the simulation of ULK1 
LIR-LC3A and ULK1 LIR-GABARAP showed that the guanidinium side chain of 
Arg70 in LC3A was in close proximity to the main chain oxygen of Met359 of the 
ULK1 LIR. Consequently, the distance between the guanidinium side chain of Arg70 
and the main chain oxygen of Met359, and the corresponding residues in GABARAP 
(side chain guanidinium of Arg67 and main chain oxygen of Met359), was calculated 
(Figure 5.10). Interestingly, the side chain of LC3A Arg70 made a consistent 
electrostatic interaction throughout the simulation at a distance of less than 3 Å 
(Figure 5.10B). To verify that it was an interaction between Arg70 and Met359, and 
not an artefact resulting from the dynamic nature of LC3A, Arg70 was replaced with 
leucine, which does not have a positively charged side chain. As expected, the Leu70 
side chain was 6–8 Å from Met359, which is beyond the distance for electrostatic 
interaction (Figure 5.10C). The side chain of Arg67 in GABARAP was also ~6 Å 
from the main chain of Met539 (Figure 5.10A). The effect of Arg70 in LC3A and 




Figure 5.10: A. The distance between the side chain of Arg67 in GABARAP and Met359 in 
the ULK1 LIR was measured using visual molecular dynamics (shown in red dots for each 
frame). The average distance throughout the simulation was ~6 Å, suggesting no interaction 
between the two residues. B. The distance between the side chain of Arg70 in LC3A and 
Met359 in the ULK1 LIR was measured, and showed an average distance of <3 Å throughout 
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the simulation, suggesting an electrostatic interaction between the residues. C. The distance 
between the side chain of Leu70 in LC3A-R70L and Met359 in the ULK1 LIR was measured, 
and the distance of approximately 6–8 Å suggested no interaction between the residues. 
5.2.5 Purification of LC3A and GABARAP wild-type protein. 
Structural studies and molecular dynamics simulations suggested that two 
amino acid positions (Arg70 and Phe52 in LC3A and Arg67 and Tyr49 in 
GABARAP) may be important for the variable binding affinity between GABARAP 
and LC3A to the ULK LIR. To study the effect of the charge of Arg70 in LC3A and 
Arg67 in GABARAP in the “L-site” binding pocket, the arginine residues were 
mutated to leucine. To determine whether the tyrosine at position 49 in the “L-site” 
binding pocket in GABARAP proteins and the phenylalanine at the equivalent 
position in LC3 proteins was functionally significant, the two residues were swapped. 
Four mutant proteins were generated: GABARAP-R67L, GABARAP-Y49F, 
LC3A-R70L and LC3A-F52Y. DNA encoding the four mutant proteins was cloned 
into pET30ΔSE, which was used to express the proteins with N-terminal His6 tags in 
E. coli BL21(DE3). Similar to wild-type purification, the four mutant proteins were 
isolated and purified from the cell lysate using Ni-NTA affinity chromatography. The 
target protein samples were purified by SEC, following cleavage of the His6 tag by 
thrombin. The purified protein samples were observed as sharp peaks in the SEC 
chromatograms (Figure 5.11A–D), and samples from the peak fractions were 
analysed by SDS-PAGE (Figure 5.11E), which revealed bands of ~15 kDa, 
corresponding to the expected molecular weights of the mutant proteins.  
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Figure 5.11: A–D. Chromatograms for SEC purification of LC3A-R70L, GABARAP-R67L, 
LC3A-F52Y and GABARAP-Y49F, respectively. The purified proteins were observed as 
distinct peaks in the chromatogram (red boxes). (E) Samples from the fractions 
corresponding to the peak were analysed by SDS-PAGE, which showed bands for LC3A-
R70L, LC3A-F52Y, GABARAP-R67L and GABARAP-Y49F at the expected size of ~15 kDa. 
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5.2.6 Differences in the interactions between Arg70 in LC3A and Arg67 in 
GABARAP contribute to the binding affinity. 
5.2.6.1 Initial binding analysis using pull-down assay shows the ULK1 
LIR peptide binds to LC3A and GABARAP and their mutants. 
Pull-down assays were performed to assess differences in ULK1 LIR binding 
affinities for LC3A, LC3A-R70L, LC3A-K49A, GABARAP, GABARAP-R67L and 
GABARAP-K46A (Figure 5.12). The LC3A-K49A and GABARAP-K46A mutants 
were used as controls because the LC3A-K49A mutant demonstrated higher binding 
affinity than LC3A in a pull-down assay (Suzuki et al., 2014). The mutants LC3A-
R70L and GABARAP-R67L bound with the GST-tagged ULK1 LIR peptide. It also 
confirmed the binding of LC3A and GABARAP, as reported previously. Incubation 
of mutants and wild-type proteins with the GST tag only demonstrated they did not 
interact with the GST tag. Although the pull-down assay results verified the binding 
of mutants and wild-type proteins with the ULK1 LIR, no differences in binding 
affinity were observed in spite of optimisation of the protein concentration, wash 
conditions and incubation time, and repeating the experiment several times.  
Consequently, the more sensitive technique of SPR was used to measure the 




Figure 5.12: SDS-PAGE gel showing the results of the pull-down assay performed between 
GST-ULK1 LIR and LC3A, LC3A-K49A, LC3A-R70L, GABARAP, GABARAP-K46A and 
GABARAP-R67L. Lane 1: GST-fused ULK1 LIR (correct band size marked in yellow). Lanes 
2–4: control proteins LC3A, LC3A-K49A and LC3A-R70L (correct band size marked in red). 
Lanes 5–7: pull-downs of LC3A, LC3A-K49A and LC3A-R70L with GST-fused ULK1 LIR. 
Lanes 8–10: control proteins GABARAP, GABARAP-K46A and GABARAP-R67L (correct 
band size marked in red). Lanes 11–13: pull-downs of GABARAP, GABARAP-K46A and 
GABARAP-R67L with GST-fused ULK1 LIR. 
5.2.6.2 Differences in the interaction between Arg70 in LC3A and Arg67 
in GABARAP contribute to the binding affinity. 
The binding affinities of LC3A-R70L and GABARAP-R67L to the ULK1 
LIR peptide were measured and compared with the wild-type protein using SPR. The 
dissociation constant for LC3A-R70L was 11 ± 1 µM, which causes a significant 
decrease in binding affinity compared with the wild-type LC3A (KD = 4.4 ± 0.5 µM). 
The dissociation constant for GABARAP-R67L of 0.4 ± 0.03 µM was similar to that 
of the wild-type GABARAP protein (KD = 0.3 ± 0.05 µM). The sensograms for 
LC3A-R70L and GABARAP-R67L followed the same trend as their wild-type 
counterparts: fast on and off rates (Figure 5.13A and 5.13C, replicate data shown in 
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Figure 5.14). Thus, an arginine residue at the “L-site” hydrophobic pocket is 
important for binding the ULK1 LIR in LC3A, but not for GABARAP.  
 
Figure 5.13: A & C. 1:1 Langmuir models for LC3A-R70L and GABARAP-R67L fitted for 
triplicate data set. Equilibrium binding constants were calculated from the response vs. 
concentration curve. The KD value of LC3A-R70L (11 ± 1 µM) showed it had 2.5 times less 
binding affinity than LC3A ( 4.4 ± 0.6 µM). There was no difference in KD between GABARAP-
R67L and GABARAP. B & D. Scatchard plots for the average of the triplicate data shows 




Figure 5.14: SPR response data collected in triplicate for LC3A-R70L and GABARAP-R67L. 
The response data is shown in black, and six concentrations of both LC3A-R70L (25 µM, 12.5 
µM, 6.25 µM, 3.125 µM, 1.56 µM and 0.78 µM) and GABARAP-R67L (1.56 µM, 0.78 µM, 0.39 
µM, 0.195 µM, 0.097 µM and 0.048 µM) were injected. The data points from the regions 
marked by red boxes were used in the 1:1 Langmuir model to calculate the binding affinity. 
5.2.6.3 Presence of Tyr49 in GABARAP or Phe52 in LC3A has little 
effect on binding affinity for the ULK1 LIR peptide. 
The dissociation constants of LC3A-F52Y and GABARAP-Y49F for the 
ULK1 LIR peptide were not different from wild-type proteins. The dissociation 
constant for LC3A-F52Y was 3.8 ± 0.5 µM, compared with 4.4 ± 0.5 µM for LC3A. 
The dissociation constant for the GABARAP-Y49F mutant was 0.42 ± 0.03 µM, 
compared with 0.3 ± 0.05 µM for GABARAP. The sensograms for LC3A-F52Y and 
GABARAP-Y49F were consistent with the wild-type and arginine mutant data, with 
the same trend of fast on and off rates (Figures 5.15A and 5.15C, replicate data shown 
in Figure 5.16). Thus, the presence or absence of the hydroxyl group had little effect 
on the binding affinity of LC3A and GABARAP for the ULK1-LIR. 
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Figure 5.15: A & C. 1:1 Langmuir models for LC3-F52Y and GABARAP-Y49F fitted for 
triplicate data sets. The equilibrium binding constants were calculated from the response vs. 
concentration curve. There were no differences in KD between LC3A-F52Y and LC3A-wt or 
between GABARAP-Y49F and GABARAP-wt. B & D. Scatchard plots for the average from 
the triplicate data show GABARAP-Y49F has higher binding affinity for the ULK1-LIR than 
LC3A-F52Y, which agrees with the 1:1 Langmuir model. 
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Figure 5.16: SPR response data collected in triplicate for LC3A-F52Y and GABARAP-Y49F. 
The response data is shown in black, and six concentrations of both LC3A-F52Y (25 µM, 12.5 
µM, 6.25 µM, 3.125 µM, 1.56 µM and 0.78 µM) and GABARAP-Y49F (1.56 µM, 0.78 µM, 0.39 
µM, 0.195 µM, 0.097 µM and 0.048 µM) were injected. The data points from the regions 
marked by red boxes were used in the 1:1 Langmuir model to calculate the binding affinity. 
5.3 Summary 
The GABARAP protein has a 14-fold higher binding affinity towards the 
ULK1 LIR than LC3A, as demonstrated by SPR. Although the binding affinities 
differ significantly, LC3A and GABARAP displayed a similar response profile (box 
shape), which matched the response profile reported by Suzuki et al. (2014). The 
difference in binding affinity, despite the close sequence similarity and similar 
binding response profile, suggested that the ULK1 LIR interaction mechanisms of 
GABARAP and LC3A are different. 
The interaction of the ULK1 LIR motif with GABARAP was verified by 
solving the crystal structure of the ULK1 LIR fused to GABARAP. Structural 
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comparison of liganded and unliganded forms of GABARAP and LC3A 
demonstrated that LC3A has a more dynamic “W-site” hydrophobic pocket, which 
resembles an open-and-close mechanism, whereas the GABARAP “W-site” 
hydrophobic pocket remained in an open state regardless of ligand binding, 
suggesting a more stable and less dynamic “W-site”.  
Molecular dynamic simulation suggested that LC3A was more dynamic than 
GABARAP. Interestingly, thermostability data supported the simulation data by 
demonstrating that GABARAP has a higher melting temperature than the more 
flexible LC3A. Further analysis of the “W-site” hydrophobic pocket suggested that 
the aromatic side chain of Phe357 in the ULK1 LIR made a more stable interaction 
with GABARAP than with LC3A. Taken together, the structural, SPR and MD 
simulation data suggest that the “W-site” hydrophobic pocket regulates the ULK1 
LIR interaction differently in LC3A than in GABARAP. Further investigation of the 
role of Arg70 in LC3A and Arg67 in GABARAP suggested that the former plays a 
key role in the interaction with Met359 in the ULK1 LIR, whereas the latter does not 
have a role in LIR interaction. 
Mutating the corresponding arginines in both LC3A (Arg70) and GABARAP 
(Arg67) to leucine affected the LIR binding affinities of the respective proteins 
differently. The R70L mutation in LC3A caused a significant 2.5-fold decrease in 
binding affinity compared with wild-type LC3A, whereas the R67L mutant of 
GABARAP displayed no difference in binding affinity compared with wild-type 
GABARAP. The presence or absence of a hydroxyl group in Tyr49 (GABARAP) or 
Phe52 (LC3A) did not have an effect on the binding affinity. The above observations 
suggested that arginines at corresponding positions in LC3A and GABARAP interact 
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differently with the ULK1 LIR, and that the charge of the side chain of residue 70, 
located at the hydrophobic pocket, is important for LC3A but not for GABARAP. 
In conclusion, this chapter provides an explanation for the differences in 
binding affinities of the ULK1 LIR towards LC3A and GABARAP, despite the 
structural and sequence similarities between these two proteins. The overall 
architecture of the GABARAP structure allows a stable hydrophobic interaction of the 
aromatic amino acid residue from the LIR motif at the “W-site”, whereas the dynamic 
nature of the LC3A “W-site” hydrophobic surface results in a less stable interaction 
with the aromatic amino acid from the LIR. Introducing amino acids to stabilise the 
LC3A “W-site” pocket and analysing their effects on binding affinity would provide 
more information on the role of the “W-site” hydrophobic pocket in preferential 
binding of the LIR motifs. To balance the weak hydrophobic LIR interaction in 
LC3A, Arg70 plays a key role by interacting with the LIR, as shown by the change in 
binding affinity when it is replaced by leucine. In contrast, the arginine at the 
corresponding position in GABARAP does not have any effect on the binding 
affinity. These findings show a clear difference in the interaction mechanisms of 




Chapter 6.  CONCLUSIONS 
In eukaryotic cells, degradation of unstable proteins, protein aggregates, and 
organelles through a complex cellular pathway called autophagy is important for 
maintaining homeostasis (Mizushima et al., 2008). More than 32 autophagy-related 
proteins orchestrate the autophagy pathway through a complex protein-protein 
interaction network (Behrends et al., 2010). Although considerable effort has gone 
into understanding this pathway, the interaction between the proteins involved in 
autophagy is not well understood. 
The work in this thesis focused on two interactions: (i) the LIR-independent 
interaction between ATG13 and FIP200, which are components of the human 
autophagy initiation complex known as the ULK1 complex; and (ii) the LIR-
dependent interaction between members of the human ATG8 protein family and the 
PLEKHM1 LIR peptide, and the LIR-dependent interaction between LC3A and 
GABARAP with the ULK1 LIR peptide. 
6.1 Mapping the ATG13 binding region in FIP200. 
FIP200 and ATG13 are components of the ULK1 initiation complex. 
However, it is not known how the two proteins interact with one another. Previous 
studies suggest that the ULK1-ATG13-FIP200 complex is important for the 
regulation of starvation-induced autophagy (Jung et al., 2009, Chang & Neufeld, 
2009). The working model is that, under nutrient-rich growth conditions, the 
serine/threonine kinase activity of ULK1 is supressed by the phosphorylation of 
ULK1 and ATG13 by mTOR. During starvation, inhibition of mTOR leads to 
phosphorylation of ATG13 and FIP200 by ULK1, which in turn leads to the induction 
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of autophagy (Chan, 2009). However, a knock-out study by Alers et al. (2011) that 
investigated the role of the ULK1-ATG13-FIP200 complex showed that the combined 
action of ATG13 and FIP200 was critical for the induction of autophagy, whereas the 
ULK1/ULK2 has no significant function in starvation-induced autophagy. 
Furthermore, in a co-immunoprecipitation assay, the amount of FIP200 that bound to 
ATG13 was higher than that of ULK1 and ULK2, suggesting that ATG13 binds 
FIP200 more tightly than ULK1/ULK2 (Jung et al., 2009). Therefore, understanding 
the interaction between ATG13 and FIP200 is an important step towards a clear 
understanding of the function of the ULK1 initiation complex. 
Previous work by Jung et al. (2009) showed that residues 384–517 in the C-
terminal region of ATG13 bind FIP200, ULK1 and ULK2. Although the ATG13 
binding sites on ULK1 (829–1051) and ULK2 (651–1036) have been mapped, the site 
on FIP200 that binds ATG13 is unknown. In this thesis, attempts were made to map 
the region of FIP200 that binds to ATG13. To narrow down the location of the 
binding region in FIP200, the full length FIP200 gene was divided into six parts, P1 
(2–266), P2 (267–531), P3 (532–796), P4 (797–1061), P5 (1062–1328) and P6 
(1327–1591), and each was cloned into the pCold™ TF expression vector to aid 
expression and solubility. 
Pull-down assays were performed to map the ATG13 interaction site in 
FIP200. Because of the false positive interaction of FIP200 polypeptides with the 
GST tag, the pull-down assay analysis did not provide results that could be used for 
further analysis. A possible cause for this false positive could be that the FIP200 
polypeptides were improperly folded, causing them to interact with the GST tag. Use 
of a different tag, such as maltose-binding protein, could be useful for improved 
purification of ATG13 and clearer results in the pull-down assay. Future experiments 
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to map the ATG13-binding region of FIP200 should include careful consideration of 
the regions to be truncated, further optimisation of the expression and purification 
parameters to ensure the quality of protein used in the pull-down assay is acceptable, 
verification of the folding of the FIP200 polypeptides and ATG13, and exploration of 
different techniques, such as SPR, to map the interaction.  
6.2 GABARAP family proteins have higher binding affinity 
towards the PLEKHM1 LIR than LC3 family proteins. 
GABARAP family proteins have higher binding affinity towards the 
PLEKHM1 LIR than LC3 family proteins. In Chapter 4, the interaction between the 
PLEKHM1 LIR and human ATG8 protein family members was investigated by 
solving the crystal structures of the PLEKHM1 LIR in complex with LC3A, LC3C, 
GABARAP and GABARAPL1. The crystal structure of the PLEKHM1 LIR in 
complex with LC3B (PDB code: 3X0W, (McEwan et al., 2015)) was included in the 
analysis.  
Recently, PLEKHM1 was identified as a human ATG8 interaction partner that 
facilitates fusion between autophagosomes and lysosomes (McEwan et al., 2015). 
Interestingly, unpublished ITC data (refer to Chapter 4, Table 4.1) kindly provided by 
Vladimir Rogov from Prof. Ivan Dikic’s lab shows that GABARAP family proteins 
have significantly higher binding affinity towards the PLEKHM1 LIR peptide 
(GABARAP: KD = 0.55 µM and GABARPL1: KD = 0.77 µM) than LC3 family 
proteins (LC3A: KD = 4.22 µM, LC3B KD = 6.33 µM and LC3C KD = 3.45 µM). 
Similar findings were reported for the interaction between the human ATG8 family 
proteins with the members of the ULK1 initiation complex (ULK1, FIP200 and 
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ATG13), where GABARAP family proteins were shown to have higher binding 
affinity than LC3 family proteins (Alemu et al., 2012). 
Based on this information, it was predicted that the structural comparison of 
the PLEKHM1 LIR in complex with LC3A, LC3B, LC3C, GABARAP and 
GABARAPL1 would show significant differences in the interaction of the 
PLEKHM1 LIR across the five human ATG8 proteins, and provide a possible 
explanation for the difference in binding affinity between GABARAP proteins and 
LC3 proteins. However, all five structures of the PLEKHM1 LIR in complex with 
human ATG8 proteins were comparable, and interacted with the PLEKHM1 LIR in a 
similar manner (refer to Section 4.2.2). Despite this similarity across all five human 
ATG8 structures (LC3A, LC3B, LC3C, GABARAP and GABARAPL1), subtle 
differences may contribute to the tighter interaction of the PLEKHM1 LIR with the 
GABARAP proteins than with the LC3 proteins. 
In particular, the interaction of the PLEKHM1 LIR residues Asn637 and 
Trp635 with the human ATG8 proteins was explored (refer to Section 4.2.3). There 
are several reasons why these electrostatic interactions show promise as an 
explanation for the higher binding affinity of the PLEKHM1 LIR towards GABARAP 
proteins (refer to Table 4.3 for summary of interactions and binding affinity). First, 
the presence of Arg28 in GABARAP and GABARAPL1, compared with lysine at the 
corresponding position in LC3 proteins, allows the side chain of Arg28 to structurally 
rearrange by 4 Å, and interact with Asn637 of the PLEKHM1 LIR (refer Figure 4.7). 
A similar interaction was found between Lys36 (without side chain structural re-
arrangement) of LC3C, which has the highest binding affinity among LC3 proteins, 
and Asn637 of the PLEKHM1 LIR; however, this residue not found in other LC3 
proteins. Second, the PLEKHM1 LIR residue Trp635 interacts with Glu17 in 
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GABARAP and GABARAPL1, whereas a similar interaction was not observed in 
LC3 proteins (refer Figure 4.7).  
A survey of the Protein Data Bank for GABARAP family proteins in complex 
with other LIR motifs was conducted. In the case of the autophagy-linked FYVE 
protein (ALFY) LIR-GABARAP complex structure (a comparison of PLEKHM1 
LIR-GABARAP and ALFY LIR-GABARAP complexes is shown in Figure 6.1A and 
B), the electrostatic interaction between GABARAP residues Lys24/Tyr25/Asp54 and 
ALFY residues Asp3344 and Tyr3351 may contribute to the binding affinity (Lystad 
et al., 2014). However, residues at the corresponding positions in LC3A and LC3B 
(Gln26/His27/His57) did not interact with ALFY residues Asp3344 and Tyr3351 
(Lystad et al., 2014). The interaction of Asp3344 and Tyr3351 of the ALFY LIR with 
GABARAP, but not with LC3A and LC3B, is only a subtle difference but is proposed 
to have an effect on binding affinity with the LIR (Lystad et al., 2014). Similarly, the 
interaction of Trp635 and Asn637 in the PLEKHM1 LIR with GABARAP proteins, 
which is either weak or absent in LC3 proteins (see Section 4.2.3), may contribute to 





Figure 6.1: A. Interaction of the PLEKHM1 LIR with GABARAP. Comparison between 
liganded (green) and unliganded (orange) Glu17 shows that Trp635 of the PLEKHM1 LIR 
interacts with Glu17 in the liganded form. Similarly, Arg28 interacts with Asn637 of the 
PLEKHM1 LIR. B. Interaction of the ALFY LIR (orange) with GABARAP. Lys24 and Tyr25 of 
GABARAP interact with Asp3344 of the ALFY LIR, and Asp54 of GABARAP interacts with 
Tyr3351 of the ALFY LIR, demonstrating electrostatic interactions besides the hydrophobic 
interaction. 
In addition to the differences in electrostatic interactions between LC3 and 
GABARAP proteins, there is a difference in the “W-site” hydrophobic pocket (refer 
to Section 4.2.4). In GABARAP proteins, the “W-site” hydrophobic pocket is deeper 
than in LC3 proteins, and has a conformation that can better accommodate the bulkier 
aromatic amino acid from the LIR motif (refer to Figure 4.8). This notable difference 
in the architecture of the “W-site” hydrophobic pocket between the two protein 
families may also contribute to the variation in binding affinity for the PLEKHM1 
LIR across the members of the human ATG8 family of proteins.  
Taken together, the above discussion provides a possible rationale for the 
higher binding affinity towards the PLEKHM1 LIR demonstrated by GABARAP 
family proteins. These interactions could be further probed by verifying the binding 
affinity of Glu17/Arg28 double mutants of GABARAP proteins towards the 
PLEKHM1 LIR. 
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The difference in binding affinity might also have implications for biological 
function. Because PLEKHM1 mediates the fusion of the lysosome to the 
autophagosome (called the autolysosome) (McEwan et al., 2015), which occurs 
during the final stage of autophagosome formation, it is possible that PLEKHM1 has 
a preference for GABARAP proteins over LC3 proteins. This may be explained by 
the observations that GABARAP plays a role in the closure of the autophagosome 
double membrane vesicle, whereas LC3 plays a role during the initial stage of 
autophagosome formation (Weidberg et al., 2010). 
6.3 The “W-site” hydrophobic pocket and Arg70 in LC3A 
affect the interaction with the ULK1 LIR. 
Chapter 5 describes the role of the “W-site” hydrophobic pocket during the 
interaction with the ULK1 LIR peptide and the involvement of Arg70 in LC3A and 
Arg67 in GABARAP. Behrends et al. (2010) demonstrated that 18 proteins with an 
LIR motif bound with lower affinity to LC3B-Arg70Ala than to the wild-type protein. 
In contrast, Arg67Ala in GABARAP (the equivalent mutation) had no effect on 
binding affinity. Therefore, in Chapter 5, amino acids Arg70 in LC3A and Arg67 in 
GABARAP were probed structurally and kinetically using SPR, MD simulation and 
X-ray crystallography, to understand the arginine-mediated mechanistic difference in 
LIR interaction between GABARAP and LC3A.  
SPR experiments demonstrated that the GABARAP protein has 14-fold higher 
binding affinity towards the ULK1 LIR compared with LC3A (refer to Section 5.2.2). 
The difference in binding affinity, despite the close sequence similarity and similar 
binding response profile, suggests that the GABARAP and LC3A interact differently 
with the ULK1 LIR. Structural comparison of the liganded (ULK1-GABARAP and 
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previously solved ATG13-LC3A) and unliganded states of GABARAP and LC3A 
showed both open and closed conformations of the “W-site” hydrophobic pocket in 
the LC3A structure, whereas the “W-site” of GABARAP had an open conformation, 
regardless of its ligand-binding state (refer to Section 5.2.3 and Figure 5.7).  
Molecular dynamics simulations suggested that LC3A was more dynamic than 
GABARAP, and that ULK1 LIR residue Phe357 interacting with the “W-site” 
hydrophobic pocket is more dynamic in LC3A than in GABARAP, suggesting that 
GABARAP makes a more stable interaction with the ULK1 LIR. The simulation also 
suggested the interaction of Arg70 in LC3A with Met359 of the ULK1 LIR. This 
provided key information that the side chain charge of Arg70 could be important for 
the LIR interaction in LC3A.   
It was therefore predicted that when Arg70 in LC3A and Arg67 in GABARAP 
were mutated to leucine, it would affect the binding affinity towards the ULK1 LIR 
differently for the two proteins. It was further hypothesised that the mutation would 
have opposite effects on the binding affinity of LC3A and GABARAP with the 
ULK1-LIR, and this effect on binding affinity would be caused by the loss of the 
charge in the side chain of the arginine. Using SPR, the effect of mutating Arg70 in 
LC3A and Arg67 in GABARAP to leucine was probed (refer to Section 5.2.6.2). 
LC3A-R70L displayed a significant 2.5-fold decrease in binding affinity compared 
with the wild-type LC3A, whereas the binding affinity of GABARAP-R67L remained 
unchanged from wild-type GABARAP (refer Figure 5.13). This suggests that Arg70 
in LC3A plays a role in LIR interaction, but Arg67 in GABARAP does not. 
The key finding for this section was that the “W-site” hydrophobic pocket 
plays an important role in the preferential binding of the LIR motif. This is 
 135 
demonstrated by: 1) SPR data shows higher binding affinity for the ULK1 LIR 
towards GABARAP than to LC3A, 2) structural comparison of ULK1 LIR-
GABARAP and ATG13 LIR-LC3A shows a more dynamic LC3A “W-site” 
hydrophobic pocket between its LIR-bound and -unbound states, 3) molecular 
dynamics simulation shows that interaction of F357 of the ULK1 LIR at the “W-site” 
in LC3A and GABARAP is more dynamic in the former than the in the latter, 
suggesting a less stable interaction in LC3A. 
A second finding is that there may be differences in the mechanisms by which 
LC3A and GABARAP bind to the LIR peptide. This is shown by: 1) the observation 
that mutation of Arg70 in LC3A affects the binding affinity for the ULK1 LIR, but 
mutation at the equivalent residue in GABARAP (Arg67) does not, and 2) the MD 
simulation suggests an electrostatic interaction between Arg70 of LC3A and Met359 
of the ULK1 LIR, whereas no such interaction is observed between GABARAP 
Arg67 and Met359 of the ULK1 LIR. 
In future, performing SPR to measure binding affinities of LC3A with Phe52 
mutated to a non-aromatic amino acid or Arg70/Phe52 double mutants will shed some 
light on the importance of Phe52 in LC3A. Performing cell culture studies on 
GABARAP-R67L and LC3A-R70L mutants would provide evidence on the 
biological functions of Arg70 in LC3A and Arg67 in GABARAP. Solving the crystal 
structure of GABARAP-R67L and LC3A-R70L in complex with the ULK1 LIR and 
comparing them ULK1 LIR-bound wild-type structures will also provide insight into 
the structural changes occurring in Arg70 during LIR interaction.  
 136 
 
Figure 6.2: A. Interaction of the PLEKHM1 LIR (green) and the ULK1 LIR (cyan) with 
GABARAP. Both LIRs interact in similar binding conformations, especially Trp635 of 
PLEKHM1 and Phe357 of ULK1. B. Glu17 and Arg28 of GABARAP interact with Trp635 and 
Asn637 of the PLEKHM1 LIR, whereas neither of these interactions are observed in the ULK1 
LIR-GABARAP structure. 
Overall, two types of LIR motifs were probed in this study: the PLEKHM1 
LIR, from a selective autophagy receptor, and the ULK1 LIR, from the 
macroautophagy pathway. Studies showed the importance of the “W-site” 
hydrophobic pocket in preferential interaction with both LIR motifs. This was 
demonstrated by the interaction of Glu17 at the “W-site” of GABARAP with Trp635 
of the PLEKHM1 LIR, and a the less dynamic interaction between F357 of the ULK1 
LIR and the GABARAP “W-site”. Surprisingly, the binding conformation of Trp635 
in the PLEKHM1 LIR and Phe357 of the ULK1 LIR is very similar, suggesting that 
the interaction at the “W-site” is important in GABARAP (Figure 6.2A). However, 
the interaction between GABARAP Arg28 and the PLEKHM1 LIR Asn637 was not 
found in the ULK1 LIR-GABARAP structure (Figure 6.2B). The work in this thesis 
provides initial insights into differences in LIR interaction mechanisms for LC3 and 
GABARAP proteins, which can be used in future studies to understand the need for 









Chapter 7.  REFERENCES 








Córdoba,	 S.	 R.,	 Knecht,	 E.	 &	 Rubinsztein,	 D.	 C.	 (2010).	 Laforin,	 the	most	








Olsvik,	 H.,	 Øvervatn,	 A.,	 Kirkin,	 V.	 &	 Johansen,	 T.	 (2012).	 ATG8	 family	













Baumeister,	 W.,	 Walz,	 J.,	 Zühl,	 F.	 &	 Seemüller,	 E.	 (1998).	 The	 proteasome:	
Paradigm	of	a	self-compartmentalizing	protease,	Cell	92,	367-380.	
	
Bavro,	 V.	 N.,	 Sola,	 M.,	 Bracher,	 A.,	 Kneussel,	 M.,	 Betz,	 H.	 &	 Weissenhorn,	 W.	






Berendsen,	 H.	 J.	 C.,	 van	 der	 Spoel,	 D.	 &	 van	 Drunen,	 R.	 (1995).	 GROMACS:	 A	








Bjørkøy,	 G.,	 Lamark,	 T.,	 Brech,	 A.,	 Outzen,	 H.,	 Perander,	 M.,	 Øvervatn,	 A.,	
Stenmark,	 H.	 &	 Johansen,	 T.	 (2005).	 p62/SQSTM1	 forms	 protein	








Campbell,	 G.	 R.	 &	 Spector,	 S.	 A.	 (2011).	 Hormonally	 active	 vitamin	 D3	 (1α,25-





a	 protective	mechanism	 in	 normal	 cartilage,	 and	 its	 aging-related	 loss	 is	






Chan,	 E.	 Y.	 W.,	 Kir,	 S.	 &	 Tooze,	 S.	 A.	 (2007).	 siRNA	 Screening	 of	 the	 Kinome	




TOR-mediated	 Autophagy	 Regulation,	 Molecular	 Biology	 of	 the	 Cell	 20,	
2004-2014.	
	
Chano,	 T.,	 Ikegawa,	 S.,	 Kontani,	 K.,	 Okabe,	 H.,	 Baldini,	 N.	 &	 Saeki,	 Y.	 (2002).	























De	 Duve,	 C.	 &	 Wattiaux,	 R.	 (1966).	 Functions	 of	 lysosomes,	 Annual	 Review	 of	
Physiology	28,	435-492.	
	
De	Kreutzenberg,	 S.	 V.,	 Ceolotto,	 G.,	 Papparella,	 I.,	 Bortoluzzi,	 A.,	 Semplicini,	 A.,	
Dalla	 Man,	 C.,	 Cobelli,	 C.,	 Fadini,	 G.	 P.	 &	 Avogaro,	 A.	 (2010).	
Downregulation	 of	 the	 longevity-associated	 protein	 sirtuin	 1	 in	 insulin	
resistance	 and	 metabolic	 syndrome:	 Potential	 biochemical	 mechanisms,	
Diabetes	59,	1006-1015.	
	
DeSelm,	 C.	 J.,	 Miller,	 B.	 C.,	 Zou,	 W.,	 Beatty,	 W.	 L.,	 van	 Meel,	 H.,	 Takahata,	 Y.,	





Tempst,	 P.	 &	 Sabatini,	 D.	 M.	 (2004).	 Rictor,	 a	 Novel	 Binding	 Partner	 of	
mTOR,	Defines	 a	Rapamycin-Insensitive	 and	Raptor-Independent	 Pathway	
that	Regulates	the	Cytoskeleton,	Current	Biology	14,	1296-1302.	
	
Emsley,	 P.,	 Lohkamp,	 B.,	 Scott,	 W.	 G.	 &	 Cowtan,	 K.	 (2010).	 Features	 and	




D.,	 Leib,	 D.,	 Norbury,	 C.,	 Lippé,	 R.	 &	 Desjardins,	 M.	 (2009).	 Autophagy	







Evans,	P.	R.	&	Murshudov,	G.	N.	 (2013).	How	good	are	my	data	and	what	 is	 the	






Fleming,	 A.,	 Noda,	 T.,	 Yoshimori,	 T.	 &	 Rubinsztein,	 D.	 C.	 (2011).	 Chemical	








cardiac	 and	 liver	 development	 and	 its	 regulation	 of	 TNFα	and	TSC-mTOR	
signaling	pathways,	Journal	of	Cell	Biology	175,	121-133.	
	
Gasteiger,	 E.,	 Hoogland,	 C.,	 Gattiker,	 A.,	 Duvaud,	 S.	 e.,	 Wilkins,	 M.,	 Appel,	 R.	 &	




Behrends,	 C.	 (2015).	 CUL3-KBTBD6/KBTBD7Ubiquitin	 Ligase	 Cooperates	




















Harding,	T.	M.,	Morano,	K.	A.,	 Scott,	 S.	V.	&	Klionsky,	D.	 J.	 (1995).	 Isolation	and	
characterization	 of	 yeast	 mutants	 in	 the	 cytoplasm	 to	 vacuole	 protein	
targeting	pathway,	Journal	of	Cell	Biology	131,	591-602.	
	
Hayashi-Nishino,	 M.,	 Fujita,	 N.,	 Noda,	 T.,	 Yamaguchi,	 A.,	 Yoshimori,	 T.	 &	





Xiao,	 G.,	 Bassel-Duby,	 R.,	 Scherer,	 P.	 E.	 &	 Levine,	 B.	 (2012).	 Exercise-
induced	 BCL2-regulated	 autophagy	 is	 required	 for	 muscle	 glucose	
homeostasis,	Nature	481,	511-515.	
	






members	 of	 the	 human	MAP1LC3	 family	 and	 detection	 of	 a	 novel	 type	 of	




Proteinase	 yscE,	 the	 yeast	 proteasome/multicatalytic-multifunctional	
proteinase:	Mutants	 unravel	 its	 function	 in	 stress	 induced	 proteolysis	 and	
uncover	its	necessity	for	cell	survival,	EMBO	Journal	10,	555-562.	
	
Hess,	 B.,	 Kutzner,	 C.,	 van	 der	 Spoel,	 D.	 &	 Lindahl,	 E.	 (2008).	 GROMACS	 4: 	
Algorithms	 for	 Highly	 Efficient,	 Load-Balanced,	 and	 Scalable	 Molecular	
Simulation,	Journal	of	Chemical	Theory	and	Computation	4,	435-447.	
	





N.	 (2009).	 Nutrient-dependent	mTORCl	 association	with	 the	ULK1-Atg13-
FIP200	complex	 required	 for	autophagy,	Molecular	Biology	of	 the	Cell	20,	
1981-1991.	
	
Huang,	 J.	 &	 Manning,	 B.	 D.	 (2008).	 The	 TSC1–TSC2	 complex:	 a	 molecular	








Hutchins,	M.	U.	&	Klionsky,	D.	 J.	 (2001).	 Vacuolar	 Localization	 of	 Oligomeric	 α-
Mannosidase	Requires	the	Cytoplasm	to	Vacuole	Targeting	and	Autophagy	






Ichimura,	 Y.,	 Kumanomidou,	 T.,	 Sou,	 Y.-s.,	 Mizushima,	 T.,	 Ezaki,	 J.,	 Ueno,	 T.,	
Kominami,	 E.,	 Yamane,	 T.,	 Tanaka,	 K.	 &	 Komatsu,	 M.	 (2008).	 Structural	
Basis	 for	 Sorting	Mechanism	 of	 p62	 in	 Selective	 Autophagy,	 J.	 Biol.	 Chem.	
283,	22847-22857.	
	
Igloi,	 G.	 L.	 (2001).	 Cloning,	 expression	 patterns,	 and	 chromosome	 localization	 of	









Otto,	N.	M.,	Otto	Nm	Fau	 -	Cao,	 J.,	Cao	 J	Fau	 -	Kundu,	M.,	Kundu	M	Fau	 -	









Atg17	 functions	 in	 cooperation	with	 Atg1	 and	 Atg13	 in	 yeast	 autophagy,	
Molecular	Biology	of	the	Cell	16,	2544-2553.	
	
Kabeya,	 Y.,	 Mizushima,	 N.,	 Ueno,	 T.,	 Yamamoto,	 A.,	 Kirisako,	 T.,	 Noda,	 T.,	




Kabeya,	 Y.,	 Mizushima,	 N.,	 Yamamoto,	 A.,	 Oshitani-Okamoto,	 S.,	 Ohsumi,	 Y.	 &	




Kabsch,	 W.	 (2010a).	 XDS,	 Acta	 Crystallographica	 Section	 D:	 Biological	
Crystallography	66,	125-132.	
	
Kabsch,	 W.	 (2010b).	 Integration,	 scaling,	 space-group	 assignment	 and	 post-
refinement,	 Acta	 Crystallographica	 Section	 D:	 Biological	 Crystallography	
66,	133-144.	
	
Kamada,	 Y.,	 Funakoshi,	 T.,	 Shintani,	 T.,	 Nagano,	 K.,	 Ohsumi,	 M.	 &	 Ohsumi,	 Y.	












T.	 &	 Ohsumi,	 Y.	 (1999).	 Formation	 Process	 of	 Autophagosome	 Is	 Traced	
with	Apg8/Aut7p	in	Yeast,	The	Journal	of	Cell	Biology	147,	435-446.	
	
Kirkin,	 V.,	 Lamark,	 T.,	 Sou,	 Y.	 S.,	 Bjørkøy,	G.,	Nunn,	 J.	 L.,	 Bruun,	 J.	 A.,	 Shvets,	 E.,	
McEwan,	D.	G.,	Clausen,	T.	H.,	Wild,	P.,	Bilusic,	I.,	Theurillat,	J.	P.,	Øvervatn,	
A.,	 Ishii,	T.,	Elazar,	Z.,	Komatsu,	M.,	Dikic,	I.	&	Johansen,	T.	(2009).	A	Role	






Knight,	 D.,	 Harris,	 R.,	 McAlister,	 M.	 S.	 B.,	 Phelan,	 J.	 P.,	 Geddes,	 S.,	 Moss,	 S.	 J.,	
Driscoll,	 P.	 C.	 &	 Keep,	 N.	 H.	 (2002).	 The	 X-ray	 Crystal	 Structure	 and	
Putative	Ligand-derived	Peptide	Binding	Properties	of	γ-Aminobutyric	Acid	
Receptor	 Type	 A	 Receptor-associated	 Protein,	 Journal	 of	 Biological	
Chemistry	277,	5556-5561.	
	
Kunzt,	 J.	 B.,	 Schwarz,	 H.	 &	Mayer,	 A.	 (2004).	 Determination	 of	 Four	 Sequential	






























Levine,	 B.,	 Mizushima,	 N.	 &	 Virgin,	 H.	 W.	 (2011).	 Autophagy	 in	 immunity	 and	
inflammation,	Nature	469,	323-335.	
	




presentation	 depends	 on	 autophagy	 in	 tumor	 cells,	 Cancer	 Research	 68,	
6889-6895.	
	
Liang,	 X.	 H.,	 Jackson,	 S.,	 Seaman,	 M.,	 Brown,	 K.,	 Kempkes,	 B.,	 Hibshoosh,	 H.	 &	




Liang,	 X.	 H.,	 Kleeman,	 L.	 K.,	 Jiang,	 H.	 H.,	 Gordon,	 G.,	 Goldman,	 J.	 E.,	 Berry,	 G.,	








Lipinski,	 M.	 M.,	 Zheng,	 B.,	 Lu,	 T.,	 Yan,	 Z.,	 Py,	 B.	 F.,	 Ng,	 A.,	 Xavier,	 R.	 J.,	 Li,	 C.,	
Yankner,	 B.	 A.,	 Scherzer,	 C.	 R.	 &	 Yuan,	 J.	 (2010).	 Genome-wide	 analysis	























Otín,	 C.	 (2007).	 Tissue-specific	 autophagy	 alterations	 and	 increased	








Read,	 R.	 J.	 (2007).	 Phaser	 crystallographic	 software,	 Journal	 of	 Applied	
Crystallography	40,	658-674.	
	
McEwan,	 David	G.,	 Popovic,	 D.,	 Gubas,	 A.,	 Terawaki,	 S.,	 Suzuki,	 H.,	 Stadel,	 D.,	














Metcalf,	 D.	 J.,	 García-Arencibia,	M.,	Hochfeld,	W.	 E.	&	Rubinsztein,	D.	 C.	 (2012).	




Mitch,	 W.	 E.	 &	 Goldberg,	 A.	 L.	 (1996).	 Mechanisms	 of	 disease:	 Mechanisms	 of	






Mizushima,	 N.,	 Sugita,	 H.,	 Yoshimori,	 T.	 &	 Ohsumi,	 Y.	 (1998).	 A	 new	 protein	











Mortimore,	 G.	 E.	 &	 Poso,	 A.	 R.	 (1987).	 Intracellular	 Protein	 Catabolism	 and	 its	

























Paz,	 Y.,	 Elazar,	 Z.	&	 Fass,	D.	 (2000).	 Structure	 of	 GATE-16,	membrane	 transport	
modulator	 and	 mammalian	 ortholog	 of	 autophagocytosis	 factor	 Aut7p,	
Journal	of	Biological	Chemistry	275,	25445-25450.	
	
Pickford,	 F.,	 Masliah,	 E.,	 Britschgi,	 M.,	 Lucin,	 K.,	 Narasimhan,	 R.,	 Jaeger,	 P.	 A.,	
Small,	S.,	Spencer,	B.,	Rockenstein,	E.,	Levine,	B.	&	Wyss-Coray,	T.	(2008).	









E.	 L.,	 Mizushima,	 N.,	 Ohsumi,	 Y.,	 Cattoretti,	 G.	 &	 Levine,	 B.	 (2003).	
Promotion	 of	 tumorigenesis	 by	 heterozygous	 disruption	 of	 the	 beclin	 1	
autophagy	gene,	Journal	of	Clinical	Investigation	112,	1809-1820.	
	
Ravikumar,	B.,	Duden,	R.	&	Rubinsztein,	D.	 C.	 (2002).	 Aggregate-prone	proteins	








Rogov,	 V.	 V.,	 Suzuki,	 H.,	 Fiskin,	 E.,	 Wild,	 P.,	 Kniss,	 A.,	 Rozenknop,	 A.,	 Kato,	 R.,	
Kawasaki,	M.,	McEwan,	D.	G.,	Loehr,	F.,	Guentert,	P.,	Dikic,	I.,	Wakatsuki,	S.	










Rubinsztein,	D.	 C.,	 Codogno,	P.	&	Levine,	B.	 (2012).	 Autophagy	modulation	as	 a	
potential	 therapeutic	 target	 for	 diverse	 diseases,	 Nature	 Reviews	 Drug	
Discovery	11,	709-730.	
	
Rubinsztein,	 D.	 C.,	Mariño,	 G.	 &	 Kroemer,	 G.	 (2011).	 Autophagy	 and	 aging,	Cell	
146,	682-695.	
	
Scherz-Shouval,	 R.,	 Shvets,	 E.,	 Fass,	 E.,	 Shorer,	 H.,	 Gil,	 L.	 &	 Elazar,	 Z.	 (2007).	
Reactive	 oxygen	 species	 are	 essential	 for	 autophagy	 and	 specifically	
regulate	the	activity	of	Atg4,	EMBO	Journal	26,	1749-1760.	
	
Schmid,	 D.,	 Pypaert,	 M.	 &	 Münz,	 C.	 (2007).	 Antigen-Loading	 Compartments	 for	








Shibata,	 M.,	 Lu,	 T.,	 Furuya,	 T.,	 Degterev,	 A.,	 Mizushima,	 N.,	 Yoshimori,	 T.,	
MacDonald,	M.,	Yankner,	B.	&	Yuan,	 J.	 (2006).	Regulation	of	 intracellular	
















and	 differentiation	 in	 mice,	 Journal	 of	 Clinical	 Investigation	 119,	 3329-
3339.	
	
Sou,	 Y.-s.,	 Tanida,	 I.,	 Komatsu,	 M.,	 Ueno,	 T.	 &	 Kominami,	 E.	 (2006).	
Phosphatidylserine	 in	Addition	to	Phosphatidylethanolamine	 Is	an	 in	Vitro	








Sugawara,	 K.,	 Suzuki,	 N.	N.,	 Fujioka,	 Y.,	Mizushima,	N.,	 Ohsumi,	 Y.	&	 Inagaki,	 F.	
(2004).	The	crystal	structure	of	microtubule-associated	protein	light	chain	
3,	 a	 mammalian	 homologue	 of	 Saccharomyces	 cerevisiae	 Atg8,	 Genes	 to	
Cells	9,	611-618.	
	
Suzuki,	 H.,	 Tabata,	 K.,	 Morita,	 E.,	 Kawasaki,	 M.,	 Kato,	 R.,	 Dobson,	 R.	 C.	 J.,	
Yoshimori,	 T.	&	Wakatsuki,	 S.	 (2014).	 Structural	 basis	 of	 the	 autophagy-
related	 LC3/Atg13	 LIR	 complex:	 Recognition	 and	 interaction	 mechanism,	
Structure	22,	47-58.	
	
Szeto,	 J.,	 Kaniuk,	 N.	 A.,	 Canadien,	 V.,	 Nisman,	 R.,	 Mizushima,	 N.,	 Yoshimori,	 T.,	
Bazett-Jones,	D.	P.	&	Brumell,	J.	H.	(2006).	ALIS	are	stress-induced	protein	




Hino,	 O.,	 Tanaka,	 K.	 &	 Mizushima,	 N.	 (2011).	 Autophagy-deficient	 mice	
develop	multiple	liver	tumors,	Genes	and	Development	25,	795-800.	
	
Tanida,	 I.,	 Ueno,	 T.	 &	 Kominami,	 E.	 (2004).	 Human	 light	 chain	 3/MAP1LC3B	 Is	
cleaved	at	its	carboxyl-terminal	Met	121	to	expose	Gly120	for	lipidation	and	

























Peruzzi,	 B.,	 Teti,	 A.,	 Helfrich,	M.	H.,	 Rogers,	M.	 J.,	 Villa,	 A.	&	Van	Hul,	W.	
(2007).	 Involvement	 of	 PLEKHM1	 in	 osteoclastic	 vesicular	 transport	 and	
osteopetrosis	 in	 incisors	absent	rats	and	humans,	 J.	Clin.	 Invest.	117,	919-
930.	
	




J.,	 Freund,	 S.	 M.	 V.,	 Komander,	 D.	 &	 Randow,	 F.	 (2012a).	 LC3C,	 Bound	




J.,	 Freund,	 S.	 M.	 V.,	 Komander,	 D.	 &	 Randow,	 F.	 (2012b).	 LC3C,	 Bound	





synuclein	 Is	Degraded	by	Both	Autophagy	and	 the	Proteasome,	 Journal	 of	
Biological	Chemistry	278,	25009-25013.	
	














D.	 C.	 (2008).	 Novel	 targets	 for	 Huntington's	 disease	 in	 an	 mTOR-
independent	autophagy	pathway,	Nature	Chemical	Biology	4,	295-305.	
	















dependent	 cycling	 of	 mammalian	 Atg9	 between	 the	 TGN	 and	 endosomes,	
Journal	of	Cell	Science	119,	3888-3900.	
	










Zhao,	 H.,	 Laitala-Leinonen,	 T.,	 Parikka,	 V.	 &	 Vaananen,	 H.	 K.	 (2001).	
Downregulation	of	small	GTPase	Rab7	impairs	osteoclast	polarization	and	
bone	resorption,	J.	Biol.	Chem.	276,	39295-39302.	
	
Zheng,	S.,	Clabough,	E.	B.	D.,	Sarkar,	S.,	Futter,	M.,	Rubinsztein,	D.	C.	&	Zeitlin,	S.	O.	
(2010).	Deletion	of	the	huntingtin	polyglutamine	stretch	enhances	neuronal	
autophagy	and	longevity	in	mice,	PLoS	Genetics	6.	
	
 
